supp.fit

Omega-3 Fatty Acids: study protocols

1,405 study groups say how much Omega-3 Fatty Acids participants took a day. These are the doses the studies gave. They are not a recommendation.

Omega-3 Fatty Acids: what the research found →

Dose per serving from products

4,566 products in our catalogue print how much Omega-3 Fatty Acids a serving holds.

Most common: 500 mcg to 1 mg, 18% of 4,566 products.

Dose per servingProducts
500 mcg or less
11
500 mcg to 1 mg
842
1 mg to 2.5 mg
128
2.5 mg to 5 mg
392
5 mg to 10 mg
13
10 mg to 25 mg
49
25 mg to 50 mg
162
50 mg to 100 mg
331
100 mg to 250 mg
788
250 mg to 500 mg
579
500 mg to 1 g
701
1 g to 2.5 g
503
over 2.5 g
67

Dose per serving from research

1,392 study groups in 1,023 studies say how much Omega-3 Fatty Acids participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g, 36% of 1,392 study groups.

Daily doseStudy groups
100 mg or less
22
100 mg to 250 mg
52
250 mg to 500 mg
85
500 mg to 1 g
272
1 g to 2.5 g
495
2.5 g to 5 g
408
over 5 g
58

Commonly used together

516 of 1,405 study groups took Omega-3 Fatty Acids with something else. Shown: what 3 or more different studies gave. The 10 most common of 44.

What was given together, not what works together.

Taken withStudy groups
Docosahexaenoic Acid
244
Fish Oil
124
Vitamin E
57
Vitamin D
37
Vitamin C
17
EPA
15
Lutein
13
Phytosterols
12
Selenium
12
Vitamin A
12

1,405 study groups

Study
Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial
2024 · Marine n-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses
1 g1936 days12,933
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
2007 · EPA group · Japanese hypercholesterolaemic patients with total cholesterol of 6.5 mmol/L or greater
1.8 g5 years9,326
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial
2025 · icosapent ethyl group · Adults aged 45 years or older with cardiovascular disease, or aged 50 years or older with diabetes and at least one cardiovascular risk factor; statin-treated with elevated triglycerides and high cardiovascular risk
4 g—4,089
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
2008 · n-3 PUFA group · Patients with chronic heart failure, New York Heart Association class II–IV
1 g1424 days3,494
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
2024 · icosapent ethyl group · Adults with established atherosclerotic cardiovascular disease and elevated triglycerides, receiving stable statin therapy
4 g1752 days2,892
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico
1999 · n-3 PUFA · Patients who survived a recent myocardial infarction (within 3 months); age and sex not specified
1 g1278 days2,836
Identifying women who may benefit from higher dose omega-3 supplementation during pregnancy to reduce their risk of prematurity: exploratory analyses from the ORIP trial
2023 · n-3 arm · Pregnant women with singleton pregnancies; age range and condition other than pregnancy not specified
900 mg—2,654
Predictors of compliance with higher dose omega-3 fatty acid supplementation during pregnancy and implications for the risk of prematurity: exploratory analysis of the ORIP randomised trial
2023 · intervention group · Pregnant women enrolled before 20 weeks’ gestation; analysis restricted to singleton pregnancies with known gestational age at birth
900 mg—2,654
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI
2022 · Icosapent ethyl · Adults with prior percutaneous coronary intervention, elevated triglycerides despite statin therapy, and established cardiovascular disease or diabetes with additional risk factors; at least 45 years old with established cardiovascular disease or at least 50 years old with diabetes
4 g1752 days1,737
Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States
2024 · icosapent ethyl (IPE) · Adults with elevated triglycerides and controlled LDL-C who had cardiovascular disease or diabetes plus additional cardiovascular risk factors; statin-stabilized
4 g1789 days1,548
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG
2021 · icosapent ethyl · Statin-treated patients with a history of coronary artery bypass grafting, controlled low-density lipoprotein cholesterol, and mild to moderate hypertriglyceridemia
4 g1752 days897
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
2023 · Icosapent ethyl (current smokers) · Adults with hypertriglyceridaemia and high cardiovascular risk receiving statin treatment; current cigarette smokers
4 g1789 days628
Changes in eicosapentaenoic acid and docosahexaenoic acid and risk of cardiovascular events and atrial fibrillation: A secondary analysis of the OMEMI trial
2022 · EPA/DHA · Elderly patients with a recent acute myocardial infarction
1.8 g2 years438
Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth
2014 · omega-3 supplements · Pregnant women with a singleton gestation and a prior spontaneous preterm birth
2 g—434
Atopic and non-atopic effects of fish oil supplementation during pregnancy
2023 · n-3 LCPUFA · Pregnant women enrolled at pregnancy week 24; age and specific health conditions not stated
2.4 g—368
Effect of six month's treatment with omega-3 acid ethyl esters on long-term outcomes after acute myocardial infarction: The OMEGA-REMODEL randomized clinical trial
2024 · O3-FA · Patients with acute myocardial infarction; age and sex range not specified
4 g26 weeks180
Marine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes
2026 · low-dose fish oil · Adults aged 40–75 with type 2 diabetes
1.5 g426 days140
Marine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes
2026 · high-dose fish oil · Adults aged 40–75 with type 2 diabetes
3 g426 days137
Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
2023 · Aspirin & EPA · Adults aged 55–73 years with high-risk colorectal polyp findings at screening colonoscopy
2 g1 year136
Fatty acid desaturase insertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n-3 fatty acid eicosapentaenoic acid: a secondary analysis of the seAFOod polyp prevention trial
2024 · Aspirin and EPA · Predominantly White European adults, median age about 65 years, mostly men, at high risk of colorectal polyps after removal of multiple sporadic polyps
2 g1 year131
Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
2023 · EPA only · Adults aged 55–73 years with high-risk colorectal polyp findings at screening colonoscopy
2 g1 year126
Fatty acid desaturase insertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n-3 fatty acid eicosapentaenoic acid: a secondary analysis of the seAFOod polyp prevention trial
2024 · EPA only · Predominantly White European adults, median age about 65 years, mostly men, at high risk of colorectal polyps after removal of multiple sporadic polyps
2 g1 year123
Omega-3 polyunsaturated Fatty acids reduce the incidence of postoperative atrial fibrillation in patients with history of prior myocardial infarction undergoing isolated coronary artery bypass grafting
2014 · omega-3 PUFA treatment group · Patients with recent myocardial infarction (within 3 months) undergoing isolated coronary artery bypass grafting
2 g—99
N-3 polyunsaturated fatty acids reduces post-operative atrial fibrillation incidence in patients undergoing "on-pump" coronary artery bypass graft surgery
2011 · n-3 polyunsaturated fatty acids 2 g/day group · Patients undergoing coronary artery bypass graft surgery; age and sex not specified; included on-pump and off-pump surgery
2 g—96
Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion
2012 · omega-3 group · Patients with persistent atrial fibrillation lasting more than 1 month
6 g1 year91
A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study
2014 · EPA group · Patients with subarachnoid hemorrhage who underwent surgical clipping within 72 hours of onset; age and sex not specified
2.7 g30 days81
N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial
2005 · PUFAs 2 g/day · Adults undergoing elective coronary artery bypass graft surgery; mean age 66.2 years; 11 female; patients with coronary artery disease requiring CABG
2 g—79
Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study
2014 · EPA group · Patients with acute myocardial infarction; age range and sex not reported
1.8 g30 days57
Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial
2010 · omega-3 group · Adolescents and young adults aged 13 to 25 years at ultra-high risk of psychotic disorder with subthreshold psychosis
1.2 g12 weeks41
Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial
2012 · omega-3 supplemented group · Women aged 30–70 with node-positive breast cancer receiving paclitaxel chemotherapy
1.92 g93 days30
Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis
2010 · EPA-FFA · Patients with familial adenomatous polyposis undergoing endoscopic surveillance of the retained rectum after colectomy
2 g26 weeks28
The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial
2021 · intervention group · Critically ill adults aged 35–85 with COVID-19 admitted to ICU and indicated for enteral nutrition
1 g2 weeks28
Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study
1995 · 9 g EPA (low-dose EPA) · Cadaveric renal transplant recipients receiving cyclosporine A, prednisone and azathioprine; age and sex not reported
9 g26 weeks22
Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study
2005 · Group I · Children aged 5–16 years with Crohn's disease in remission
3 g1 year18
Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study
1995 · 18 g EPA (high-dose EPA) · Cadaveric renal transplant recipients receiving cyclosporine A, prednisone and azathioprine; age and sex not reported
18 g26 weeks18
Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial
2015 · N-3 group · Adults aged 25–72 with biopsy-confirmed non-alcoholic steatohepatitis (NASH)
3 g1 year17
Omega-3 Intake Improves Clinical Pregnancy Rate in Polycystic Ovary Syndrome Patients: A Double-Blind, Randomized Study
2023 · omega-3 supplements · Women with PCOS-related oligo/anovulation and infertility; mean age 33.9 years. The subgroup analysis included overweight/obese women with BMI 25–35.
1.8 g—17
Oral eicosapentaenoic acid for complications of bone marrow transplantation
2001 · EPA group · Patients undergoing bone marrow transplantation with unrelated donors
1.8 g201 days7
Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol
2001 · n-3 group · Adults with acute myocardial infarction
4 g2 years—
Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione
2002 · n-3 PUFAs · Patients who survived a recent myocardial infarction (<3 months)
1 g——
Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease
2009 · EPA group · Patients with established coronary artery disease and total cholesterol ≥250 mg/dL; age and sex not reported
1.8 g1679 days—
A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk
2010 · n-3 PUFA supplementation without diet counseling · Norwegian men aged 64–76 at high cardiovascular risk; 72% of the trial population had no overt cardiovascular disease
2.4 g3 years—
A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk
2010 · n-3 PUFA supplementation with diet counseling · Norwegian men aged 64–76 at high cardiovascular risk; 72% of the trial population had no overt cardiovascular disease
2.4 g3 years—
A low-fat high-carbohydrate diet supplemented with long-chain n-3 PUFA reduces the risk of the metabolic syndrome
2011 · LFHCC n-3 · Adults with MetS risk criteria; age and sex not specified
1.24 g12 weeks—
n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study
2011 · n-3 PUFAs · Patients with persistent atrial fibrillation and at least one relapse after cardioversion, treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor; age and sex not stated
2 g——
Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction
2012 · EPA-DHA · Adults with a history of myocardial infarction; statin users and non-users
400 mg——
Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use
2015 · FO group · DMARD-naïve patients with rheumatoid arthritis of less than 12 months' duration
5.5 g——
Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use
2015 · control group · DMARD-naïve patients with rheumatoid arthritis of less than 12 months' duration
400 mg——
The clinical benefits of long-term supplementation with omega-3 fatty acids in cystic fibrosis patients - A pilot study
2016 · omega-3 fish oil supplementation · ΔF508-homozygous patients with cystic fibrosis undergoing chronic azithromycin
60 mg/kg1 year—
Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study
2017 · EPA group · Patients with acute coronary syndrome; age and sex not specified
1.8 g1 year—
The Efficacy of Omega-3 Supplement on Prevention of Retinopathy of Prematurity in Premature Infants: A Randomized Double-blinded Controlled trial
2018 · intervention group · Premature infants with gestational age under 32 weeks and birth weight under 1500 g, at risk of retinopathy of prematurity
300 mg——
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
2019 · icosapent ethyl group · Patients with established cardiovascular disease or diabetes and other cardiovascular risk factors, elevated triglycerides, and receiving statin therapy
4 g1789 days—
Fish Oil Supplementation in Pregnancy Increases Gestational Age, Size for Gestational Age, and Birth Weight in Infants: A Randomized Controlled Trial
2019 · n-3 LCPUFA group · Pregnant women recruited at 22–26 weeks of gestation
2.4 g——
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
2019 · icosapent ethyl · Statin-treated patients with elevated triglycerides and a history of atherosclerosis or diabetes
4 g1789 days—
Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder
2019 · EPA group · Adults with major depressive disorder
3 g12 weeks—
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
2020 · icosapent ethyl · Adults aged 45 years or older with established cardiovascular disease, or adults aged 50 years or older with diabetes and at least one additional cardiovascular risk factor; statin-treated with elevated triglycerides
4 g1789 days—
Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure
2020 · n-3 group · older adults; mean age 67.1 years, 50.6% women; no condition specified
1 g1935 days—
Omega-3 fatty acids reduce post-operative risk of deep vein thrombosis and pulmonary embolism after surgery for elderly patients with proximal femoral fractures: a randomized placebo-controlled, double-blind clinical trial
2020 · omega-3 fatty acids · elderly patients over 60 years of age with proximal femoral fractures after surgery
1 g30 days—
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
2021 · icosapent ethyl · Statin-treated adults with elevated triglycerides and high cardiovascular risk, with established cardiovascular disease or diabetes plus additional cardiovascular risk factors
4 g1789 days—
Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial
2020 · Marine omega-3 fatty acids active · Men aged 50 years or older and women aged 55 years or older without cancer or cardiovascular disease at study entry
1 g1937 days—
Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: Findings from the OFFER randomized controlled study
2021 · EPA + DHA group · Adults with first-episode schizophrenia
2.2 g26 weeks—
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
2021 · Icosapent ethyl · Adults aged 50 years or older with established cardiovascular disease, or with medically treated type 1 or type 2 diabetes and at least one other major cardiovascular risk factor; on statin therapy with elevated triglycerides
4 g1789 days—
Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial
2022 · Marine omega-3 supplementation (with or without vitamin D supplementation; exercise assignment varied) · Community-dwelling adults aged 70 years and older, generally healthy and active, without major health events in the prior 5 years
1 g3 years—
Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization
2022 · marine omega-3 fatty acids group · Adults enrolled in VITAL; mean age 67.1 years, 50.6% women, with and without type 2 diabetes
1 g1935 days—
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
2022 · icosapent ethyl (IPE) · Statin-treated patients with prior myocardial infarction, controlled low-density lipoprotein cholesterol, and moderately elevated triglycerides
4 g——
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT
2023 · icosapent ethyl (IPE) · Statin-treated adults with controlled LDL cholesterol, elevated triglycerides, and cardiovascular risk, with or without a history of atrial fibrillation
4 g1789 days—
Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation': A secondary analysis from the OMEMI trial
2023 · n-3 PUFA group · Adults aged 70–82 with a recent myocardial infarction
1.8 g2 years—
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes
2023 · n−3 fatty acid supplementation group · Men aged 50 years or older and women aged 55 years or older, free of known cardiovascular disease or cancer, from the general US population
1 g1935 days—
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial
2024 · icosapent ethyl (IPE) · Statin-treated patients with recent acute coronary syndrome (MI or unstable angina within 12 months before randomization) and controlled LDL cholesterol and moderately elevated triglycerides; age and sex not specified
4 g1734 days—
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
2024 · icosapent ethyl (IPE) · Participants receiving statin therapy with established cardiovascular disease, or aged 50 years or older with diabetes and at least one additional cardiovascular risk factor; fasting triglycerides 1.69 to 5.63 mmol/L and LDL cholesterol 1.06 to 2.59 mmol/L
4 g——
A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events
2025 · ω-3 fatty acid supplementation · Older adults in the United States enrolled in a primary-prevention trial; age range and sex distribution are not stated in the abstract.
840 mg1935 days—
[n-3 polyunsaturated fatty acids, heart rate variability and ventricular arrhythmias in post-AMI-patients. A clinical controlled trial]
1997 · n-3 PUFA group · Patients with a previous myocardial infarction; age and sex not reported
5.2 g12 weeks—
Identification of individuals who benefit from omega-3 fatty acid supplementation to prevent coronary heart disease: a machine-learning analysis of the VITAL
2025 · omega-3 FA supplementation arm · US men aged 50 years or older and women aged 55 years or older in a primary-prevention trial
840 mg5 years12,933
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico
1999 · n-3 PUFA and vitamin E · Patients who survived a recent myocardial infarction (within 3 months); age and sex not specified
1 g1278 days2,830
The impact of pre- and postnatal exposures on allergy related diseases in childhood: a controlled multicentre intervention study in primary health care
2013 · intervention cohort · Pregnant women and their children in the general population of Trondheim; no age range or sex restriction stated
1.2 g—1,374
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis
2026 · fish-oil group · Adults receiving maintenance hemodialysis
4 g1278 days610
The effect of omega-3 supplementation on pregnancy outcomes by smoking status
2017 · omega-3 supplementation · Pregnant women enrolled at 16 0/7 to 21 6/7 weeks of gestation with a singleton pregnancy and a prior spontaneous preterm delivery; included smokers and nonsmokers
2 g—434
Fish oil intake compared with olive oil intake in late pregnancy and asthma in the offspring: 16 y of registry-based follow-up from a randomized controlled trial
2008 · fish oil · Women with normal pregnancies, recruited around gestation week 30
2.7 g—266
n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes
2011 · EPA-DHA · Adults aged 60–80 with diabetes and a previous myocardial infarction
400 mg1217 days262
n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes
2011 · EPA-DHA plus ALA · Adults aged 60–80 with diabetes and a previous myocardial infarction
400 mg1217 days245
CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study
2015 · DHA group · Adults aged 55–85 with early AMD in the study eye and neovascular AMD in the fellow eye
270 mg3 years127
Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT)
2002 · omega-3 FA group · Patients undergoing balloon-only percutaneous transluminal coronary angioplasty (PTCA)
3 g240 days125
A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement
2013 · supplemented group · Patients scheduled for on-pump cardiac surgery; age and sex not specified
2 g—103
Effect of dietary fish oil on atrial fibrillation after cardiac surgery
2011 · fish oil group · Adults undergoing CABG or valve cardiac surgery; age and sex not reported
4.6 g3 weeks97
Allergic disease in infants up to 2 years of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and lactation
2011 · ω-3-supplemented group · Pregnant women at risk of having an allergic infant, starting in the 25th gestational week and continuing through breastfeeding
1.6 g—54
Fish oil supplementation in pregnancy and lactation may decrease the risk of infant allergy
2009 · omega-3 group · Pregnant and breastfeeding women with an allergy themselves or a husband or previous child with allergies
1.6 g—52
Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study
2015 · omega-3 PUFA group · People aged 13–25 years at ultrahigh risk for psychosis
1.18 g12 weeks41
Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease
1996 · fish-oil group · Patients with Crohn's disease in remission at high risk of relapse; age and sex not specified
2.7 g1 year39
Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial
1998 · fish oil · Adults with generalized solid tumors, including well-nourished and malnourished patients
18 g—30
Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial
2020 · juice-based TMN · Patients with non-small-cell lung cancer receiving first-line chemotherapy, with weight loss or low BMI
2 g12 weeks26
Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo
2021 · ω-3-FA · Peri- and postmenopausal women younger than 70 with BMI ≥28 and increased breast-cancer risk
2.2 g1 year23
The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial
2025 · n-3 PUFAs group · Patients with late-life depression who were euthymic at enrollment; ages and sex not reported
1.2 g52 weeks19
Perioperative immunonutrition and outcomes in head and neck cancer surgery - a randomized clinical trial: Effects of perioperative immunonutrition in patients with head and neck cancer
2026 · IN (intervention group) · Adults aged 18–75 with newly diagnosed head and neck cancer undergoing first-line surgery; predominantly men; body-weight loss was common
3 g15 days17
Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration
1992 · fish oil · Healthy Danish women in week 30 of pregnancy
2.7 g——
Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction
2012 · EPA-DHA plus ALA · Adults with a history of myocardial infarction; statin users and non-users
400 mg——
Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial
2013 · 1 capsule daily, ages 2–4 years · Children aged 2–4 years with homozygous sickle cell disease
317 mg1 year—
Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial
2013 · 2 capsules daily, ages 5–10 years · Children aged 5–10 years with homozygous sickle cell disease
634 mg1 year—
Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial
2013 · 3 capsules daily, ages 11–16 years · Adolescents aged 11–16 years with homozygous sickle cell disease
833 mg1 year—
Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial
2013 · 4 capsules daily, ages 17 years and older · People aged 17 years or older with homozygous sickle cell disease
1.27 g1 year—
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
650 mg5 years—
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3
2014 · DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified
1 g1789 days—
Maternal obesity, fish intake, and recurrent spontaneous preterm birth
2019 · study drug · Pregnant women recruited at 16–22.9 weeks’ gestation with one or more prior spontaneous preterm births
2 g——
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
2019 · n-3 fatty acids group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial
840 mg1936 days—
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
2019 · n-3 fatty acids plus vitamin D group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial
840 mg1936 days—
Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder
2019 · EPA + DHA group · Adults with major depressive disorder
1.5 g12 weeks—
No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18
2019 · Omega-3 fatty acids addition · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye
1 g5 years—
Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial
2020 · Vitamin D3 and marine omega-3 fatty acids active · Men aged 50 years or older and women aged 55 years or older without cancer or cardiovascular disease at study entry
1 g1937 days—
Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial
2022 · Vitamin D plus marine omega-3 supplementation (exercise assignment varied) · Community-dwelling adults aged 70 years and older, generally healthy and active, without major health events in the prior 5 years
1 g3 years—
Effect of a collagen-enriched beverage with or without omega-3 fatty acids on wound healing, metabolic biomarkers, and adipokines in patients with major burns
2023 · collagen plus omega-3 · Patients with 20–45% deep partial- or full-thickness burns
3 g4 weeks—
Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old
2023 · fish oil + placebo · Women in early pregnancy
220 mg——
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes
2023 · combination supplementation group · Men aged 50 years or older and women aged 55 years or older, free of known cardiovascular disease or cancer, from the general US population
1 g1935 days—
Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial
2024 · Vitamin D and n-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses
1 g1936 days—
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
2025 · Marine omega-3 · Men aged 50 years or older and women aged 55 years or older, without type 2 diabetes at baseline; older US adults
840 mg1935 days—
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
2025 · Vitamin D plus marine omega-3 · Men aged 50 years or older and women aged 55 years or older, without type 2 diabetes at baseline; older US adults
840 mg1935 days—
A randomized clinical trial of omega-3 fatty acid and vitamin D supplementation on electrocardiographic risk profiles
2023 · EPA/DHA active treatment · Men aged 50 years or older and women aged 55 years or older in the VITAL ECG substudy; no specific disease required
1 g2 years457
Effect of fish oil supplementation in pregnancy on bone, lean, and fat mass at six years: randomised clinical trial
2018 · n-3 LCPUFA supplementation group · Pregnant women, randomised at pregnancy week 24; offspring followed through age 6 years
2.4 g—368
Effects of food supplementation on cognitive function, cerebral blood flow, and nutritional status in young children at risk of undernutrition: randomized controlled trial
2020 · NEWSUP · Children aged 15 months to 7 years living in rural Guinea-Bissau and considered at risk of undernutrition; both sexes
534 mg23 weeks359
The effect of eicosapentaenoic and docosahexaenoic acids on physical function, exercise, and joint replacement in patients with coronary artery disease: A secondary analysis of a randomized clinical trial
2018 · Lovaza · Adults aged 21–80 with stable coronary artery disease and overweight or metabolic risk criteria
3.36 g1 year147
Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927
2015 · O3-FA arm · Women with early-stage breast cancer receiving an aromatase inhibitor and with a worst joint pain/stiffness score of at least 5/10
3.3 g24 weeks122
Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer
2020 · ω-3 PUFAs group · Adults with stage III or IV colon cancer receiving oxaliplatin and capecitabine chemotherapy
1.92 g22 weeks98
Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial
2003 · Experimental (E) · Patients with advanced pancreatic cancer and cachexia; age and sex not reported
2.2 g8 weeks95
Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia
2008 · Group A · Patients with nonalcoholic fatty liver disease associated with hyperlipidemia; age and sex not reported
6 g24 weeks72
The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo-controlled trial
2016 · n-3 PUFA group · Adults older than 18 years with psoriatic arthritis
3 g24 weeks72
Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial
2021 · n-3 PUFA group · Adults with psoriatic arthritis; age and sex ranges not specified
3 g24 weeks71
Evaluation of the effect of omega-3 fatty acids in the treatment of premenstrual syndrome: "a pilot trial"
2013 · omega-3 group (group A) · Women with premenstrual syndrome (PMS); age range not stated
2 g90 days70
The comparison of the effect of soybean and fish oil on supplementation on menopausal symptoms in postmenopausal women: A randomized, double-blind, placebo-controlled trial
2020 · Omega-rex · Postmenopausal women; age range and specific condition not reported
1 g12 weeks60
High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels
2019 · n-3 PUFAs (EPA) group · Children and adolescents aged 6–18 years with ADHD; participants were stratified by baseline EPA level, including a low-EPA subgroup.
1.2 g12 weeks48
Efficacy of omega 3 fatty acid as an adjunct in the management of chronic periodontitis: A randomized controlled trial
2020 · test group · Patients with chronic moderate periodontitis; age and sex not reported
1 g30 days48
Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome
2009 · EPA-treated group · Obese Japanese subjects with metabolic syndrome; age and sex not reported
1.8 g90 days46
Omega-3 fatty acids reduce depressive symptoms only among the socially stressed: A corollary of the social signal transduction theory of depression
2023 · 1.25 grams per day (g/d) omega-3 supplementation group · Healthy, sedentary, generally overweight and obese middle-aged and older adults
1.25 g120 days46
Omega-3 fatty acids reduce depressive symptoms only among the socially stressed: A corollary of the social signal transduction theory of depression
2023 · 2.5 g/d omega-3 supplementation group · Healthy, sedentary, generally overweight and obese middle-aged and older adults
2.5 g120 days46
Efficacy of omega-3 in the treatment of polycystic ovary syndrome
2013 · omega-3 · Non-obese women with polycystic ovary syndrome
1.5 g26 weeks45
Effect of omega-3 and vitamin D co-supplementation on psychological distress in reproductive-aged women with pre-diabetes and hypovitaminosis D: A randomized controlled trial
2021 · Group 2 Omega-3 group · Women aged 15–50 with pre-diabetes and hypovitaminosis D
2 g8 weeks42
Eicosapentaenoic Acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease
2014 · EPA group · Adults with established coronary artery disease, impaired flow-mediated dilation, and LDL-C below 100 mg/dl while receiving statin treatment
1.8 g158 days40
Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients: A cross-over randomized clinical trial
2022 · Omega-3 treatment period · Hemodialysis patients with pruritus; age and sex not reported
3 g4 weeks40
The Role of Omega-3 Polyunsaturated Fatty Acids in Patients with Metabolic Syndrome and Endothelial Dysfunction
2024 · n-3 PUFAs group · Adults aged 31–81 years, both sexes, with metabolic syndrome
2.4 g90 days40
Untitled
2012 · A1 (Al) · Men aged 52.5 ± 1.3 years with Q-wave myocardial infarction and I–III grade ventricular heart rhythm disturbances
1 g26 weeks39
Omega-3 versus isoflavones in the control of vasomotor symptoms in postmenopausal women
2017 · omega-3 · Healthy postmenopausal women aged 45–65
850 mg16 weeks38
A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia
2016 · n-3 PUFA group · Patients aged 16–35 with first-episode schizophrenia
2.2 g26 weeks36
Effect of Eicosapentaenoic Acid on Body Composition and Inflammation Markers in Patients with Head and Neck Squamous Cell Cancer from a Public Hospital in Mexico
2018 · EPA group · Patients with head and neck squamous cell cancer; age and sex not reported
2 g6 weeks32
Untitled
2012 · A2 · Men aged 52.5 ± 1.3 years with Q-wave myocardial infarction and IV–V grade ventricular heart rhythm disturbances
1 g26 weeks31
Effect of oral omega-3 Fatty Acid supplementation on contrast sensitivity in patients with moderate meibomian gland dysfunction: a prospective placebo-controlled study
2015 · Treatment group · Patients with moderate meibomian gland dysfunction; age and sex not reported
1.2 g12 weeks30
Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients
2016 · omega-3 fatty acid + alpha-tocopherol placebo · Chronic hemodialysis patients; age and sex not specified
1.25 g12 weeks30
Oral Omega-3 Fatty Acid Supplementation for Laser In Situ Keratomileusis-Associated Dry Eye
2017 · treatment group · Patients undergoing LASIK
1.2 g13 weeks30
Clinical and metabolic response to flaxseed oil omega-3 fatty acids supplementation in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial
2017 · omega-3 fatty acids supplementation · Adults aged 40–85 with grade 3 diabetic foot ulcer
2 g12 weeks30
Omega 3 fatty acids can reduce early doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia
2022 · group I · Children with newly diagnosed acute lymphoblastic leukemia receiving chemotherapy including doxorubicin
1 g26 weeks30
A Randomized Trial of the Effects of Dietary n3-PUFAs on Skeletal Muscle Function and Acute Exercise Response in Healthy Older Adults
2022 · n3-PUFA group · Adults aged 65–85 years, male and female, independently living and without a known chronic debilitating disease
3.9 g26 weeks30
Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial
2017 · MPL group · Adults aged 18 years or older with pancreatic carcinoma and tumor-associated weight loss of at least 5% since diagnosis
300 mg6 weeks29
The Effect of Omega-3 Fatty Acids on Thromboxane, Brain-Derived Neurotrophic Factor, Homocysteine, and Vitamin D in Depressive Children and Adolescents: Randomized Controlled Trial
2021 · Om3 group · Children and adolescents with depressive disorder or mixed anxiety and depressive disorder, alongside standard antidepressant therapy
2.4 g12 weeks29
Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial
2009 · EPA-enriched enteral nutrition · Patients undergoing esophagectomy for esophageal cancer; age and sex not stated
2.2 g26 days28
The effect of omega-3 fatty acids supplementation on social and behavioral disorders of children with autism: a randomized clinical trial
2021 · intervention group · Children aged 5–15 years with moderate or severe autism spectrum disorder
1 g8 weeks28
Effects of Omega-3 PUFAs on lipid profiles and antioxidant response in depressed adolescents: A metabolomic and lipidomic study
2025 · ω3 + Paxil group · Adolescents aged 13–24 years with depression
2.7 g12 weeks27
Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes
2009 · n-3 PUFA · Healthy adults aged 29.9 ± 6.2 years, men and women, with at least one parent diagnosed with type 2 diabetes; included participants with normal or impaired glucose tolerance
2 g12 weeks26
Effects of marine-derived omega-3 fatty acids on systemic hemodynamics at rest and during stress: a dose-response study
2012 · low-dose treatment · Adults aged 21–65 with moderate hypertriglyceridemia; 23 men and three postmenopausal women in the study population
850 mg8 weeks26
Effects of marine-derived omega-3 fatty acids on systemic hemodynamics at rest and during stress: a dose-response study
2012 · high-dose treatment · Adults aged 21–65 with moderate hypertriglyceridemia; 23 men and three postmenopausal women in the study population
3.4 g8 weeks26
Effects of n-3 polyunsaturated fatty acids on depressive symptoms, anxiety and emotional state in patients with acute myocardial infarction
2013 · group P · Patients with acute myocardial infarction and no history of mental disorders
1 g30 days26
Effects of omega-3 fatty acid supplementation on heart rate variability at rest and during acute stress in adults with moderate hypertriglyceridemia
2013 · Low-dose EPA + DHA · Men and postmenopausal women aged 21–65 with moderate hypertriglyceridemia (150–500 mg/dl)
850 mg8 weeks26
Effects of omega-3 fatty acid supplementation on heart rate variability at rest and during acute stress in adults with moderate hypertriglyceridemia
2013 · High-dose EPA + DHA · Men and postmenopausal women aged 21–65 with moderate hypertriglyceridemia (150–500 mg/dl)
3.4 g8 weeks26
Gallstone Dissolution Effects of Combination Therapy with n-3 Polyunsaturated Fatty Acids and Ursodeoxycholic Acid: A Randomized, Prospective, Preliminary Clinical Trial
2024 · Combination group · Adults aged 19 years or older with gallbladder stones 15 mm or smaller and no or mild symptoms
3 g26 weeks26
Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study
2006 · 2 g/day ethyl-EPA · People with bipolar depression
2 g12 weeks25
Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study
2011 · EPA-plus-statin group (combined-therapy group) · Patients with coronary artery disease and dyslipidemia receiving statin therapy
1.8 g48 weeks25
Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study
2006 · 1 g/day ethyl-EPA · People with bipolar depression
1 g12 weeks24
The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial
2024 · group 1: omega-3 supplementation (ω3) · Women aged 28–64 with newly diagnosed stage II or III breast cancer, before first chemotherapy treatment
600 mg9 weeks24
Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial
2010 · n-3 group · Depressed women aged 66–95 years living in a nursing home
2.5 g8 weeks22
Comparison between the AA/EPA ratio in depressed and non depressed elderly females: omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters
2012 · Omega-3 group · Women aged 65–95 with depression, institutionalized in a nursing home
2.5 g8 weeks22
Impact of Omega-3 Fatty Acid Supplementation on Memory Functions in Healthy Older Adults
2016 · LC-n3-FA · Cognitively healthy adults aged 50–75 years
2.2 g26 weeks22
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain
2018 · n-3 PUFA group · Postmenopausal women aged 43–76 with stage I–III hormone-receptor-positive breast cancer, starting aromatase inhibitor therapy
4.3 g24 weeks22
Variable effects of 12 weeks of omega-3 supplementation on resting skeletal muscle metabolism
2014 · omega-3 supplementation · Recreationally active, healthy young men
3 g12 weeks21
Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study(‡)
2020 · omega-3 LCPUFA (OM) · Children aged 2.5–8 years with autism spectrum disorder
722 mg1 year21
omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study
2003 · E-EPA · Women with moderately severe borderline personality disorder meeting Revised Diagnostic Interview for Borderlines and DSM-IV criteria
1 g8 weeks20
N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction
2011 · study group (group P) · Adults with acute myocardial infarction who had successful percutaneous coronary intervention; age and sex not reported
1 g30 days20
Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy
2016 · ω3-FA supplementation · Adults with familial hypercholesterolaemia on optimal cholesterol-lowering therapy
4 g8 weeks20
The effect of omega-3 fatty acid supplementation on weight loss and cognitive function in overweight or obese individuals on weight-loss diet
2022 · omega-3 group · Adults aged 30–60 years with overweight or obesity (BMI 27.0–35.0 kg/m²) on a weight-loss diet
1.02 g12 weeks20
Effect of omega-3 fatty acid ethyl esters on postprandial arterial elasticity in patients with familial hypercholesterolemia
2023 · ω-3FAEE · Adults with familial hypercholesterolemia
4 g8 weeks20
Discrepancy Between Fasting Flow-Mediated Dilation and Parameter of Lipids in Blood: A Randomized Exploratory Study of the Effect of Omega-3 Fatty Acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia
2020 · 4-g group · Men or postmenopausal women aged 20 years or older with dyslipidemia and hypertriglyceridemia, receiving an HMG-CoA reductase inhibitor
4 g8 weeks19
Dietary Intake of n-3 PUFA-Enriched Hen Eggs Changes Inflammatory Markers' Concentration and Treg/Th17 Cells Distribution in Blood of Young Healthy Adults-A Randomised Study
2021 · n-3 PUFAs group · Healthy adults aged 19–28 years, both sexes
1.05 g3 weeks19
Discrepancy Between Fasting Flow-Mediated Dilation and Parameter of Lipids in Blood: A Randomized Exploratory Study of the Effect of Omega-3 Fatty Acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia
2020 · 2-g group · Men or postmenopausal women aged 20 years or older with dyslipidemia and hypertriglyceridemia, receiving an HMG-CoA reductase inhibitor
2 g8 weeks18
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs
2002 · 1 g/d ethyl-eicosapentaenoate · Adults with persistent depression despite ongoing adequate-dose standard antidepressant treatment
1 g12 weeks17
A high-fat meal enriched with eicosapentaenoic acid reduces postprandial arterial stiffness measured by digital volume pulse analysis in healthy men
2008 · EPA plus high-oleic sunflower oil (HOS) · 17 healthy men
5 g1 day17
A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder
2009 · EPA · Adults aged 18–80 with major depressive disorder, with baseline HAM-D-17 score of at least 18
1 g8 weeks17
The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans
2012 · EPA+DHA · Healthy men and women aged 18–50 years
3.4 g1 day16
The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans
2012 · Aspirin plus EPA+DHA · Healthy men and women aged 18–50 years
3.4 g1 day16
Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia
2000 · omega-3 fatty acids · Hypercholesterolemic subjects with no other known cause for endothelial dysfunction; age and sex not reported
4 g120 days15
Untitled
2012 · group SE (statin plus EPA) · Adults with type 2 diabetes and dyslipidemia, receiving statin therapy
1.8 g26 weeks15
Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study
2011 · 1 g/d n3-PUFA · Patients with severe, nonischemic chronic heart failure
1 g90 days14
n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers
2006 · n-3 PUFA group · Patients with substance use disorders
3 g90 days13
Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study
2011 · 4 g/d n3-PUFA · Patients with severe, nonischemic chronic heart failure
4 g90 days13
Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis
2021 · EPA · Adults with major depressive disorder meeting DSM-IV criteria and baseline 21-item Hamilton Rating Scale for Depression scores of at least 18; sex and age range not reported
3 g12 weeks11
Acute ingestion of a meal rich in n-3 polyunsaturated fatty acids results in rapid gastric emptying in humans
2002 · n-3 PUFA meal · Healthy women aged 50–62 years
40 g1 day10
The effects of omega-3 supplementation on pulmonary function of young wrestlers during intensive training
2010 · experimental group · Healthy young male wrestlers
1 g12 weeks10
Nonsurgical Treatment of Periodontitis in Menopausal Patients: A Randomized Control Trial
2024 · Group II (SRP + omega-3FAs) · Menopausal women aged 45–55 with generalized chronic periodontitis and periodontal pockets of at least 5 mm
1 g1 year10
Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis
2006 · low-dose group · Patients with ankylosing spondylitis
1.95 g21 weeks9
Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis
2006 · high-dose group · Patients with ankylosing spondylitis
4.55 g21 weeks9
Incorporation and washout of n-3 PUFA after high dose intravenous and oral supplementation in healthy volunteers
2015 · oral n-3PUFA · healthy volunteers
600 mg/kg3 days8
Long-Chain Omega-3 Fatty Acid Supplementation and Exercise-Induced Muscle Damage: EPA or DHA?
2024 · EPA + DHA · Males; age and health status not reported
4 g52 days8
Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression
2006 · 2.8 g/day group · Women with postpartum depression; ages and sex details beyond postpartum mothers not reported
2.8 g8 weeks7
The effect of Omega-3 polyunsaturated fatty acid supplementation on exercise-induced muscle damage
2021 · N-3 · Healthy, physically active males aged 18–35 years without a stated disease
3 g4 weeks7
Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression
2006 · 0.5 g/day group · Women with postpartum depression; ages and sex details beyond postpartum mothers not reported
500 mg8 weeks6
Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression
2006 · 1.4 g/day group · Women with postpartum depression; ages and sex details beyond postpartum mothers not reported
1.4 g8 weeks3
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial
1999 · omega3 fatty acids · Patients with bipolar disorder
9.6 g120 days—
Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids
1999 · 6.6 g n-3 PUFA group · Healthy volunteers
6.6 g12 weeks—
Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids
1999 · 2.0 g n-3 PUFA group · Healthy volunteers
2 g12 weeks—
Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men
2000 · EPA · Overweight, mildly hyperlipidemic men
4 g6 weeks—
A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms
2002 · 1 g/day E-E · Adults with DSM-IV-defined schizophrenia receiving typical antipsychotics, new atypical antipsychotics, or clozapine
1 g12 weeks—
A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms
2002 · 2 g/day E-E · Adults with DSM-IV-defined schizophrenia receiving typical antipsychotics, new atypical antipsychotics, or clozapine
2 g12 weeks—
A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms
2002 · 4 g/day E-E · Adults with DSM-IV-defined schizophrenia receiving typical antipsychotics, new atypical antipsychotics, or clozapine
4 g12 weeks—
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs
2002 · 2 g/d ethyl-eicosapentaenoate · Adults with persistent depression despite ongoing adequate-dose standard antidepressant treatment
2 g12 weeks—
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs
2002 · 4 g/d ethyl-eicosapentaenoate · Adults with persistent depression despite ongoing adequate-dose standard antidepressant treatment
4 g12 weeks—
Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers
2003 · EPA group · Healthy subjects; age and sex not stated
4 g90 days—
Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial
2003 · omega-3 PUFA group · Patients with major depressive disorder
6.6 g8 weeks—
The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a randomized, double blind trial
1992 · n-3 PUFA · Patients with active rheumatoid arthritis
3.6 g12 weeks—
Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans
2005 · n-3 fatty acids group · Patients with at least 1440 premature ventricular complexes per 24 hours on a previous Holter recording
1.5 g14 weeks—
Supplementation of fish oil and olive oil in patients with rheumatoid arthritis
2005 · G2 · Adults with rheumatoid arthritis; 34 women and 9 men across the study, mean age 49 years
3 g24 weeks—
A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus
2008 · fish oil group · Patients with systemic lupus erythematosus; age and sex not specified
3 g24 weeks—
Tolerability of omega-3 fatty acid supplements in perinatal women
2007 · omega-3 fatty acids · Pregnant and postpartum women with major depressive disorder
1.84 g8 weeks—
Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial
2007 · E-EPA · Patients with first-episode psychosis
2 g12 weeks—
Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder
2008 · EPA · Outpatients with major depressive disorder, age and sex not reported
1 g8 weeks—
Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder
2008 · EPA + fluoxetine · Outpatients with major depressive disorder, age and sex not reported
1 g8 weeks—
Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial
2008 · omega-3 PUFAs · Pregnant women with major depressive disorder
3.4 g8 weeks—
The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study
2008 · omega-3 PUFAs · People with mild or moderate Alzheimer's disease or mild cognitive impairment
1.8 g24 weeks—
Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus
1991 · MaxEPA · Patients with active systemic lupus erythematosus
20 g34 weeks—
The effects of ingestion of omega-3 fatty acids on perceived pain and external symptoms of delayed onset muscle soreness in untrained men
2009 · experimental group · Untrained men who had not participated in a training program in the preceding 60 days
1.8 g——
EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD
2010 · EPA · Children aged 7–12 years with ADHD
500 mg15 weeks—
Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
2011 · n-3 PUFAs group · Patients with chronic heart failure due to nonischemic dilated cardiomyopathy and minimal symptoms receiving standard therapy; age and sex not specified
2 g1 year—
Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study
2011 · EPA and DHA group · Infertile men with idiopathic oligoasthenoteratospermia (OAT)
1.84 g32 weeks—
Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial
2012 · n-3FA (Lovaza) 4 g · Postmenopausal women at increased risk for breast cancer (breast density ≥ 25%)
4 g2 years—
Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial
2012 · Lovaza 4 g+Ral 30 mg · Postmenopausal women at increased risk for breast cancer (breast density ≥ 25%)
4 g2 years—
Untitled
2012 · ω-3 PUFA group · Patients with ischemic heart disease and ventricular arrhythmias
1 g26 weeks—
Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial
2013 · EPA group · Adults with mild-to-moderate depression receiving maintenance medication
1 g12 weeks—
Randomized controlled trial of oral omega-3 PUFA in solar-simulated radiation-induced suppression of human cutaneous immune responses
2013 · n-3 PUFA group · Nickel-allergic women aged 22–60 years with phototype I or II
5 g90 days—
Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?
2013 · ω-3 PUFA group · Young patients at ultra-high risk for psychosis
1.2 g12 weeks—
Long-chain omega-3 fatty acids improve brain function and structure in older adults
2014 · fish oil · Healthy adults aged 50–75 years
2.2 g26 weeks—
Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial
2013 · n-3 PUFA group · Adolescents with borderline personality disorder who also met ultra-high-risk criteria for psychosis; mean age 16.2 years
1.2 g12 weeks—
Effect of low doses of long chain n-3 polyunsaturated fatty acids on sleep-time heart rate variability: a randomized, controlled trial
2013 · 0.45 g/day n-3 PUFA group · Non-smoking men and women aged 45–70 years, healthy and at moderate cardiovascular risk
450 mg1 year—
Effect of low doses of long chain n-3 polyunsaturated fatty acids on sleep-time heart rate variability: a randomized, controlled trial
2013 · 0.9 g/day n-3 PUFA group · Non-smoking men and women aged 45–70 years, healthy and at moderate cardiovascular risk
900 mg1 year—
Effect of low doses of long chain n-3 polyunsaturated fatty acids on sleep-time heart rate variability: a randomized, controlled trial
2013 · 1.8 g/day n-3 PUFA group · Non-smoking men and women aged 45–70 years, healthy and at moderate cardiovascular risk
1.8 g1 year—
Efficacy of omega-3 in treatment of recurrent aphthous stomatitis and improvement of quality of life: a randomized, double-blind, placebo-controlled study
2014 · omega-3 · Participants with recurrent aphthous stomatitis; age and sex not specified
3 g26 weeks—
B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial
2014 · n-3 fatty acids only · Adults aged 45–80 with a recent history of myocardial infarction, unstable angina, or ischemic stroke
600 mg1716 days—
Effect of dietary supplementation with omega-3 fatty acid and gamma-linolenic acid on acne vulgaris: a randomised, double-blind, controlled trial
2014 · omega-3 fatty acid group · Participants with mild to moderate acne; age and sex not reported
2 g10 weeks—
Omega-3 supplementation and loneliness-related memory problems: secondary analyses of a randomized controlled trial
2014 · 1.25 g/d omega-3 supplementation group · Healthy, overweight, sedentary adults aged 40–85
1.25 g120 days—
Omega-3 supplementation and loneliness-related memory problems: secondary analyses of a randomized controlled trial
2014 · 2.50 g/d omega-3 supplementation group · Healthy, overweight, sedentary adults aged 40–85
2.5 g120 days—
Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals - a randomized cross-over trial
2014 · omega-3 fatty acids supplementation · Healthy volunteers; age and sex not reported.
4 g4 weeks—
Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss
2015 · EPA · Healthy overweight or obese women following an energy-restricted diet
1.3 g10 weeks—
Short-term supplementation of acute long-chain omega-3 polyunsaturated fatty acids may alter depression status and decrease symptomology among young adults with depression: A preliminary randomized and placebo controlled trial
2015 · LCPUFAs group · Young adults with depressive symptoms (BDI score greater than 10); mean age 20.2 years, 78% female
1.4 g3 weeks—
Omega-3 fatty acids supplementation improves endothelial function and arterial stiffness in hypertensive patients with hypertriglyceridemia and high cardiovascular risk
2017 · omega-3 fatty acids · Adults with hypertriglyceridemia (triglycerides 150–499 mg/dL), including low- and high-cardiovascular-risk hypertensive patients
1.8 g12 weeks—
Beneficial effect of n-3 polyunsaturated fatty acids on inflammation and analgesic use in psoriatic arthritis: a randomized, double blind, placebo-controlled trial
2018 · n-3 PUFA group · Patients with established psoriatic arthritis; age and sex not specified
3 g24 weeks—
Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)
2017 · study group · Men aged 50–70 with LUTS and BPH and no other comorbidities
900 mg26 weeks—
The effect of omega 3 fatty acid supplementation on premenstrual syndrome and health-related quality of life: a randomized clinical trial
2018 · omega-3 supplement group · Iranian women aged 20–35 years with premenstrual symptoms
1 g——
Effects of n-3 Polyunsaturated Fatty Acid Supplementation on Serum Leptin Levels, Appetite Sensations, and Intake of Energy and Macronutrients in Obese People: A Randomized Clinical Trial
2018 · intervention group · Obese adults with BMI 30 kg/m² or above; age range and sex distribution not reported
1 g4 weeks—
Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate
2018 · omega-3 fatty acid group · Patients with schizophrenia taking clozapine and sodium valproate
4 g8 weeks—
Effect of vitamin D and omega-3 on nocturnal enuresis of 7-15-year-old children
2018 · Group B · Children aged 7–15 with nocturnal enuresis
1 g60 days—
Effects of omega-3 polyunsaturated fatty acids on fibrosis, endothelial function and myocardial performance, in ischemic heart failure patients
2019 · intervention arm · Patients with ischemic heart failure; age and sex not specified
2 g8 weeks—
Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927)
2018 · O3-FA · Post-menopausal women with stage I–III breast cancer taking an aromatase inhibitor for at least 90 days and with aromatase inhibitor-related arthralgia; results were analysed separately for BMI <30 and BMI ≥30 kg/m².
3.3 g24 weeks—
Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study)
2018 · PE group (pitavastatin with EPA) · Patients with type 2 diabetes mellitus
1.8 g1 year—
Omega-3 fatty acid supplementation attenuates skeletal muscle disuse atrophy during two weeks of unilateral leg immobilization in healthy young women
2019 · n-3 fatty acid group · Healthy women aged 22 ± 3 years
5 g8 weeks—
Effect of n-3 fatty acids supplementation during life style modification in women with overweight
2018 · LSM & n-3 · Women with overweight
1.5 g12 weeks—
Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women
2020 · omega-3 group · Pregnant women at 12–24 weeks of gestation with Edinburgh Postnatal Depression Scale scores ≥9
1.8 g12 weeks—
Fish oil decreases the severity of treatment-related adverse events in gastrointestinal cancer patients undergoing chemotherapy: A randomized, placebo-controlled, triple-blind clinical trial
2019 · Fish oil group (FOG) · Gastrointestinal cancer patients undergoing chemotherapy; age and sex not specified
1.55 g9 weeks—
Effects of n-3 PUFA on endothelial function in patients with peripheral arterial disease: a randomised, placebo-controlled, double-blind trial
2019 · n-3 PUFA · Adults with stable peripheral arterial disease, Rutherford stage 2 or 3
4 g90 days—
Efficacy of ω-3 supplementation on nutritional status, skeletal muscle, and chemoradiotherapy toxicity in cervical cancer patients: A randomized, triple-blind, clinical trial conducted in a middle-income country
2019 · intervention group · Women with cervical cancer undergoing chemoradiotherapy; average age 44.53 years
2.5 g45 days—
Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction-Post-hoc analysis from the OMEGA-REMODEL randomized controlled trial
2019 · O-3FA · Adults with acute myocardial infarction, treated 2–4 weeks after the event; mean age 59 years and 19% female in the overall cohort
4 g26 weeks—
The Effect of Marine n-3 Polyunsaturated Fatty Acids on Heart Rate Variability in Renal Transplant Recipients: A Randomized Controlled Trial
2019 · marine n-3 PUFA · Adults older than 18 years with a functional kidney graft, 6–8 weeks after renal transplantation
3 g44 weeks—
Efficacy of omega-3 fatty acids and punctal plugs in the prevention of isotretinoin-associated ocular surface disease
2021 · O3FAs/PPs group · Patients receiving systemic isotretinoin therapy; age and sex not specified
1.04 g26 weeks—
ω-3 Ethyl ester results in better cognitive function at 12 and 30 months than control in cognitively healthy subjects with coronary artery disease: a secondary analysis of a randomized clinical trial
2021 · EPA and DHA · Cognitively healthy older adults with stable coronary artery disease receiving statin treatment
3.36 g900 days—
Nutritional Status Predicts Fatty Acid Uptake from Fish and Soybean Oil Supplements for Treatment of Cancer-Related Fatigue: Results from a Phase II Nationwide Study
2021 · 6 g fish oil · Adult female breast cancer survivors aged 18 or older, with stage 0–III cancer, 4–36 months post-treatment and self-reported fatigue
6 g6 weeks—
Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial
2025 · EPA group · Adults with chronic migraine; most participants were female
2 g8 weeks—
Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial
2025 · Omega-3s, without vitamin D3 · Generally healthy, community-dwelling adults aged 70 years or older; men and women
1 g3 years—
Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates
1995 · fish oil group · Patients with rheumatoid arthritis
130 mg/kg30 weeks—
Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study
1994 · 2.6 gm of omega 3 · People with active rheumatoid arthritis; age and sex not stated
2.6 g1 year—
[Fish oils and rheumatoid arthritis. A randomized and double-blind study]
1994 · n-3 PUFA · Patients with active rheumatoid arthritis
3.6 g12 weeks—
Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4
1993 · EPA · Patients with cystic fibrosis colonised with Pseudomonas aeruginosa; age and sex not reported
2.7 g6 weeks—
Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans
1998 · EPA group · Healthy, nonsmoking men aged 36–56 years
4 g——
The effect of prenatal docosahexaenoic acid supplementation on infant outcomes in African American women living in low-income environments: A randomized, controlled trial
2016 · Active supplement (groups B and C; identical doses) · African American pregnant women aged 20–30 living in low-income environments, with sea fish consumption below 2 servings per week
90 mg—43
Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial
2018 · TMN · Adults aged 50 years or older with moderate-to-severe COPD and pre-cachexia or cachexia
4 g12 weeks22
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
650 mg5 years—
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3
2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified
1 g1789 days—
No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18
2019 · Lutein and zeaxanthin plus omega-3 fatty acids · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye
1 g5 years—
Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old
2023 · fish oil + probiotics · Women in early pregnancy
220 mg——
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)
2021 · Omega 3 Polyunsaturated Fatty Acids · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait
113 mg3 years381
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)
2021 · Combined intervention · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait
113 mg3 years374
The Influence of Prenatal DHA Supplementation on Individual Domains of Behavioral Functioning in School-Aged Children: Follow-Up of a Randomized Controlled Trial
2021 · DHA-rich fish oil · Pregnant women with singleton pregnancies enrolled before 21 weeks’ gestation; no specific diagnosed condition stated
100 mg—351
Effect of Omega-3 on HLA-DR Expression by Conjunctival Cells and Tear Cytokine Concentrations in the Dry Eye Assessment and Management Study
2022 · active supplement group (ω3) · Adults with moderate to severe dry eye disease
2 g1 year349
Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye
2015 · O3FA group · Symptomatic computer users using computers more than 3 hours per day for at least 1 year; sex and age not specified; computer vision syndrome-related dry eye
360 mg90 days220
Omega-3 Supplementation for the Prevention of Cognitive Decline in Older Adults: Does It Depend on Homocysteine Levels?
2022 · Omega-3 fatty acid supplementation · Community-dwelling men and women aged 70 years or older without dementia, with spontaneous memory complaints, slow gait speed, or limitations in instrumental activities of daily living
513 mg3 years187
Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial
2023 · Multidomain plus omega 3 · Adults aged 70 years and over, non-demented, with memory complaint, limitation in one instrumental activity of daily living, or slow gait speed
400 mg3 years129
Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials
2021 · DHA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use
270 mg26 weeks113
Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials
2021 · EPA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use
900 mg26 weeks112
Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial
2023 · Omega 3 alone · Adults aged 70 years and over, non-demented, with memory complaint, limitation in one instrumental activity of daily living, or slow gait speed
400 mg3 years112
Cognitive Changes with Omega-3 Polyunsaturated Fatty Acids in Non-Demented Older Adults with Low Omega-3 Index
2017 · n-3 PUFA supplementation group · Men and women aged 70 or older without dementia, with low omega-3 index (≤4.83%) and at least one risk criterion for dementia: subjective memory complaints, limitation in an instrumental activity of daily living, or slow gait speed
513 mg3 years98
Fish oil n-3 polyunsaturated fatty acids selectively affect plasma cytokines and decrease illness in Thai schoolchildren: a randomized, double-blind, placebo-controlled intervention trial
2009 · fish oil · Thai schoolchildren aged 9 to 12 years
200 mg26 weeks94
Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study
2009 · Omega-3/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease
600 mg1 year89
Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study
2019 · omega-3 fatty acid supplementation · Community-based patients with mild to moderate Alzheimer's disease, MMSE ≥15; 88 participants received supplementation
600 mg26 weeks88
Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development
2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required
300 mg26 weeks87
Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study
2009 · Placebo/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease
600 mg26 weeks85
Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension
2011 · PS-DHA treatment group (double-blind phase) · Men and women aged 50–90 years with memory complaints and without dementia
79 mg15 weeks79
Re-Esterified Triglyceride ω-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction: A Randomized Clinical Trial
2024 · ω-3 group · Korean adults aged 20–75 with dry eye disease and concurrent meibomian gland dysfunction; both sexes
1.68 g12 weeks66
The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients
2008 · low-dose medical food emulsion (Trial 2) · Adults with asthma
500 mg4 weeks65
The Effect of Dietary Supplementation on Aggressive Behaviour in Australian Adult Male Prisoners: A Feasibility and Pilot Study for a Randomised, Double Blind Placebo Controlled Trial
2020 · omega-3 group · Adult male prisoners over 18 years at the South Coast Correctional Centre
960 mg16 weeks65
Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA)
2023 · MAG-EPA intervention group · Adult men with aggressive localized prostate cancer (Gleason score ≥ 7, ISUP Grade group ≥ 2) treated by radical prostatectomy
3.3 g1 year65
l-Serine and EPA Relieve Chronic Low-Back and Knee Pain in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
2020 · l-Ser + EPA supplementation group · Adults aged 20 years or older with chronic pain in at least the low back and knee for at least 3 months
149 mg8 weeks60
Effect of a conjugated linoleic acid and omega-3 fatty acid mixture on body composition and adiponectin
2008 · CLA plus n-3 LC-PUFA · Young and older men, ages about 31 and 57 years, both lean and obese
3 g12 weeks59
Effect of Omega-3 fatty acid supplementation on sexual function of pregnant women: a double blind randomized controlled trial
2024 · intervention group · Pregnant women aged 18–42, at 16–22 weeks’ gestation, with sexual dysfunction and low dietary PUFA intake
600 mg8 weeks59
Effects of Marine n-3 Polyunsaturated Fatty Acids on Heart Rate Variability and Heart Rate in Patients on Chronic Dialysis: A Randomized Controlled Trial
2018 · n-3 PUFA group · Adults over 18 years receiving chronic dialysis for more than 3 months
2 g90 days56
Long-chain Polyunsaturated Fatty Acid Supplementation Improves Mood in Elderly Japanese Men
2017 · LCPUFA group · Japanese men aged 55–64 years
100 mg4 weeks51
Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis
2008 · cod liver oil group · Adults with rheumatoid arthritis; age and sex not specified
2.2 g39 weeks49
The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial
2017 · n-3 PUFA · Chinese adults aged 60 years or older with mild cognitive impairment
720 mg26 weeks44
Effect of omega-3 and vitamin D co-supplementation on psychological distress in reproductive-aged women with pre-diabetes and hypovitaminosis D: A randomized controlled trial
2021 · Group 4 Vitamin D + Omega-3 group · Women aged 15–50 with pre-diabetes and hypovitaminosis D
2 g8 weeks42
Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial
2013 · Fish + S · Adults aged 18–60 years with overweight or obesity (BMI 25–37 kg/m²), otherwise healthy
420 mg1 year40
Untitled
2012 · omega-3 PUFA · Healthy adults aged 51–72 years, women and men, with BMI 20–30 kg/m² and no known metabolic disease or cognitive decline
3 g5 weeks38
Does supplementation with leucine-enriched protein alone and in combination with fish-oil-derived n-3 PUFA affect muscle mass, strength, physical performance, and muscle protein synthesis in well-nourished older adults? A randomized, double-blind, placebo-controlled trial
2021 · LEU-PRO plus LC n−3 PUFAs · Men and women aged 65 years or older at increased risk of sarcopenia
4.8 g24 weeks38
Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease
2010 · omega-3 arm · Adults with documented coronary heart disease and current major depressive episode
1.68 g10 weeks36
A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine
2024 · EPA group · Adults with episodic migraine; age and sex range not reported
1.8 g12 weeks35
Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial
2008 · fish oil group · Pregnant women receiving supplementation from 20 weeks’ gestation until delivery; their children were assessed at age 2.5 years
1.1 g—33
Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome
2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation
242 mg/kg1 year33
Effects of the re-esterified triglyceride (rTG) form of omega-3 supplements on dry eye following cataract surgery
2021 · omega-3 group · Adults with newly developed dry-eye symptoms one month after uncomplicated cataract surgery; mean age 65.47 years, 63.6% women
2.19 g8 weeks32
The effects of Omega-3 supplementation on stress, anxiety, depression, sleep quality, and everyday memory in individuals with psychological distress: A randomized, double-blind, placebo-controlled trial
2026 · intervention group · Participants with high levels of stress, anxiety and depression, memory issues, and poor sleep quality
750 mg90 days32
Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial
2017 · FO group · Adults aged 18 years or older with pancreatic carcinoma and tumor-associated weight loss of at least 5% since diagnosis
300 mg6 weeks31
Effect of the omega-3 fatty acid plus vitamin E supplementation on subjective global assessment score, glucose metabolism, and lipid concentrations in chronic hemodialysis patients
2016 · omega-3 fatty acids + vitamin E · Chronic hemodialysis patients; age and sex not specified
1.25 g12 weeks30
The Effect of Omega-3 Fatty Acids in Patients With Active Rheumatoid Arthritis Receiving DMARDs Therapy: Double-Blind Randomized Controlled Trial
2015 · omega-3 group · Adults aged 20-70 with newly diagnosed active rheumatoid arthritis; 49 women and 11 men were enrolled across the study
3.9 g12 weeks30
Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients
2016 · omega-3 fatty acids + alpha-tocopherol · Chronic hemodialysis patients; age and sex not specified
1.25 g12 weeks30
The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
2024 · n-3 PUFAs group · Adults aged 18–65 with major depressive disorder and HRSD-21 score >18
3.2 g12 weeks30
Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial
2021 · DHA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week
270 mg26 weeks29
Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial
2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day
900 mg90 days27
Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial
2021 · EPA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week
900 mg26 weeks27
Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial
2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder
2.13 g12 weeks27
Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment
2018 · FO + BB · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment
1.6 g24 weeks26
An Oral Polyphenol Formulation to Modulate the Ocular Surface Inflammatory Process and to Improve the Symptomatology Associated with Dry Eye Disease
2022 · group A · Adults aged 18–55 with mild to moderate dry eye disease and visual strain who worked looking at a screen for more than 8 hours per day
250 mg12 weeks26
Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus
2015 · fish oil · Adults aged 18–64 with systemic lupus erythematosus
4.5 g26 weeks25
A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone
2019 · omega-3 · People aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum disorders or bipolar I disorder with psychotic features
1.14 g16 weeks25
Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial
2020 · TG1 · Adults aged 35 or older with type 2 diabetes and moderate-to-severe generalized chronic periodontitis
900 mg60 days25
Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial
2020 · TG2 · Adults aged 35 or older with type 2 diabetes and moderate-to-severe generalized chronic periodontitis
900 mg60 days25
Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial
2021 · Risperidone + fish oil (FO) · Patients aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum and bipolar disorder with psychosis
740 mg16 weeks25
An Oral Polyphenol Formulation to Modulate the Ocular Surface Inflammatory Process and to Improve the Symptomatology Associated with Dry Eye Disease
2022 · group A + L · Adults aged 18–55 with mild to moderate dry eye disease and visual strain who worked looking at a screen for more than 8 hours per day
250 mg12 weeks25
Effect of Omega-3 Supplementation in Pregnant Women with Obesity on Newborn Body Composition, Growth and Length of Gestation: A Randomized Controlled Pilot Study
2021 · n-3 PUFA group · Pregnant women with BMI >25 kg/m², aged about 26.9 years on average, with a singleton pregnancy and no stated pre-existing metabolic disorder
2 g25 weeks24
Clinical Assessment of Efficacy of Omega 3 in Oral Submucous Fibrosis Patients - A Randomized Controlled Trial
2022 · Group B · Adults aged 19–52 with grade II or III oral submucous fibrosis; all consumed areca nut
3 g90 days24
The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial
2024 · group 3: both omega-3 and vitamin D supplementation (ω3+VitD) · Women aged 28–64 with newly diagnosed stage II or III breast cancer, before first chemotherapy treatment
600 mg9 weeks24
Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders: secondary analyses of the omega 3 and therapy (OATS) trials
2018 · Ω3 monotherapy · Children aged 7–14 with a depressive disorder, cyclothymic disorder, or bipolar disorder not otherwise specified
2 g12 weeks23
Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial
2007 · n-3 EFA group · Patients presenting after recurrent self-harm
1.2 g12 weeks22
Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders: secondary analyses of the omega 3 and therapy (OATS) trials
2018 · Combined intervention · Children aged 7–14 with a depressive disorder, cyclothymic disorder, or bipolar disorder not otherwise specified; also received PEP therapy
2 g12 weeks22
Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment
2018 · FO · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment
1.6 g24 weeks21
Emotion-Related Network Reorganization Following Fish Oil Supplementation in Depressed Bipolar Offspring: An fMRI Graph-Based Connectome Analysis
2021 · Fish oil · Patients aged 9–21 with a depressive disorder and a biological parent with bipolar I disorder
1.47 g12 weeks21
The Influence of Vitamin E and Omega-3 Fatty Acids on Reproductive Health Indices Among Male Workers Exposed to Electromagnetic Fields
2022 · Omega-3 group · Male workers aged 20–50 years employed for at least 2 years and exposed to electromagnetic fields; no stated fertility diagnosis
300 mg90 days21
Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents
1996 · First group: fish oil followed by placebo · Adolescent girls with dysmenorrhea
1.08 g60 days21
Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents
1996 · Second group: placebo followed by fish oil · Adolescent girls with dysmenorrhea
1.08 g60 days21
Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure
2006 · omega-3 fatty acid · Adults aged 65 years or older with grade II or III chronic heart failure
1.8 g6 weeks20
Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder
2012 · citalopram + omega-3 treatment group · Adults aged 18–65 with major depressive disorder and HAM-D score greater than 17
1 g8 weeks20
Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects
1990 · low-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified
27 mg/kg24 weeks20
The effects of omega-3 and vitamin E co-supplementation on parameters of mental health and gene expression related to insulin and inflammation in subjects with polycystic ovary syndrome
2018 · omega-3 fatty acids plus vitamin E · Women with polycystic ovary syndrome (PCOS)
1 g12 weeks20
Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial
2023 · n-3 PUFAs group · Adults with cardiovascular diseases comorbid with major depressive disorder; mean age 60 ± 9 years, 58% male
2 g12 weeks20
The Influence of Vitamin E and Omega-3 Fatty Acids on Reproductive Health Indices Among Male Workers Exposed to Electromagnetic Fields
2022 · Vitamin E + Omega-3 group · Male workers aged 20–50 years employed for at least 2 years and exposed to electromagnetic fields; no stated fertility diagnosis
300 mg90 days19
Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial
2012 · DHA-rich supplement · Adults older than 65 years with mild cognitive impairment
400 mg26 weeks18
The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery
940 mg30 days18
Omega-3 Fatty Acid Supplementation Improves Endothelial Function in Primary Antiphospholipid Syndrome: A Small-Scale Randomized Double-Blind Placebo-Controlled Trial
2018 · n-3 PUFA (ω-3) group · Adult women aged 27–45 with primary antiphospholipid syndrome
3.1 g16 weeks18
[Polyunsaturated omega-3 fatty acids in the treatment of experimental human gingivitis]
1996 · treatment group · Healthy volunteers; age and sex not specified; no stated condition
1.8 g7 days18
Pilot study on n-3 polyunsaturated fatty acids in the treatment of human experimental gingivitis
1997 · drug (fish oil) group · Healthy volunteers with experimentally induced gingivitis; age and sex not stated
1.8 g8 days18
Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial
2012 · EPA-rich supplement · Adults older than 65 years with mild cognitive impairment
1.67 g26 weeks17
Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects
1990 · high-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified
54 mg/kg24 weeks17
Fish oil supplemented for 9 months does not improve glycaemic control or insulin sensitivity in subjects with impaired glucose regulation: a parallel randomised controlled trial
2016 · Fish oil (FO) · Adults with impaired glucose regulation; age and sex not reported
3.9 g270 days16
Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment
2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified
1.6 g24 weeks15
Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study(‡)
2020 · vitamin D and omega-3 LCPUFA (VIDOM) · Children aged 2.5–8 years with autism spectrum disorder
722 mg1 year15
Long Chain Omega-3 Polyunsaturated Fatty Acids Improve Vascular Stiffness in Abdominal Aortic Aneurysm: A Randomized Controlled Trial
2020 · LC n-3 PUFA capsules · Men aged 60–86 with a small abdominal aortic aneurysm (<5 cm)
1.8 g12 weeks15
Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial
2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis
300 mg90 days15
Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers
2008 · PUFA group · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders
250 mg90 days13
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
2023 · EPA 1 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL)
1 g12 weeks13
Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise
2008 · DHA + EPA · Healthy adult men and women; ages not reported
3 g6 weeks12
Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females
2015 · fish oil (FO) · Community-dwelling females aged 60–76 years in generally good health, with low fish intake and no omega-3 supplement use
3 g12 weeks12
Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial
2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition
600 mg62 days12
Psychoeducational Psychotherapy and Omega-3 Supplementation Improve Co-Occurring Behavioral Problems in Youth with Depression: Results from a Pilot RCT
2017 · combined treatment (PEP + omega-3 supplementation) · Children and adolescents aged 7–14 with depressive disorders
1 g12 weeks12
Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults
2020 · Fish oil group · Healthy physically active men and women aged 60–75 years
2 g12 weeks12
Alleviation of Pain, PAIN Interference, and Oxidative Stress by a Novel Combination of Hemp Oil, Calamari Oil, and Broccoli: A Randomized, Double-Blind, Placebo-Controlled Trial
2023 · intervention group · Adults aged 37–74 with chronic pain at two locations
230 mg12 weeks12
Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study
1992 · fish oil · 11 patients with mild to moderate active ulcerative colitis
4.2 g240 days11
Psychoeducational Psychotherapy and Omega-3 Supplementation Improve Co-Occurring Behavioral Problems in Youth with Depression: Results from a Pilot RCT
2017 · omega-3 monotherapy · Children and adolescents aged 7–14 with depressive disorders
1 g12 weeks11
4-week eicosapentaenoic acid-rich fish oil supplementation partially protects muscular damage following eccentric contractions
2021 · EPA and DHA group · Healthy recreationally untrained men; age range not stated
3 g33 days11
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
2023 · EPA 2 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL)
2 g12 weeks11
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
2023 · EPA 4 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL)
4 g12 weeks11
Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions
2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition
600 mg62 days10
The effect of fish oil supplementation on resistance training-induced adaptations
2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease
2.28 g10 weeks10
Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance
2025 · Omega-3 + USRPT (OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition
680 mg8 weeks10
Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids
2004 · n-3 fatty acid enriched oral nutritional supplement · Adults with unresectable pancreatic cancer, age 65–70 on average, with weight loss and cachexia
2.2 g8 weeks9
Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma
2006 · fish oil diet · Asthmatic patients with documented exercise-induced bronchoconstriction; age and sex not reported
5.2 g3 weeks8
Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study
2017 · ω-3 EFA supplements · Adults with moderate dry eye disease; age and sex not reported
1 g90 days8
Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors
2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training
600 mg62 days8
Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers
2008 · PUFA group, six-month follow-up subset · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders
250 mg90 days6
Effects of Omega-3 Fatty Acids on Resting Cerebral Perfusion in Patients with Mild Cognitive Impairment: A Randomized Controlled Trial
2018 · omega group · Adults aged 50–80 with amnestic mild cognitive impairment
2.2 g26 weeks5
Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids
2001 · dietary n-3FA therapy · Patients with sickle cell disease; age and sex not stated
100 mg/kg30 days—
Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomised clinical trial
2002 · lipid extract group · Patients with steroid-naïve atopic asthma; age and sex not reported
100 mg8 weeks—
Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial
1992 · fish oil · Patients with ulcerative colitis, including patients entering in relapse and patients in remission
4.5 g1 year—
Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis
1992 · Group 2 · Patients with active rheumatoid arthritis
3.8 g16 weeks—
Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis
1992 · Group 3 · Patients with active rheumatoid arthritis
3.8 g16 weeks—
Supplementation of fish oil and olive oil in patients with rheumatoid arthritis
2005 · G3 · Adults with rheumatoid arthritis; 34 women and 9 men across the study, mean age 49 years
3 g24 weeks—
Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study
2007 · omega-3 fatty acids · Children aged 5 to 17 years with autistic disorders accompanied by severe tantrums, aggression, or self-injurious behavior
1.5 g6 weeks—
Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
2006 · omega-3 fatty acid-treated group · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified
600 mg26 weeks—
Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
2006 · placebo group after crossover to omega-3 fatty acid supplementation · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified
600 mg26 weeks—
Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers
2007 · fish oil supplementation · Healthy men aged 26.0 ± 3.1 years
1.8 g4 weeks—
Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia
2007 · Australia DHA+EPA only · Children aged 6–10 years in Australia, described as well-nourished
110 mg1 year—
Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia
2007 · Indonesia DHA+EPA only · Children aged 6–10 years in Indonesia, described as marginally nourished
110 mg1 year—
Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers
2008 · PUFA group · Men admitted to substance-abuse outpatient clinics, with polysubstance abuse and suboptimal dietary intake of long-chain n-3 PUFAs
2.5 g90 days—
Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study
2007 · fish oil group · Women with type 2 diabetes without hypertriglyceridemia
1.8 g60 days—
Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids
2008 · PL-n-3 group · Children aged 8–13 years with impaired visual sustained attention performance
250 mg90 days—
The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study
2011 · drug group · Adults aged 65 years or older with mild to moderate depression
300 mg26 weeks—
Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age
2011 · fish-oil group · healthy pregnant women
150 mg——
Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age
2011 · combined fish-oil and 5-MTHF group · healthy pregnant women
150 mg——
Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study
2012 · n-3 group · Patients with advanced inoperable non-small-cell lung cancer undergoing chemotherapy
510 mg66 days—
Fish oil supplementation improves neutrophil function during cancer chemotherapy
2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated
300 mg8 weeks—
The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial
2014 · omega-3 group · Maintenance hemodialysis patients; age range and sex not reported
540 mg120 days—
Effects of omega-3 fatty acids on tobacco craving in cigarette smokers: A double-blind, randomized, placebo-controlled pilot study
2014 · omega-3 fatty acid supplementation · Regular cigarette smokers
2.71 g30 days—
Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss
2015 · EPA+α-lipoic acid · Healthy overweight or obese women following an energy-restricted diet
1.3 g10 weeks—
Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder
2015 · ADHD Active · Boys aged 8–14 with ADHD
650 mg16 weeks—
Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder
2015 · RG Active · Typically developing boys matched to the ADHD participants for age, hand preference, and BMI
650 mg16 weeks—
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study
2016 · EPA-enriched mix · Adults aged 18–80 with major depressive disorder
1.06 g8 weeks—
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study
2016 · DHA-enriched mix · Adults aged 18–80 with major depressive disorder
180 mg8 weeks—
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · DHA/EPA · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
650 mg5 years—
Change in blood levels of eicosapentaenoic acid and posttraumatic stress symptom: A secondary analysis of data from a placebo-controlled trial of omega3 supplements
2016 · omega3 supplements arm · Participants with severe physical injury; age and sex not reported
147 mg12 weeks—
Effect of an acute dose of omega-3 fish oil following exercise-induced muscle damage
2017 · Low EPA · Physically active males, mean age 26 ± 4 years, after exercise-induced muscle damage
250 mg1 day—
Effect of an acute dose of omega-3 fish oil following exercise-induced muscle damage
2017 · High EPA · Physically active males, mean age 26 ± 4 years, after exercise-induced muscle damage
750 mg1 day—
Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: a randomized controlled trial
2018 · MCP and omega-3 fatty acid group · Colorectal cancer patients on chemotherapy
2 g8 weeks—
Effects of multidomain lifestyle intervention, omega-3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial
2018 · omega-3 supplementation · Community-dwelling adults aged 70 years or older with subjective memory complaints
1.03 g3 years—
Effects of multidomain lifestyle intervention, omega-3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial
2018 · omega-3 plus multidomain intervention · Community-dwelling adults aged 70 years or older with subjective memory complaints
1.03 g3 years—
ω-3 and ω-6 Fatty Acid Supplementation May Reduce Autism Symptoms Based on Parent Report in Preterm Toddlers
2018 · Omega-3-6-9 Junior treatment · Children aged 18–38 months born at 29 weeks’ gestation or earlier, exhibiting early signs of ASD
338 mg90 days—
Effect of vitamin D and omega-3 on nocturnal enuresis of 7-15-year-old children
2018 · Group C · Children aged 7–15 with nocturnal enuresis
1 g60 days—
Adding omega-3 fatty acids to a protein-based supplement during pre-season training results in reduced muscle soreness and the better maintenance of explosive power in professional Rugby Union players
2018 · FO · Professional Rugby Union players undergoing pre-season training; age and sex not stated
3.09 g5 weeks—
Low-Dose Omega-3 Fatty Acid and Vitamin D for Anthropometric, Biochemical Blood Indices and Respiratory Function. Does it work?
2020 · experimental group · Office workers aged 40–60 years; sex and health condition not stated
330 mg16 weeks—
Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: A randomised clinical trial
2022 · omega-3 supplementation (G3) · Children with ADHD; age and sex not specified
775 mg8 weeks—
Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: A randomised clinical trial
2022 · Mediterranean diet plus omega-3 supplementation (G4) · Children with ADHD; age and sex not specified
775 mg8 weeks—
Re-esterified DHA improves ventilatory threshold 2 in competitive amateur cyclists
2020 · DHA · Male amateur cyclists older than 18 years, competing at regional level and training 2–4 sessions per week
1.22 g30 days—
Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women
2021 · omega-3 group (n-3) · Women aged 55–70 who were overweight or obese and postmenopausal
1.95 g16 weeks—
Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women
2021 · omega-3 + resistance training group (n-3+RT) · Women aged 55–70 who were overweight or obese and postmenopausal
1.95 g16 weeks—
Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: a randomised clinical trial
2022 · omega-3 supplementation · children with ADHD
775 mg8 weeks—
Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: a randomised clinical trial
2022 · Mediterranean diet plus omega-3 supplementation · children with ADHD
775 mg8 weeks—
Nutritional Status Predicts Fatty Acid Uptake from Fish and Soybean Oil Supplements for Treatment of Cancer-Related Fatigue: Results from a Phase II Nationwide Study
2021 · 3 g fish oil + 3 g soybean oil · Adult female breast cancer survivors aged 18 or older, with stage 0–III cancer, 4–36 months post-treatment and self-reported fatigue
3 g6 weeks—
Effects of an Omega-3 Supplemented, High-Protein Diet in Combination with Vibration and Resistance Exercise on Muscle Power and Inflammation in Old Adults: A Pilot Randomized Controlled Trial
2022 · high-protein, omega-3-enriched · Community-dwelling adults aged 65–85 years
2.2 g8 weeks—
Effectiveness of a Novel Food Composed of Leucine, Omega-3 Fatty Acids and Probiotic Lactobacillus paracasei PS23 for the Treatment of Sarcopenia in Elderly Subjects: A 2-Month Randomized Double-Blind Placebo-Controlled Trial
2022 · intervention group (OLEP) · men and women aged 55 years or older with sarcopenia
500 mg60 days—
Eicosapentaenoic Acid and Medium-Chain Triacylglycerol Structured Lipids Improve Endurance Performance
2023 · STG group · Sedentary, untrained healthy men; age range not reported
5.24 g58 days—
Eicosapentaenoic Acid and Medium-Chain Triacylglycerol Structured Lipids Improve Endurance Performance
2023 · PM group · Sedentary, untrained healthy men; age range not reported
5.24 g58 days—
The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial
2025 · ω3+VitD group · Women newly diagnosed with breast cancer receiving chemotherapy; age range not reported
600 mg9 weeks—
Omega and heart rate variability in overweight and obese schoolchildren
2025 · interventional (cases) · Children aged 5–12 years, both sexes, with overweight or simple obesity
600 mg90 days—
Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial
2025 · Vitamin D3 and omega-3s, without SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women
1 g3 years—
Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial
2025 · Vitamin D3 and omega-3s with SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women
1 g3 years—
Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study
1994 · 1.3 gm of omega 3 + 3 gm of olive oil · People with active rheumatoid arthritis; age and sex not stated
1.3 g1 year—
Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study
1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported
1.71 g1 year—
Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis
1993 · fish-oil group · Patients with moderate-to-severe psoriasis; age and sex not specified
5 g120 days—
High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study
2018 · phase 1: EPA · Adults with abdominal obesity and subclinical inflammation at risk of cardiovascular disease; 48 men and 106 women enrolled
2.7 g10 weeks154
Marine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial
2021 · n-3 PUFA supplements · Adult kidney transplant recipients with stable kidney function in the early post-transplant phase
2.6 g44 weeks66
Effects of omega-3 on metabolic markers in postmenopausal women with metabolic syndrome
2015 · diet plus omega-3 supplementation · Postmenopausal Brazilian women aged 45 years or older with metabolic syndrome
900 mg26 weeks44
Blood pressure-lowering effects of long chain n-3 fatty acids from meals enriched with liquid fish oil and from microencapsulated powder
2016 · Group 1 · Community-dwelling adults older than 50 years
1.5 g4 weeks38
The effects of low doses of n-3 fatty acid supplementation on blood pressure in hypertensive subjects. A randomized controlled trial
1991 · n-3 fatty acid supplementation · Adults with mild hypertension; age and sex not specified
2.04 g12 weeks33
Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia
2011 · prescription omega-3-acid ethyl esters (POM3) · men and women with primary, isolated hypercholesterolemia (LDL-C 130–220 mg/dL and triglycerides less than 150 mg/dL)
4 g6 weeks31
Blood pressure-lowering effects of long chain n-3 fatty acids from meals enriched with liquid fish oil and from microencapsulated powder
2016 · Group 2 · Community-dwelling adults older than 50 years
1.5 g4 weeks30
Blood pressure lowering in elderly subjects: a double-blind crossover study of omega-3 and omega-6 fatty acids
1991 · fish oil · Elderly subjects aged 60 years or older with hypertension
9 g8 weeks22
Ethyl EPA and ethyl DHA cause similar and differential changes in plasma lipid concentrations and lipid metabolism in subjects with low-grade chronic inflammation
2022 · EPA supplementation · Adults aged 50–75 with low-grade chronic inflammation and at least one characteristic of metabolic syndrome; women were postmenopausal
3 g10 weeks21
Effects of fish oil, nifedipine and their combination on blood pressure and lipids in primary hypertension
1993 · fish oil treatment · 18 males with primary hypertension (WHO stage I–II) and elevated lipid levels
4.55 g4 weeks18
The Effects of Omega-3 Supplementation Combined with Strength Training on Neuro-Biomarkers, Inflammatory and Antioxidant Responses, and the Lipid Profile in Physically Healthy Adults
2025 · experimental group (omega-3 supplementation group) · healthy, resistance-trained males aged 18–30 years
3.15 g8 weeks15
Effect of sodium restriction and fish oil supplementation on BP and thrombotic risk factors in patients treated with ACE inhibitors
1994 · Low sodium with fish oil · Patients with hypertension treated with captopril or enalapril
5 g6 weeks14
Effect of sodium restriction and fish oil supplementation on BP and thrombotic risk factors in patients treated with ACE inhibitors
1994 · Normal sodium with fish oil · Patients with hypertension treated with captopril or enalapril
5 g6 weeks14
Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients
1997 · omega-3 fatty acids treatment group · heart transplant recipients, from the fourth postoperative day
4 g26 weeks14
n-3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects
1990 · group 1 · Hypertriglyceridemic subjects; age range and sex not reported
2.2 g20 weeks10
Cyclosporine-induced hypertension. Efficacy of omega-3 fatty acids in patients after cardiac transplantation
1993 · omega-3 fatty acids treatment group · Hypertensive cardiac transplant recipients treated with cyclosporine
3 g12 weeks10
Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans
1999 · purified EPA · overweight, mildly hyperlipidemic men
4 g6 weeks—
Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients
2001 · omega-3 fatty acids · Hypertensive heart transplant recipients, studied 1–12 years after transplantation
3.4 g1 year—
Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia
2005 · omega-3 FA + placebo · Patients with type II hypercholesterolaemia
2 g8 weeks—
The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial
2009 · omega3FA · Nondiabetic patients with stage 3–4 chronic kidney disease
4 g8 weeks—
n-3 fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants
1990 · EPA plus DHA diet · Normotensive and mildly hypercholesterolemic men
3.4 g6 weeks—
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy
2010 · P-OM3 · Men and women with high triglycerides (200 to 499 mg/dl) and mixed dyslipidemia receiving diet plus simvastatin therapy
4 g8 weeks—
Preliminary evidence that acute long-chain omega-3 supplementation reduces cardiovascular reactivity to mental stress: a randomized and placebo controlled trial
2012 · omega-3 fatty acids · young, healthy individuals
1.4 g3 weeks—
Untitled
2012 · fish oil group · Women with metabolic syndrome; mean age 47.9 years
3 g90 days—
Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients
2013 · 1.8 g/d ω-3 PUFA group · Non-dialyzed patients with stage IV/V chronic kidney disease; age and sex not stated
1.8 g10 weeks—
Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults
2014 · 0.45 g/d EPA and DHA · Healthy adults; age range and sex not stated
450 mg1 year—
Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults
2014 · 0.9 g/d EPA and DHA · Healthy adults; age range and sex not stated
900 mg1 year—
Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults
2014 · 1.8 g/d EPA and DHA · Healthy adults; age range and sex not stated
1.8 g1 year—
Lipidomic changes of LDL in overweight and moderately hypercholesterolemic subjects taking phytosterol- and omega-3-supplemented milk
2015 · ω3-milk · Overweight and moderately hypercholesterolemic subjects; age and sex not specified
375 mg4 weeks—
Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives
1998 · daily fish meal · Overweight adults with medication-treated hypertension
3.65 g16 weeks—
Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives
1998 · fish meal plus weight reduction · Overweight adults with medication-treated hypertension
3.65 g16 weeks—
The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial
2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition
1 g18 weeks134
Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years: a randomized, double-blind, placebo-controlled, stratified, parallel-group trial
2015 · omega-3 group · Children aged 8–16 years living in the community
2 g26 weeks100
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
100 mg12 weeks96
Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial
2017 · PCSO-524® · Children and adolescents aged 6–14 years with elevated ADHD symptoms, including participants with and without an ADHD diagnosis
38.4 mg14 weeks74
Nutritional supplementation to reduce child aggression: a randomized, stratified, single-blind, factorial trial
2016 · Nutrition + CBT · Children aged 11–12 years at high risk for aggression or antisocial behavior, including full or borderline conduct disorder or oppositional defiant disorder criteria, or elevated proactive or reactive aggression scores
1 g90 days73
Effects of a 6-Month Multifaceted Diet and Exercise Intervention on Cognition in Older Adults at Risk of Cognitive Decline: The PONDER Double-Blind, Placebo-Controlled Randomized Trial
2022 · Multimodal exercise program with daily supplement · Community-dwelling older adults with subjective memory impairment; mean age 70.2 years, 70% female
1.5 g26 weeks73
Nutritional supplementation to reduce child aggression: a randomized, stratified, single-blind, factorial trial
2016 · Nutrition only · Children aged 11–12 years at high risk for aggression or antisocial behavior, including full or borderline conduct disorder or oppositional defiant disorder criteria, or elevated proactive or reactive aggression scores
1 g90 days72
Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
2016 · n-3 PUFA treatment · Men and women aged 45–80 with stable coronary artery disease participating in cardiac rehabilitation, with or without a depressive episode
1.9 g12 weeks46
Association between cognitive function and supplementation with omega-3 PUFAs and other nutrients in ≥ 75 years old patients: A randomized multicenter study
2018 · intervention group · Institutionalized adults aged 75 years or older without dementia, with or without mild cognitive impairment
870 mg1 year44
Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids
2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis
1.42 g12 weeks40
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
100 mg24 weeks40
TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD
2007 · Sham MCS and nutritional supplement · Adults aged 50–90 with dry age-related macular degeneration in at least one eye
300 mg24 weeks37
A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction
2013 · Group B (study oral supplement formulation, Brudysec 1.5 g) · Adults aged 23–85 years, both sexes, diagnosed with meibomian gland dysfunction
1.27 g90 days33
Lipid Profile, Lipoprotein Subfractions, and Fluidity of Membranes in Children and Adolescents with Depressive Disorder: Effect of Omega-3 Fatty Acids in a Double-Blind Randomized Controlled Study
2020 · Om3 group · Children and adolescents aged 11–17 years with depressive disorder or mixed anxiety and depressive disorder
4.15 g12 weeks29
The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis
2021 · OMEGA group · Adults with relapsing-remitting multiple sclerosis; mean age 38.4 years (SD 7.1)
4.95 g2 years27
Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children
2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis
600 mg120 days26
Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial
2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis
2.6 g26 weeks24
The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment
2020 · omega supplementation group · Adults aged 65 years or older with mild cognitive impairment
810 mg26 weeks23
Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study
2011 · EPA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions
590 mg30 days22
Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study
2011 · DHA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions
159 mg30 days22
Benefits of Krill Oil Supplementation During Alternate-Day Fasting in Adults With Overweight and Obesity: A Randomized Trial
2025 · KO group · Healthy adults aged 25–65 with BMI >25 kg/m² and overweight or obesity; 25 women and 16 men enrolled
570 mg12 weeks21
Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial
2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis
2.6 g90 days20
Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: A randomized, double-blind, placebo-controlled trial
2021 · Neuroaspis PLP10™ · Patients with Parkinson's disease; age and sex not reported.
810 mg913 days20
Antioxidant and Anti-Inflammatory Effects of Oral Supplementation with a Highly-Concentrated Docosahexaenoic Acid (DHA) Triglyceride in Patients with Keratoconus: A Randomized Controlled Preliminary Study
2023 · DHA group · Adults aged 18 years or older with stage I–III keratoconus
602 mg90 days19
21 days of mammalian omega-3 fatty acid supplementation improves aspects of neuromuscular function and performance in male athletes compared to olive oil placebo
2015 · N-3 PUFA · Healthy male athletes competing in summer Olympic sports; ages not otherwise specified
10 g3 weeks18
An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553]
2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress
120 mg6 weeks16
A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study
2016 · Efalex Active 50+ intervention · Women aged 60 years and older, community-dwelling and able to walk at least 50 m and negotiate stairs independently; nonacutely ill
160 mg24 weeks15
A multicomponent intervention consisting of exercise, proteins and omega-3 supplementation to improve sarcopenia in community-dwelling older adults: Lessons learned from a 5-armed randomized controlled feasibility trial
2026 · Exercise intervention + protein supplementation + omega-3 (group 4) · Adults aged 65 years or older with sarcopenia; women and men
950 mg12 weeks12
A Combination of Essential Fatty Acids, Panax Ginseng Extract, and Green Tea Catechins Modifies Brain fMRI Signals in Healthy Older Adults
2018 · Investigational product (Cerbella) · Adults aged 55–75 years who were cognitively healthy and non-demented
1.58 g26 days10
Effects of Supplementation with Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins, Combined with High-Intensity Functional Training, on Exercise Performance and Body Composition: A Randomized, Double-Blind, Placebo-Controlled Trial
2024 · experimental supplement group (SG) · Healthy young adult women and men, aged approximately 29 years, familiar with high-intensity functional training and with at least 6 months of similar exercise experience
6.9 g8 weeks10
Eicosapentaenoic Acid and Medium-Chain Triacylglycerol Structured Lipid Supplementation Improves Muscular Endurance Exercise Performance and Reduces Muscle Fatigue in Young Healthy Male
2025 · EPA/MCT group · Healthy young men
600 mg8 weeks10
Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance
2025 · Probiotics + Omega-3 + USRPT (PRO + OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition
680 mg8 weeks10
Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients
1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported
216 mg6 weeks—
Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia
2007 · Australia micronutrient mix plus DHA+EPA · Children aged 6–10 years in Australia, described as well-nourished
110 mg1 year—
Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia
2007 · Indonesia micronutrient mix plus DHA+EPA · Children aged 6–10 years in Indonesia, described as marginally nourished
110 mg1 year—
Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders
2013 · DEDG+S · Adults aged 23–80 years, both sexes, with mild-to-moderate dry eye disorders
845 mg90 days—
Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders
2013 · CG+S · Healthy adults aged 23–80 years, both sexes
845 mg90 days—
B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial
2014 · B vitamins plus n-3 fatty acids · Adults aged 45–80 with a recent history of myocardial infarction, unstable angina, or ischemic stroke
600 mg1716 days—
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
650 mg5 years—
Effect of Omega-3 and -6 Supplementation on Language in Preterm Toddlers Exhibiting Autism Spectrum Disorder Symptoms
2017 · treatment group · Children aged 18–38 months, born before 30 completed gestational weeks, screened as at risk for ASD
563 mg90 days—
Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial
2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms
706 mg90 days—
EPA and DHA as markers of nutraceutical treatment response in major depressive disorder
2020 · combination nutraceutical · Adults with major depressive disorder; age and sex not reported
1 g8 weeks—
Effects of a Long Chain n-3 Polyunsaturated Fatty Acid-rich Multi-ingredient Nutrition Supplement on Body Composition and Physical Function in Older Adults with Low Skeletal Muscle Mass
2022 · supplement (SUPP) · Community-dwelling older adults with low skeletal muscle mass; mean age 74.9 years; 18 men and 19 women in the study overall
3 g26 weeks—
Supplemental Protein and a Multinutrient Beverage Speed Wound Healing after Acute Sleep Restriction in Healthy Adults
2022 · NUT · Generally healthy young adults aged 18–approximately 20 years (18 males and 2 females), after acute sleep restriction
1 g7 days—
Effects of Omega-3-6-9 fatty acid supplementation on behavior and sleep in preterm toddlers with autism symptomatology: Secondary analysis of a randomized clinical trial
2022 · omega 3-6-9 treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation, with symptoms commonly associated with autism spectrum disorder
1.04 g90 days—
Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation
2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²)
1.95 g16 weeks—
Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation
2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²)
1.95 g16 weeks—
Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension
2011 · PS-DHA continuers (open-label extension) · Men and women aged 50–90 years with memory complaints who had received PS-DHA in the double-blind phase
26 mg15 weeks61
Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension
2011 · PS-DHA naive group (open-label extension) · Men and women aged 50–90 years with memory complaints who had received placebo during the double-blind phase
26 mg15 weeks61
Evaluating the Impact of Omega-3 Fatty Acid (Soloways(TM)) Supplementation on Lipid Profiles in Adults with PPARG Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial
2023 · omega-3 fatty acids group · Adults aged 40–75 with LDL-C levels of 70–190 mg/dL and low-to-moderate cardiovascular risk, including participants with and without PPARG polymorphisms
1.8 g90 days51
Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study
2018 · FO concentrate · Obese men and women with BMI >30
1.6 g12 weeks12
Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia
2005 · omega-3 FA + policosanol 5 mg/day · Patients with type II hypercholesterolaemia
2 g8 weeks—
Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia
2005 · omega-3 FA + policosanol 10 mg/day · Patients with type II hypercholesterolaemia
2 g8 weeks—
The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial
2009 · both supplements · Nondiabetic patients with stage 3–4 chronic kidney disease
4 g8 weeks—
Untitled
2012 · fish oil and kinako group · Women with metabolic syndrome; mean age 47.9 years
3 g90 days—
Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis
2016 · Fish oil providing 0.7 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31.
700 mg8 weeks—
Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis
2016 · Fish oil providing 1.8 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31.
1.8 g8 weeks—
Effect of combined use of a low-carbohydrate, high-protein diet with omega-3 polyunsaturated fatty acid supplementation on glycemic control in newly diagnosed type 2 diabetes: a randomized, double-blind, parallel-controlled trial
2018 · ω-3 diet group · Newly diagnosed participants with type 2 diabetes; age and sex not reported
3.65 g12 weeks—
Effect of combined use of a low-carbohydrate, high-protein diet with omega-3 polyunsaturated fatty acid supplementation on glycemic control in newly diagnosed type 2 diabetes: a randomized, double-blind, parallel-controlled trial
2018 · LCHP+ω-3 diet group · Newly diagnosed participants with type 2 diabetes; age and sex not reported
3.65 g12 weeks—
Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the Trials of Hypertension Prevention
1994 · fish oil group · Normotensive men and women aged 30–54 years
3 g26 weeks—
Effects of 12-week supplementation of marine Omega-3 PUFA-based formulation Omega3Q10 in older adults with prehypertension and/or elevated blood cholesterol
2017 · Omega3Q10 treatment group · Adults aged at least 50 years with elevated blood pressure and/or elevated blood cholesterol
514 mg12 weeks48
Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects
2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia
1.7 g4 weeks21
Reduction in Serum LDL Cholesterol Using a Nutrient Compendium in Hyperlipidemic Adults Unable or Unwilling to Use Statin Therapy: A Double-Blind Randomized Crossover Clinical Trial
2022 · Treatment foods · Adult men and women with hyperlipidemia who were unable or unwilling to use statin therapy
2 g4 weeks—
Supplementation with high-dose docosahexaenoic acid increases the Omega-3 Index more than high-dose eicosapentaenoic acid
2017 · EPA treatment phase · Men and women with abdominal obesity and subclinical inflammation; ages not reported
2.7 g10 weeks154
The effects of omega-3 fatty acid supplementation in pregnancy on maternal eicosanoid, cytokine, and chemokine secretion
2009 · omega-3 LCPUFA · Pregnant women with allergic disease in their immediate family
2.7 g—70
Omega-3 Eicosapentaenoic Acid (EPA) Rich Extract from the Microalga Nannochloropsis Decreases Cholesterol in Healthy Individuals: A Double-Blind, Randomized, Placebo-Controlled, Three-Month Supplementation Study
2020 · active intervention group · Generally healthy men and women over 25 years of age with low omega-3 index
1 g12 weeks60
Bioavailability of long-chain n-3 fatty acids from enriched meals and from microencapsulated powder
2015 · Group 1 · Adults aged 50 years or older; no condition stated
1.5 g4 weeks38
FADS1 Genetic Variant and Omega-3 Supplementation Are Associated with Changes in Fatty Acid Composition in Red Blood Cells of Subjects with Obesity
2024 · omega-3 group · Men and women aged 30 to 50 years with obesity
1.5 g120 days38
Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial
2023 · treatment group (study group) · Full-term neonates with intrauterine growth restriction (IUGR)
40 mg/kg2 weeks35
Omega-3 decreases IL-6 levels in HIV and human herpesvirus-8 coinfected patients in Uganda
2018 · ω-3 arm · Adults aged 18 years or older with HIV and HHV-8 coinfection, including participants with early-stage Kaposi sarcoma
3 g12 weeks33
Dietary supplementation with seed oil from transgenic Camelina sativa induces similar increments in plasma and erythrocyte DHA and EPA to fish oil in healthy humans
2020 · Camelina sativa seed oil (CSO) · Healthy men and women aged 20–74 years
450 mg8 weeks31
Bioavailability of long-chain n-3 fatty acids from enriched meals and from microencapsulated powder
2015 · Group 2 · Adults aged 50 years or older; no condition stated
1.5 g4 weeks30
Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents
2010 · n-3 treatment · Obese adolescents, 14 female and 11 male, mean age 15.7 years
1.2 g90 days25
Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid Technologies(TM) (ALT(®))-based formulation
2017 · SC401 under fasted, low-fat meal, and high-fat meal conditions · 24 healthy subjects
1.53 g1 day24
Essential fatty acid status in neonates after fish-oil supplementation during late pregnancy
1995 · fish-oil-supplemented group · Healthy pregnant women, from the 30th week of gestation until delivery
2.7 g—23
Oral Bioavailability of Omega-3 Fatty Acids and Carotenoids from the Microalgae Phaeodactylum tricornutum in Healthy Young Adults
2021 · Fish oil (FO) capsule · Healthy adults aged 18–50 years, women and men
310 mg2 weeks22
Equal bioavailability of omega-3 PUFA from Calanus oil, fish oil and krill oil: A 12-week randomized parallel study
2023 · CO group · Healthy volunteers; mean age 29.7 years; sex not specified
242 mg12 weeks21
Dietary supplementation with very long-chain n-3 fatty acids in man decreases expression of the interleukin-2 receptor (CD25) on mitogen-stimulated lymphocytes from patients with inflammatory skin diseases
1994 · n-3 fatty acids group · Patients with psoriasis or atopic dermatitis; ages and sex not stated
6 g120 days21
Preoperative oral supplementation with long-chain Omega-3 fatty acids beneficially alters phospholipid fatty acid patterns in liver, gut mucosa, and tumor tissue
2005 · PUFA group · Patients with malignancies of the upper gastrointestinal tract undergoing major gastrointestinal surgery; age and sex not specified
3.7 g5 days20
Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial
2021 · monoglyceride rich oil (MAG) · Healthy men and women aged 18–60 years
3 g1 day20
Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial
2021 · ethyl ester (EE) · Healthy men and women aged 18–60 years
3 g1 day20
A novel n-3 glyceride mixture enhances enrichment of EPA and DHA after single dosing in healthy older adults: results from a double-blind crossover trial
2021 · glyceride-EPA + DHA formulation · Healthy adults aged 50–70 years
2.8 g1 day20
A novel n-3 glyceride mixture enhances enrichment of EPA and DHA after single dosing in healthy older adults: results from a double-blind crossover trial
2021 · ethyl ester EPA + DHA formulation · Healthy adults aged 50–70 years
2.8 g1 day20
Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study
2007 · fish oil group · Haemodialysis patients; age and sex not reported
1.3 g12 weeks18
Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study
2014 · n-3 FA supplement group · Patients with mild Alzheimer's disease
2.3 g26 weeks18
Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels
2012 · rosuvastatin 10 mg plus omega-3 fatty acids 2 g · Patients with mixed dyslipidemia and LDL cholesterol above 160 mg/dL plus triglycerides above 200 mg/dL
2 g90 days17
Effect of Omega-3 and Vitamins E + C Supplements on the Concentration of Serum B-Vitamins and Plasma Redox Aminothiol Antioxidant Status in Elderly Men after Strength Training for Three Months
2016 · group II · Healthy men, mean age 60 ± 6 years, undertaking strength training
700 mg90 days17
Incorporation of n-3 PUFA and γ-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial
2011 · n-3 LC-PUFA (group 1) · Adults aged 18–90 with rheumatoid arthritis or psoriatic arthritis and at least medium disease activity
3 g12 weeks15
Evidence of muscle loss delay and improvement of hyperinsulinemia and insulin resistance in Duchenne muscular dystrophy supplemented with omega-3 fatty acids: A randomized study
2019 · Ω-3LCPUFA group · Boys with Duchenne muscular dystrophy; age range not stated
2.9 g26 weeks14
Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers
2019 · 1 g group · healthy volunteers following a Therapeutic Lifestyle Change diet
1 g15 days14
Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers
2019 · 2 g group · healthy volunteers following a Therapeutic Lifestyle Change diet
2 g15 days14
Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers
2019 · 4 g group · healthy volunteers following a Therapeutic Lifestyle Change diet
4 g15 days14
Effect of Food with Low Enrichment of N-3 Fatty Acids in a Two-Month Diet on the Fatty Acid Content in the Plasma and Erythrocytes and on Cardiovascular Risk Markers in Healthy Young Men
2020 · omega-3 group · Healthy men aged 18–25 years
37 mg8 weeks14
Incorporation of eicosapentaenioic and docosahexaenoic acids into breast adipose tissue of women at high risk of breast cancer: a randomized clinical trial of dietary fish and n-3 fatty acid capsules
2015 · n-3 PUFA capsules · Women aged 18 years or older at high risk for breast cancer
1.8 g90 days13
Erythrocyte eicosapentaenoic acid versus docosahexaenoic acid as a marker for fish and fish oil consumption
1991 · Fish + Oil · Healthy men; age not reported
5 g6 weeks12
Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study
2020 · OM3-EE 4 g once daily · Adults aged 18 years or older with severe hypertriglyceridemia and a history of hospitalization for acute hypertriglyceridemia-induced pancreatitis
4 g4 weeks12
Erythrocyte eicosapentaenoic acid versus docosahexaenoic acid as a marker for fish and fish oil consumption
1991 · Fish oil alone · Healthy men; age not reported
5 g6 weeks11
Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker
2008 · SDA-SBO · Overweight healthy volunteers
24 mL16 weeks11
Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker
2008 · EPA ethyl esters · Overweight healthy volunteers
1 g16 weeks11
A short-term n-3 DPA supplementation study in humans
2013 · DPA supplementation · Adult female participants; age and health status not specified
1.14 g7 days10
A short-term n-3 DPA supplementation study in humans
2013 · EPA supplementation · Adult female participants; age and health status not specified
1.14 g7 days10
The impact of non-surgical periodontal treatment on serum levels of long chain-polyunsaturated fatty acids: a pilot randomized clinical trial
2014 · test group · Adults with generalized chronic periodontitis; mean age 44 years (10 participants)
3 g120 days10
Use of manufactured foods enriched with fish oils as a means of increasing long-chain n-3 polyunsaturated fatty acid intake
1997 · n-3 enriched · Healthy, normotriacylglycerolaemic men aged 35–60 years
1.4 g22 days9
Enhanced Production of EPA-Derived Anti-Inflammatory Metabolites after Oral Administration of a Novel Self-Emulsifying Highly Purified EPA Ethyl Ester Formulation (MND-2119)
2023 · MND-2119 2-g group · Healthy men aged 20–40 years
2 g7 days8
Enhanced Production of EPA-Derived Anti-Inflammatory Metabolites after Oral Administration of a Novel Self-Emulsifying Highly Purified EPA Ethyl Ester Formulation (MND-2119)
2023 · MND-2119 4-g group · Healthy men aged 20–40 years
4 g7 days8
Enhanced Production of EPA-Derived Anti-Inflammatory Metabolites after Oral Administration of a Novel Self-Emulsifying Highly Purified EPA Ethyl Ester Formulation (MND-2119)
2023 · EPA-E 1.8-g group · Healthy men aged 20–40 years
1.8 g7 days8
Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study
2020 · OM3-CA 2 g once daily · Adults aged 18 years or older with severe hypertriglyceridemia and a history of hospitalization for acute hypertriglyceridemia-induced pancreatitis
2 g4 weeks6
Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study
2020 · OM3-CA 4 g once daily · Adults aged 18 years or older with severe hypertriglyceridemia and a history of hospitalization for acute hypertriglyceridemia-induced pancreatitis
4 g4 weeks6
Bioavailability of n-3 polyunsaturated fatty acids (PUFA) in foods enriched with microencapsulated fish oil
2000 · capsule group · Healthy female volunteers
900 mg4 weeks—
Fatty acid composition of skeletal muscle reflects dietary fat composition in humans
2002 · Fish oil supplementation in the SFA diet group · Healthy adults (25 men and 7 women); exact numbers in this diet group not reported
3.6 g90 days—
Fatty acid composition of skeletal muscle reflects dietary fat composition in humans
2002 · Fish oil supplementation in the MUFA diet group · Healthy adults (25 men and 7 women); exact numbers in this diet group not reported
3.6 g90 days—
The influence of different combinations of gamma-linolenic, stearidonic and eicosapentaenoic acids on the fatty acid composition of blood lipids and mononuclear cells in human volunteers
2004 · STA-rich oil intake (STA alone; amount varied) · Healthy young males
1 g12 weeks—
The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters
2006 · 62.5% concentration · Adults; age and sex not reported; no condition specified
5.1 g2 weeks—
The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters
2006 · 80% concentration · Adults; age and sex not reported; no condition specified
5.1 g2 weeks—
The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters
2006 · 85% concentration · Adults; age and sex not reported; no condition specified
5.1 g2 weeks—
Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids on erythrocyte n-3 levels and cardiovascular risk factors
2007 · n-3-enriched foods · Overweight adults with triacylglycerol levels above 1.6 mmol/L
1 g26 weeks—
Effect of n-3 polyunsaturated fatty acids on Barrett's epithelium in the human lower esophagus
2008 · EPA group · Patients with Barrett's esophagus; age and sex not specified
1.5 g26 weeks—
Regular consumption of n-3 fatty acid-enriched pork modifies cardiovascular risk factors
2009 · n-3-enriched pork · Healthy adult volunteers
186 mg12 weeks—
Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers
2009 · test formulation · healthy subjects
3 g4 weeks—
Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers
2009 · reference formulation · healthy subjects
3 g4 weeks—
The incorporation of marine n-3 PUFA into platelets and adipose tissue in pre- and postmenopausal women: a randomised, double-blind, placebo-controlled trial
2010 · Marine n-3 PUFA (fish oil) · Pre- and postmenopausal women
2.2 g12 weeks—
Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition
2010 · 1 capsule/day · Women at high risk of breast cancer
840 mg26 weeks—
Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition
2010 · 3 capsules/day · Women at high risk of breast cancer
2.52 g26 weeks—
Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition
2010 · 6 capsules/day · Women at high risk of breast cancer
5.04 g26 weeks—
Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition
2010 · 9 capsules/day · Women at high risk of breast cancer
7.56 g26 weeks—
Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content
2012 · SDA 0.43 g/d · Healthy subjects; age and sex not specified
430 mg12 weeks—
Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content
2012 · SDA 1.3 g/d · Healthy subjects; age and sex not specified
1.3 g12 weeks—
Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content
2012 · SDA 2.6 g/d · Healthy subjects; age and sex not specified
2.6 g12 weeks—
Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content
2012 · SDA 5.2 g/d · Healthy subjects; age and sex not specified
5.2 g12 weeks—
Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content
2012 · EPA 0.44 g/d · Healthy subjects; age and sex not specified
440 mg12 weeks—
Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content
2012 · EPA 1.3 g/d · Healthy subjects; age and sex not specified
1.3 g12 weeks—
Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content
2012 · EPA 2.7 g/d · Healthy subjects; age and sex not specified
2.7 g12 weeks—
Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients
2012 · omega-3 FA supplement · Adults with end-stage kidney disease treated with dialysis for at least 1 year; mean age 57.4 years
3 g26 weeks—
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study
2012 · OM-3 FFA during low-fat consumption period · Overweight adults; age and sex not specified
4 g1 day—
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study
2012 · OM-3 FFA during high-fat consumption period · Overweight adults; age and sex not specified
4 g1 day—
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study
2012 · OM-3 EE during low-fat consumption period · Overweight adults; age and sex not specified
4 g1 day—
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study
2012 · OM-3 EE during high-fat consumption period · Overweight adults; age and sex not specified
4 g1 day—
Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors
2013 · yoghurt enriched with 3 g n-3 LC-PUFA/d · Mildly hypertriacylglycerolemic subjects with TAG ≥ 1.7 mmol/L; age and sex not specified
3 g10 weeks—
Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality
2013 · n-3 PUFA · Patients with chronic heart failure
1 g90 days—
Do fish oil omega-3 fatty acids enhance antioxidant capacity and mitochondrial fatty acid oxidation in human atrial myocardium via PPARγ activation?
2014 · n-3 PUFA-treated patients · Patients undergoing elective cardiac surgery; age and sex not specified
3.4 g3 weeks—
Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation
2015 · Study 2: 850 mg/day EPA + DHA · Adults aged 22–65 years with moderately elevated triglycerides and low habitual oily-fish consumption
850 mg8 weeks—
Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation
2015 · Study 2: 3400 mg/day EPA + DHA · Adults aged 22–65 years with moderately elevated triglycerides and low habitual oily-fish consumption
3.4 g8 weeks—
Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study
2015 · ω3 FA supplementation group · Adults aged 74 ± 9 years with mild to moderate Alzheimer's disease
2.3 g26 weeks—
High levels of omega-3 fatty acids in milk from omega-3 fatty acid-supplemented mothers are related to less immunoglobulin E-associated disease in infancy
2016 · omega-3 LCPUFA group · Pregnant women at risk of having an allergic infant
2.6 g——
Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure trial
2016 · O3AEE group · Patients with heart failure; age and sex not reported
1 g90 days—
Potential therapeutic impact of omega-3 long chain-polyunsaturated fatty acids on inflammation markers in Duchenne muscular dystrophy: A double-blind, controlled randomized trial
2018 · ω-3 long chain-PUFA · boys with Duchenne muscular dystrophy
2.9 g26 weeks—
Effects of a Self-micro-emulsifying Delivery System Formulation Versus a Standard ω-3 Acid Ethyl Ester Product on the Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid: A Study in Healthy Men and Women in a Fasted State
2018 · SMEDS treatment · Healthy men and women; mean age 33.8 years
500 mg1 day—
Effects of a Self-micro-emulsifying Delivery System Formulation Versus a Standard ω-3 Acid Ethyl Ester Product on the Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid: A Study in Healthy Men and Women in a Fasted State
2018 · EE treatment · Healthy men and women; mean age 33.8 years
840 mg1 day—
Compound-specific isotope analysis reveals no retroconversion of DHA to EPA but substantial conversion of EPA to DHA following supplementation: a randomized control trial
2019 · EPA group · Adults aged 21.6 ± 2.2 years; no condition stated
3 g12 weeks—
Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study
2020 · EPA · Healthy women; age range not reported
1 g6 days—
Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study
2020 · DPA · Healthy women; age range not reported
1 g6 days—
Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms
2020 · OM3-MAG (clinical trial A) · Healthy adults, both sexes, normal weight, on a low-fat diet
1 g1 day—
Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms
2020 · OM3-ethyl ester (clinical trial A) · Healthy adults, both sexes, normal weight, on a low-fat diet
1 g1 day—
Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms
2020 · OM3-FFA (clinical trial A) · Healthy adults, both sexes, normal weight, on a low-fat diet
1 g1 day—
Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms
2020 · OM3-MAG (clinical trial B) · Overweight or obese healthy adults, both sexes
380 mg1 day—
Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms
2020 · OM3-TAG (clinical trial B) · Overweight or obese healthy adults, both sexes
380 mg1 day—
High Variability in Erythrocyte, Plasma and Whole Blood EPA and DHA Levels in Response to Supplementation
2020 · 0.35 g/day group · Premenopausal women aged 18–39 with mildly elevated triglycerides and regular menstrual cycles
350 mg8 weeks—
High Variability in Erythrocyte, Plasma and Whole Blood EPA and DHA Levels in Response to Supplementation
2020 · 0.7 g/day group · Premenopausal women aged 18–39 with mildly elevated triglycerides and regular menstrual cycles
700 mg8 weeks—
High Variability in Erythrocyte, Plasma and Whole Blood EPA and DHA Levels in Response to Supplementation
2020 · 1.0 g/day group · Premenopausal women aged 18–39 with mildly elevated triglycerides and regular menstrual cycles
1 g8 weeks—
Comparison of the Effect of Omega-3 vs. MCT Supplementation on Iron-Related Indices in Patients Undergoing Dialysis
2025 · omega-3 group · Patients with chronic kidney disease undergoing dialysis; age and sex not reported
3 g8 weeks—
The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp Prevention Trial
2025 · EPA-FFA group · High-risk adults undergoing colonoscopy surveillance after removal of multiple colorectal polyps; age and sex not specified
2 g1 year—
The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp Prevention Trial
2025 · EPA-TG group · High-risk adults undergoing colonoscopy surveillance after removal of multiple colorectal polyps; age and sex not specified
2.78 g1 year—
Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors - impact on breast adipose oxylipin and DNA methylation patterns
2025 · ∼5 g/d EPA+DHA · Female breast cancer survivors with ERPR-negative stage 0–III cancer, within 5 years of completing standard therapy
5 g1 year—
Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors - impact on breast adipose oxylipin and DNA methylation patterns
2025 · ∼1 g/d EPA+DHA · Female breast cancer survivors with ERPR-negative stage 0–III cancer, within 5 years of completing standard therapy
1 g1 year—
Effects of vitamin D, omega-3 and a simple strength exercise programme in cardiovascular disease prevention: The DO-HEALTH randomized controlled trial
2024 · Omega-3 · Community-dwelling adults aged 70 years and older, generally healthy and active, without major chronic conditions
1 g3 years1,073
Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial
2025 · Omega-3 group · Generally healthy, community-dwelling adults aged 70 years and older; Swiss subgroup with DNA methylation measures at baseline and 3 years
1 g3 years385
Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial
2022 · ω-3–PL/FFA · Adults aged 18 years or older with severe hypertriglyceridemia (fasting triglycerides 500–1500 mg/dL)
4 g26 weeks372
Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial
2020 · n-3 LCPUFA · Pregnant women enrolled at pregnancy week 24; age range and health condition not specified
2.4 g17 weeks344
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies
2013 · ANCHOR IPE 2 g/day · Men and women aged over 18 at high cardiovascular risk, on stable statin therapy, with triglycerides 200–<500 mg/dL and LDL-C 40–<115 mg/dL
2 g12 weeks236
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies
2013 · ANCHOR IPE 4 g/day · Men and women aged over 18 at high cardiovascular risk, on stable statin therapy, with triglycerides 200–<500 mg/dL and LDL-C 40–<115 mg/dL
4 g12 weeks233
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)
2015 · IPE 4 g/day · Adults at high cardiovascular risk with triglycerides ≥200 and <500 mg/dL despite statin control of LDL cholesterol
4 g12 weeks216
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
2015 · Statin + OM3-CA 4 g/d · Adults aged 18 years or older, men and non-pregnant, non-lactating women, at high cardiovascular risk with residual hypertriglyceridemia while taking a statin
4 g6 weeks216
Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study
2015 · TAK-085 4 g/day · Japanese men and women aged 20 to under 75 with hypertriglyceridemia
4 g12 weeks210
Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study
2015 · TAK-085 2 g/day · Japanese men and women aged 20 to under 75 with hypertriglyceridemia
2 g12 weeks206
Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study
2013 · EPA-E 0.6 g three times daily · Japanese patients with hypertriglyceridemia (TG ≥150 mg/dL and <750 mg/dL)
1.8 g12 weeks195
Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study
2015 · EPA-E 1.8 g/day · Japanese men and women aged 20 to under 75 with hypertriglyceridemia
1.8 g12 weeks195
Insulin Resistance Modifies the Effects of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction (from the OMEGA-REMODEL Randomized Clinical Trial)
2020 · O-3FA treatment · Adults with acute myocardial infarction, enrolled 2–4 weeks after the event
4 g180 days180
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
2013 · IPE 2 g/day · Adults with type 2 diabetes (one participant had type 1 diabetes), residual triglycerides of 200–500 mg/dL, LDL-C of 40–100 mg/dL, and high cardiovascular risk while taking stable statin therapy
2 g12 weeks171
Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study
2013 · TAK-085 4 g · Japanese adults with hypertriglyceridemia undergoing lifestyle modification
4 g52 weeks171
Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study
2013 · EPA-E 1.8 g · Japanese adults with hypertriglyceridemia undergoing lifestyle modification
1.8 g52 weeks167
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
2013 · IPE 4 g/day · Adults with type 2 diabetes (one participant had type 1 diabetes), residual triglycerides of 200–500 mg/dL, LDL-C of 40–100 mg/dL, and high cardiovascular risk while taking stable statin therapy
4 g12 weeks165
Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study
2013 · TAK-085 2 g · Japanese adults with hypertriglyceridemia undergoing lifestyle modification
2 g52 weeks165
A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study
2016 · EPA · Men and women with abdominal obesity and low-grade systemic inflammation, at risk of cardiovascular disease
2.7 g10 weeks154
Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study
2022 · MND-2119 2 g/day · Adults with hypertriglyceridemia, with triglyceride levels ≥150 and <500 mg/dL
2 g12 weeks145
Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study
2022 · MND-2119 4 g/day · Adults with hypertriglyceridemia, with triglyceride levels ≥150 and <500 mg/dL
4 g12 weeks145
Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study
2022 · EPA-E 1.8 g/day · Adults with hypertriglyceridemia, with triglyceride levels ≥150 and <500 mg/dL
1.8 g12 weeks145
Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study
2022 · EPA-E 2.7 g/day · Adults with hypertriglyceridemia, with triglyceride levels ≥150 and <500 mg/dL
2.7 g12 weeks145
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study)
2019 · icosapent ethyl 4 g/day · statin-treated patients at increased cardiovascular risk with triglycerides 200 to 499 mg/dL, controlled LDL-C, and baseline hsCRP ≥2.0 mg/L
4 g12 weeks126
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia
2011 · POM3 plus atorvastatin · Men and women with mixed dyslipidemia, non-HDL-C >160 mg/dL and triglycerides 250–599 mg/dL
4 g16 weeks118
Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
2020 · ATOMEGA group · Adults aged 20–79 years with high cardiovascular risk and residual hypertriglyceridemia while treated with statins; most had type 2 diabetes
4 g8 weeks105
The effect of n-3 fatty acids on levels of methylarginines in patients with end-stage renal disease
2010 · n-3 fatty acids · Adults with end-stage renal disease and documented cardiovascular disease
1.7 g90 days103
Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents
2013 · ω-3 PUFA group · Obese, insulin-resistant children and adolescents
1.8 g12 weeks103
A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study
2022 · EPA+DPA-FFA · Men and women aged 18 years or older with elevated fasting triglycerides of 1.70–5.64 mmol/L (150–499 mg/dL)
2 g4 weeks100
A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study
2022 · EPA-EE (icosapent ethyl) · Men and women aged 18 years or older with elevated fasting triglycerides of 1.70–5.64 mmol/L (150–499 mg/dL)
2 g4 weeks100
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
2014 · OM3-FFA 4 g/d · Men and women with severe hypertriglyceridemia (triglycerides ≥500 mg/dL and <2000 mg/dL)
4 g12 weeks99
A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins
2017 · PTV/EPA group · Patients with coronary heart disease who underwent percutaneous coronary intervention and were receiving statin therapy
1.8 g240 days97
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects
2009 · P-OM3 plus FENO during the second open-label extension · Subjects with very high triglyceride levels continuing combination treatment
4 g2 years93
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials)
2017 · ANCHOR icosapent ethyl group · Women with triglyceride levels of 200–2000 mg/dL enrolled in the ANCHOR trial
4 g12 weeks91
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients
2017 · Omacor 2 g/day · Adults aged 20–79 with hypertriglyceridemia
2 g8 weeks82
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects
2009 · P-OM3 plus concomitant FENO · Subjects with very high triglyceride levels (≥500 mg/dL)
4 g8 weeks81
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies
2013 · MARINE IPE 4 g/day · Men and women aged over 18 with triglycerides 500–2000 mg/dL; some had high cardiovascular risk or coronary heart disease
4 g12 weeks77
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)
2011 · AMR101 4 g/day · Patients with fasting triglycerides of 500–2,000 mg/dl, with or without background statin therapy; age and sex not stated
4 g12 weeks76
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies
2013 · MARINE IPE 2 g/day · Men and women aged over 18 with triglycerides 500–2000 mg/dL; some had high cardiovascular risk or coronary heart disease
2 g12 weeks76
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
2018 · Icosapent ethyl 4 g/day · Women with type 2 diabetes, elevated triglycerides, and high cardiovascular risk despite stable statin therapy; ages 42–81 years
4 g12 weeks74
The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients
2009 · group C · Patients with hyperlipidemia and type II diabetes; age and sex not reported
1.8 g26 weeks72
Highly purified eicosapentaenoic acid may increase low-density lipoprotein particle size by improving triglyceride metabolism in patients with hypertriglyceridemia
2013 · EPA group · Hypertriglyceridemic subjects
1.8 g26 weeks72
Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group
2000 · eicosapentaenoic acid group · Japanese menopausal women with hyperlipidemia and symptoms
1.8 g48 weeks69
Effect of supplementation with omega-3 fatty acids on hypertriglyceridemia in pediatric patients with obesity
2019 · omega-3 fatty acids group · children and adolescents aged 10–16 years with obesity and hypertriglyceridemia
3 g12 weeks65
Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study
2022 · MND-2119 2 g/day · Patients with hypertriglyceridemia (triglyceride levels ≥150 and <500 mg/dL) undergoing lifestyle modification
2 g52 weeks61
Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study
2022 · MND-2119 4 g/day · Patients with hypertriglyceridemia (triglyceride levels ≥150 and <500 mg/dL) undergoing lifestyle modification
4 g52 weeks61
Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study
2025 · OMEGA-3 group · Japanese adults aged 20–79 with dyslipidemia, fasting triglycerides ≥177 mg/dL, and statin treatment
4 g16 weeks60
The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides
2006 · DHA + EPA group · Adults with coronary artery disease and triglycerides greater than 200 mg/dL
1.25 g8 weeks59
Dietary echium oil increases long-chain n-3 PUFAs, including docosapentaenoic acid, in blood fractions and alters biochemical markers for cardiovascular disease independently of age, sex, and metabolic syndrome
2014 · echium oil (EO) group · Adults in normal-weight age groups 20–35 and 49–69 years and overweight adults with metabolic syndrome
17 g8 weeks59
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects
2009 · P-OM3 added to stable FENO during the first open-label extension · Subjects with very high triglyceride levels who had received stable FENO monotherapy
4 g8 weeks58
Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease
2015 · Group 1 (PUFA group) · Obese children aged 9–17 years with nonalcoholic fatty liver disease
1 g1 year56
The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients
2009 · group B · Patients with hyperlipidemia and type II diabetes; age and sex not reported
1.8 g26 weeks55
Impact of Adding Eicosapentaenoic Acid to Statin Therapy on Plasma Pentraxin 3 Level in Patients with Stable Coronary Artery Disease: A 6-Month, Randomized Controlled Study
2017 · EPA group · Patients with stable coronary artery disease receiving statin therapy; age and sex not stated
1.8 g26 weeks53
Comparison of the effect of omega-3 supplements and fresh fish on lipid profile: a randomized, open-labeled trial
2017 · omega-3 supplement group · Adults with hyperlipidemia; ages and sex not restricted
2 g60 days53
Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia
2012 · omega-3 fatty acids · Patients with hypertriglyceridemia; age and sex not specified
2 g60 days50
Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients
2013 · omega-3 group · Hemodialysis patients with end-stage renal disease; age and sex not specified
3 g60 days50
Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia
2016 · n-3 FA 2g+fenofibrate 160mg (combination) · Patients with hypertriglyceridemia; age and sex range not reported
2 g60 days50
The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy
2017 · EPA group · Adults with stable coronary artery disease receiving statin treatment
1.8 g26 weeks50
Does administration of eicosapentaenoic acid increase soluble thrombomodulin level in statin-treated patients with stable coronary artery disease?
2019 · EPA group · Adults with stable coronary artery disease receiving statin therapy
1.8 g26 weeks50
Administration of eicosapentaenoic acid may alter high-density lipoprotein heterogeneity in statin-treated patients with stable coronary artery disease: A 6-month randomized trial
2020 · EPA group · Adults with stable coronary artery disease receiving statin therapy; age and sex not stated
1.8 g26 weeks50
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease
2021 · omega-3 fatty acid group · Patients with chronic kidney disease and urine albumin excretion of at least 30 mg/g creatinine
3.67 g90 days50
Supplementation of n3 long-chain polyunsaturated fatty acid synergistically decreases insulin resistance with weight loss of obese prepubertal and pubertal children
2011 · n3-LCPUFA group · Overweight, insulin-resistant children aged 9–18 years; prepubertal and pubertal; otherwise healthy
900 mg30 days49
Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound
2016 · EPA group · Patients with coronary artery disease treated with strong statin therapy for at least 6 months; age and sex not reported
1.8 g26 weeks48
Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial
2008 · EPA open-label extension · Adults with schizophrenia receiving antipsychotic medication
2 g40 weeks47
Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial
2023 · n-3FA group · Jordanian participants with vitamin D deficiency and no other medical conditions; age and sex not specified
300 mg8 weeks47
Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis
2020 · study group (group A) · Patients with chronic kidney disease undergoing hemodialysis
2.4 g12 weeks46
Omega-3 supplementation and stress reactivity of cellular aging biomarkers: an ancillary substudy of a randomized, controlled trial in midlife adults
2021 · 1.25 g/d omega-3 group · Adults aged 40–85 who were sedentary and overweight or at risk of overweight, without metabolic, autoimmune, or inflammatory disease
1.25 g120 days46
Omega-3 supplementation and stress reactivity of cellular aging biomarkers: an ancillary substudy of a randomized, controlled trial in midlife adults
2021 · 2.496 g/d omega-3 group · Adults aged 40–85 who were sedentary and overweight or at risk of overweight, without metabolic, autoimmune, or inflammatory disease
2.5 g120 days46
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression
2016 · n-3 PUFA treatment · Adults with non-alcoholic fatty liver disease; mean age 51.5 years, 57.6% men
4 g548 days45
Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia
2014 · n-3 FA 1 g (O1) · Adults with hypertriglyceridemia, including some with metabolic syndrome or type 2 diabetes mellitus; age and sex not specified
1 g60 days44
Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia
2014 · n-3 FA 2 g (O2) · Adults with hypertriglyceridemia, including some with metabolic syndrome or type 2 diabetes mellitus; age and sex not specified
2 g60 days44
Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia
2014 · n-3 FA 4 g (O4) · Adults with hypertriglyceridemia, including some with metabolic syndrome or type 2 diabetes mellitus; age and sex not specified
4 g60 days44
Beneficial Effects of n-3 Fatty Acids on Cardiometabolic and Inflammatory Markers in Type 2 Diabetes Mellitus: A Clinical Trial
2017 · n-3 PUFA group · Patients with type 2 diabetes mellitus; age and sex not specified
2.7 g10 weeks44
Lipid extract from blue mussel (Mytilus edulis) improves glycemic traits in Chinese type 2 diabetic mellitus patients: a double-blind randomized controlled trial
2023 · BMLE group · Chinese adults with type 2 diabetes mellitus
1.6 g60 days44
Protection from procedural myocardial injury by omega-3 polyunsaturated fatty acids (PUFAs): is related with lower levels of creatine kinase-MB (CK-MB) and troponin I?
2013 · Group A (omega-3 PUFAs) · Patients planned to undergo percutaneous coronary intervention (PCI)
3 g1 day43
Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid
2014 · EPA-FFA · Patients undergoing liver resection surgery for colorectal cancer liver metastases
2 g30 days43
Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis
2016 · EPA-FFA · Adults with colorectal cancer liver metastases awaiting liver resection surgery
2 g30 days43
Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids
2018 · ω-3 PUFAs group · Individuals aged 13–25 years at ultra-high risk for psychosis
1.2 g12 weeks41
Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study
2020 · EPA group · Adults with acute coronary syndrome after successful PCI; age and sex mix not restricted
1.8 g1 year40
One month of omega-3 fatty acid supplementation improves lipid profiles, glucose levels and blood pressure in overweight schoolchildren with metabolic syndrome
2016 · ω-3 fatty acid supplementation · Overweight schoolchildren with metabolic syndrome; girls and boys
2.4 g30 days39
Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial
2021 · OM3EE monotherapy in severe HTG (sHTG cohort) · Adults aged 18 years or older with severe hypertriglyceridemia (baseline triglycerides ≥500 and <1000 mg/dL)
2 g12 weeks39
Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells
2009 · 0.4 g EPA+DHA/d · Healthy Dutch elderly subjects
400 mg26 weeks37
The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia
2011 · omega-3 fatty acids · Men and women aged 35–70 with primary isolated hypertriglyceridemia; patients with triglycerides 200–500 mg/dL, total cholesterol below 200 mg/dL, and LDL cholesterol below 130 mg/dL
2 g12 weeks37
Impact of EPA ingestion on COX- and LOX-mediated eicosanoid synthesis in skin with and without a pro-inflammatory UVR challenge--report of a randomised controlled study in humans
2014 · EPA supplementation group · Women aged 18–60 years with a history of nickel contact allergy and sun-reactive skin type I or II; healthy, without active contact dermatitis
5 g12 weeks37
The effects of fish oil plus vitamin D(3) intervention on non-alcoholic fatty liver disease: a randomized controlled trial
2022 · FO group · Adults aged 56.0 ± 15.9 years with non-alcoholic fatty liver disease
2.34 g90 days37
Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells
2009 · 1.8 g EPA+DHA/d · Healthy Dutch elderly subjects
1.8 g26 weeks36
Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial
2016 · omega-3 fatty acids · HIV-seropositive adults aged 20–55 years receiving antiretroviral therapy, with elevated triglycerides or LDL cholesterol
2.4 g180 days35
The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes
2017 · omega-3 fatty acids + vitamin D placebo · Patients with gestational diabetes; age and sex not otherwise specified
2 g6 weeks35
Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus
2010 · n-3 FAs · Subjects with type 2 diabetes mellitus
2 g6 weeks34
Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial
2011 · omega-3 PUFA group · First- and second-year medical students aged 21–29, men and women, without a stated chronic illness
2.5 g12 weeks34
Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Metabolic and Inflammatory Biomarkers in Type 2 Diabetes Mellitus Patients
2017 · fish oil group (FOG) · Men and women aged 25–60 years with type 2 diabetes mellitus, without other specified chronic diseases, BMI ≤29.9, and not receiving insulin treatment
520 mg24 weeks34
Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study
2010 · omega-3 ethyl esters · Patients with stable coronary artery disease undergoing percutaneous coronary intervention; age and sex not specified
1 g30 days33
Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers
2020 · Epeleuton 2 g/day · Adults aged 18–75 with nonalcoholic fatty liver disease, BMI 25–40, and elevated alanine aminotransferase
2 g16 weeks33
Influence of fish oil on blood lipids in coronary artery disease
1991 · 2.4 g EPA/DHA phase · Patients with coronary artery disease and dyslipidaemia
2.4 g—32
Influence of fish oil on blood lipids in coronary artery disease
1991 · 3.6 g EPA/DHA open phase · Patients with coronary artery disease and dyslipidaemia
3.6 g—32
Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetes mellitus patients: a double-blind randomised clinical trial
2013 · EPA group · Overweight patients with type 2 diabetes mellitus; age and sex not specified
2 g90 days32
Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers
2020 · Epeleuton 1 g/day · Adults aged 18–75 with nonalcoholic fatty liver disease, BMI 25–40, and elevated alanine aminotransferase
1 g16 weeks32
Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability
2011 · Combination treatment group · Patients with mixed dyslipidemia, high triglyceride levels (200–499 mg per 100 ml) and total cholesterol >200 mg per 100 ml
4 g6 weeks31
The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial
2013 · n-3 PUFA supplementation period · Adults older than 21 years with adult-onset diabetes and trace or greater proteinuria
4 g6 weeks31
Randomized study of the clinical effects of ω-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer
2017 · ω-3-rich EN · Patients undergoing neoadjuvant chemotherapy for esophageal cancer
900 mg15 days31
Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids
2018 · P-OM3 treatment · Adults with metabolic syndrome; age range and sex not specified
4 g16 weeks31
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
2020 · IPE group · Adults aged 30–85 with coronary atherosclerosis and elevated fasting triglycerides (135–499 mg/dL), receiving statin therapy
4 g548 days31
Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes
2007 · EPA treated group · Japanese adults with type 2 diabetes
1.8 g767 days30
Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot)
2011 · 1 g/day n-3 PUFA · Adults with stable coronary artery disease undergoing percutaneous coronary intervention
1 g30 days30
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia
2011 · rosuvastatin 10 mg plus omega 3 fatty acids (group RΩ) · Patients with mixed dyslipidemia; age and sex not specified
2 g90 days30
Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation
2012 · n3-FA · Non-diabetic patients with documented coronary artery disease
4 g3 weeks30
Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome
2012 · Omega-3 fatty acids group · Women aged 20–35 with polycystic ovary syndrome and BMI 25–40 kg/m²
1.2 g8 weeks30
Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina
2014 · omega-3 PUFA · Patients with stable coronary artery disease undergoing percutaneous coronary intervention
1 g30 days30
The effects of vitamin E and omega-3 PUFAs on endothelial function among adolescents with metabolic syndrome
2014 · omega-3 group · Adolescents aged 10–18 years with metabolic syndrome
2.4 g8 weeks30
Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial
2017 · omega-3 fatty acid from flaxseed oil · Patients with diabetic nephropathy
1 g12 weeks30
Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Cytokines and Advanced Glycation End Products in Patients With Diabetic Nephropathy: a Randomized Controlled Trial
2016 · omega-3 fatty acid group · Patients with diabetic nephropathy; age and sex not specified
1 g12 weeks30
Randomized study of the clinical effects of ω-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer
2017 · ω-3-poor EN support · Patients undergoing neoadjuvant chemotherapy for esophageal cancer
250 mg15 days30
Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis
2018 · EPA-FFA group · Adults with ulcerative colitis in clinical remission, elevated fecal calprotectin, and stable therapy
1 g26 weeks30
A comparison between the effects of flaxseed oil and fish oil supplementation on cardiovascular health in type 2 diabetic patients with coronary heart disease: A randomized, double-blinded, placebo-controlled trial
2019 · fish oil group · Adults with type 2 diabetes and coronary heart disease; age and sex not specified
2 g12 weeks30
A comparison between the effects of flaxseed oil and fish oil supplementation on cardiovascular health in type 2 diabetic patients with coronary heart disease: A randomized, double-blinded, placebo-controlled trial
2019 · flaxseed oil group · Adults with type 2 diabetes and coronary heart disease; age and sex not specified
2 g12 weeks30
Improvement of NRF2 gene expression and antioxidant status in patients with type 2 diabetes mellitus after supplementation with omega-3 polyunsaturated fatty acids: A double-blind randomised placebo-controlled clinical trial
2020 · n-3 PUFAs group · Adults with type 2 diabetes mellitus
2.7 g—30
Administration of eicosapentaenoic acid may alter lipoprotein particle heterogeneity in statin-treated patients with stable coronary artery disease: A pilot 6-month randomized study
2020 · EPA group · Adults with stable coronary artery disease receiving statin therapy; age and sex not specified
1.8 g26 weeks30
Omega-3 polyunsaturated fatty acid supplementation improves lipid metabolism and endothelial function by providing a beneficial eicosanoid-pattern in patients with acute myocardial infarction: A randomized, controlled trial
2021 · ω-3 therapy · Adults with acute myocardial infarction after successful percutaneous coronary intervention; age and sex not specified
2 g90 days30
Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD
2022 · n-3-PUFA group · Adults with NAFLD and metabolic syndrome; ages 51.8 ± 12 years on average; 80% male
1.8 g1 year30
Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial
2025 · omega-3 PUFAs · Adults with acute myocardial infarction
2 g30 days30
Effects of maternal allergy and supplementation with ω-3 fatty acid and probiotic on human milk oligosaccharides
2025 · OP (ω-3 PUFA + placebo) · Pregnant women with a family history of allergies who intended to breastfeed for the first 3 months; maternal age median about 30.5 years
3.84 g230 days30
Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome
2014 · PUFAs · Adults with metabolic syndrome; mean age 44 ± 12 years, 15 male
2 g12 weeks29
Effects of omega-3 fatty acid supplementation on insulin metabolism and lipid profiles in gestational diabetes: Randomized, double-blind, placebo-controlled trial
2015 · omega-3 fatty acid group · Pregnant women with gestational diabetes
1 g6 weeks28
Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia
1995 · Encapsulated K85 · People with combined hyperlipidaemia who continued to meet the serum triglyceride and total cholesterol inclusion criteria after a 10-week dietary run-in
4 g12 weeks28
Long-term effects of n-3 fatty acids on serum lipids and glycaemic control
1994 · n-3 PUFA group · Non-diabetic patients with moderate hypertriglyceridaemia undergoing coronary artery bypass grafting; age and sex not stated
3.4 g26 weeks28
Omega-3 fatty acid supplementation affects pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial
2016 · omega-3 fatty acid group · pregnant women with gestational diabetes
1 g6 weeks27
Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
2016 · n-3 group · Patients with biopsy-proven non-alcoholic steatohepatitis (NASH); age and sex not stated
945 mg26 weeks27
Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia
2011 · 0.85 g/d EPA+DHA · 23 men and 3 postmenopausal women with moderate hypertriglyceridemia (150–500 mg/dL)
850 mg8 weeks26
Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia
2011 · 3.4 g/d EPA+DHA · 23 men and 3 postmenopausal women with moderate hypertriglyceridemia (150–500 mg/dL)
3.4 g8 weeks26
Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia
2015 · low dose · Middle-aged healthy nonsmoking men and post-menopausal women with triglycerides 150–500 mg/dL
850 mg8 weeks25
Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia
2015 · high dose · Middle-aged healthy nonsmoking men and post-menopausal women with triglycerides 150–500 mg/dL
3.4 g8 weeks25
Effect of Omega-3 Fatty Acids on Serum Lipid Profile and Oxidative Stress in Pediatric Patients on Regular Hemodialysis: A Randomized Placebo-Controlled Study
2017 · omega-3 group · Pediatric patients with end-stage renal disease on regular hemodialysis
1 g16 weeks25
Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study
2018 · OM-3CA · Overweight or obese patients with non-alcoholic fatty liver disease and hypertriglyceridemia
4 g12 weeks25
Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome
2012 · Rω group · Patients with mixed dyslipidaemia and metabolic syndrome
2 g12 weeks24
Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients
2013 · active treatment group · Adults aged 18 years or older with HIV infection, CD4 count above 200 cells/μL, and triglycerides above 200 mg/dL
3.6 g8 weeks24
Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
2016 · R+O group · Patients with mixed dyslipidaemia
2 g90 days24
Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia
2016 · R + O group · Adults with mixed dyslipidaemia
2 g90 days24
Effects of Omega-3 Supplementation on Ki-67 and VEGF Expression Levels and Clinical Outcomes of Locally Advanced Breast Cancer Patients Treated with Neoadjuvant CAF Chemotherapy: A Randomized Controlled Trial Report
2019 · intervention group · Women aged 25–60 with locally advanced stage IIIB breast cancer receiving neoadjuvant CAF chemotherapy
1 g51 days24
Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study
2020 · Omega-3 treatment · Patients with dyslipidemia receiving statins; age and sex not reported
4 g8 weeks24
[Antiarrhythmic activity of omega-3 polyunsaturated fatty acids in patients with stable ischemic heart disease and ventricular rhythm disturbances]
2010 · continued omega-3 group · Adults with stable coronary heart disease, ejection fraction above 45%, and ventricular arrhythmias; mean age 66.2 years
1 g60 days23
The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial
2012 · PUFA group · Adults with HIV infection, hypertriglyceridemia, and receiving HAART; nearly all were male.
4 g12 weeks23
A comparison of the changes in cardiac output and systemic vascular resistance during exercise following high-fat meals containing DHA or EPA
2012 · EPA meal · Healthy adult males
4.7 g1 day22
Effects of administration of omega-3 fatty acids with or without vitamin E supplementation on adiponectin gene expression in PBMCs and serum adiponectin and adipocyte fatty acid-binding protein levels in male patients with CAD
2015 · OP (omega-3 fatty acid & placebo) · Adult men with coronary artery disease and more than 50% stenosis
4 g8 weeks22
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
2018 · OM-3CA + dapagliflozin · Adults aged 40–75 with type 2 diabetes, overweight or obesity, and NAFLD
4 g12 weeks22
The effect of n-3 fatty acids on neutrophil chemiluminescence
1995 · 4 g n-3 PUFA group · Healthy adults; ages and sex not reported
4 g6 weeks22
Changes in peripheral immune populations during pregnancy and modulation by probiotics and ω-3 fatty acids
2020 · ω3 + placebo · Pregnant women included at gestational week 20, with at least one parent or sibling with allergic disease history or symptoms
1.28 g130 days21
EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study
2021 · EPA supplementation · Men and postmenopausal women aged 50–75 years with chronic inflammation
3 g10 weeks21
Investigating the Neuroprotective Effect of Oral Omega-3 Fatty Acid Supplementation in Type 1 Diabetes (nPROOFS1): A Randomized Placebo-Controlled Trial
2021 · n-3 · Participants with type 1 diabetes; age and sex not reported
1.8 g180 days21
Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation
2024 · EPA supplementation phase · Adults aged 50–75 years with low-grade chronic inflammation and at least one metabolic syndrome characteristic; postmenopausal women and men
3 g10 weeks21
Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study
1998 · E (n-3 PUFA) · Kidney graft recipients; age and sex range not reported
6 g1 year21
Effects of simvastain combined with omega-3 fatty acids on high sensitive C-reactive protein, lipidemia, and fibrinolysis in patients with mixed dyslipidemia
2004 · omega-3 fatty acids group · Patients with coronary heart disease or CHD risk equivalents and mixed dyslipidemia whose LDL cholesterol had reached goal on simvastatin
3 g60 days20
Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease
2008 · Group DP · Adults with nonalcoholic fatty liver disease
2 g26 weeks20
Low-dose aspirin and omega-3 fatty acids improve uterine artery blood flow velocity in women with recurrent miscarriage due to impaired uterine perfusion
2009 · Omega(3) · Women with unexplained recurrent miscarriage and impaired uterine perfusion
4 g60 days20
Low-dose aspirin and omega-3 fatty acids improve uterine artery blood flow velocity in women with recurrent miscarriage due to impaired uterine perfusion
2009 · LDA plus Omega(3) · Women with unexplained recurrent miscarriage and impaired uterine perfusion
4 g60 days20
Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects
2012 · n-3 long chain polyunsaturated fatty acids (fish oil) · Overweight and obese adults; age range and sex not stated
3.7 g6 weeks20
[Antiarrhythmic activity of omega-3 polyunsaturated fatty acids in patients with stable ischemic heart disease and ventricular rhythm disturbances]
2010 · omega-3 group that stopped after one month · Adults with stable coronary heart disease, ejection fraction above 45%, and ventricular arrhythmias; mean age 66.2 years
1 g30 days20
Effects of Ω-3 fatty acids on endothelial function, arterial wall properties, inflammatory and fibrinolytic status in smokers: a cross over study
2013 · Ω-3 fatty acids · Healthy smokers; age and sex not specified
2 g12 weeks20
Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers
2013 · ω-3 fatty acid supplementation · Male cigarette smokers; age not stated; described as healthy smokers
2 g6 weeks20
Beneficial effects of omega-3 and vitamin E coadministration on gene expression of SIRT1 and PGC1α and serum antioxidant enzymes in patients with coronary artery disease
2016 · Group 1 (OP) · Male patients with coronary artery disease; age range not reported
4 g60 days20
The effects of fish oil on gene expression in patients with polycystic ovary syndrome
2018 · omega-3 fatty acids from fish oil · Women aged 18–40 years with polycystic ovary syndrome (PCOS)
2 g12 weeks20
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
2018 · OM-3CA monotherapy · Adults aged 40–75 with type 2 diabetes, overweight or obesity, and NAFLD
4 g12 weeks20
[Influence of Omega-3 PUFA on Non-invasive factors determining the risk of arrhYthmias eXcess and sudden cardiac death in patients with HFpEF with ischemic etiology (ONYX)]
2020 · Omacor 2 g/day treatment group · Adults with ischemic heart failure with reduced left ventricular ejection fraction (HFrEF) receiving optimal drug therapy; age and sex not reported
2 g1 year20
Comparative Analysis of the Effects of Fish Oil and Fenofibrate on Plasma Metabolomic Profiles in Overweight and Obese Individuals
2022 · fish oil intervention · Overweight and obese adults (BMI ≥27 kg/m²), men and women
3.7 g6 weeks20
Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia
2023 · ω3FA treatment period · Adults aged 18–70 years with familial hypercholesterolemia, 10 men and 10 women, receiving statin with or without ezetimibe
4 g8 weeks20
The effect of highly purified eicosapentaenoic and docosahexaenoic acids on monocyte phagocytosis in man
1997 · highly purified EPA · healthy men
3.8 g7 weeks20
n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
2016 · n-3 fatty acids · Men and women aged 25–75 years with chronic renal impairment (eGFR >15 and <60 mL/min/1.73 m²)
4 g8 weeks19
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides
2019 · icosapent ethyl 4 g/day · Adults with stage 3 chronic kidney disease, high triglycerides, and increased cardiovascular risk despite statin treatment
4 g12 weeks19
Alterations in serum phosphatidylcholine fatty acyl species by eicosapentaenoic and docosahexaenoic ethyl esters in patients with severe hypertriglyceridemia
1997 · Drug treated group · Patients with severe hypertriglyceridemia; age and sex not reported
4 g6 weeks19
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials)
2017 · MARINE icosapent ethyl group · Women with triglyceride levels of 200–2000 mg/dL enrolled in the MARINE trial
4 g12 weeks18
Effect of Eicosapentaenoic acid (EPA) supplementation on cardiovascular markers in patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
2018 · EPA · Patients with type 2 diabetes mellitus
2 g8 weeks18
Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
2012 · P-OM3 · Adults aged 40–69 with metabolic syndrome
4 g16 weeks17
Effect of omega-3 ethyl esters on the triglyceride-rich lipoprotein response to endotoxin challenge in healthy young men
2023 · P-OM3 · Healthy young men
3.4 g12 weeks17
Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function
2008 · Group II · People with peripheral arterial disease (PAD); age and sex not reported
2 g90 days16
Changes in lipoprotein particle subclasses, standard lipids, and apolipoproteins after supplementation with n-3 or n-6 PUFAs in abdominal obesity: A randomized double-blind crossover study
2021 · Females: EPA + DHA (n-3) · Females with abdominal obesity
3 g7 weeks16
Functional and metabolic effects of omega-3 polyunsaturated fatty acid supplementation and the role of β-hydroxy-β-methylbutyrate addition in chronic obstructive pulmonary disease: A randomized clinical trial
2024 · EPA/DHA · Patients with COPD, GOLD stages II–IV; age and sex not stated
2 g10 weeks16
Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma
2014 · EPA + statin · Patients with untreated dyslipidemia; age and sex not reported
1.8 g270 days15
Untargeted metabolomic on urine samples after α-lipoic acid and/or eicosapentaenoic acid supplementation in healthy overweight/obese women
2018 · EPA group · Healthy sedentary overweight/obese women, mean age 37.3 years; following a hypocaloric diet
1.3 g10 weeks15
Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome
2024 · P-OM3 · Adults aged 40–69 with metabolic syndrome
4 g16 weeks15
Supplementation with n3 fatty acid ethyl esters increases large and small artery elasticity in obese adults on a weight loss diet
2013 · WL+FAEE · Obese adults on a weight-loss diet
4 g12 weeks13
Effect of ω-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state
2014 · Hypocaloric diet plus ω-3 FAEE supplementation · Obese subjects on a weight-loss diet; age and sex not specified
4 g12 weeks13
Using high-dose omega-3 fatty acid supplements to lower triglyceride levels in 10- to 19-year-olds
2014 · Omega-3 FA group · Youth aged 10–19 years with fasting triglycerides of 150–1000 mg/dL and moderate to severe hypertriglyceridemia
3.36 g26 weeks13
The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans
2002 · EPA · Dyslipidemic subjects
3 g7 weeks12
Effect of dietary supplementation with n-3 polyunsaturated fatty acids on physical properties and metabolism of low density lipoprotein in humans
1992 · n-3 fatty acid group · Humans; age, sex, and health condition not specified
6 g120 days12
Interaction of exercise training and n-3 fatty acid supplementation on postprandial lipemia
2007 · n-3 FA supplementation plus exercise training (FO+ExTr) · Previously sedentary, overweight adults; 12 women and 10 men across the study, BMI 26.6 ± 0.7 kg/m²
4 g4 weeks12
Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
2017 · EPA+DHA · Adults with non-alcoholic fatty liver disease (NAFLD); age range and sex not specified
4 g78 weeks12
Polyunsaturated fatty acids supplementation impairs anti-oxidant high-density lipoprotein function in heart failure
2018 · 1 g/day n3-PUFA · Adults with advanced chronic heart failure of nonischaemic origin, NT-proBNP >2000 pg/mL, NYHA class III or IV, and LVEF <35%
1 g12 weeks12
Polyunsaturated fatty acids supplementation impairs anti-oxidant high-density lipoprotein function in heart failure
2018 · 4 g/day n3-PUFA · Adults with advanced chronic heart failure of nonischaemic origin, NT-proBNP >2000 pg/mL, NYHA class III or IV, and LVEF <35%
4 g12 weeks12
Improvement of coronary vasomotion with eicosapentaenoic acid does not inhibit acetylcholine-induced coronary vasospasm in patients with variant angina
1995 · EPA-treated group · Patients with variant angina
1.8 g120 days12
(n-3) fatty acid supplementation in moderately hypertriglyceridemic adults changes postprandial lipid and apolipoprotein B responses to a standardized test meal
1999 · (n-3) fatty acid period (FOP) · Adults with moderately elevated fasting triacylglycerides
5.2 g6 weeks11
High Dose Omega-3 Fatty Acid Administration and Skeletal Muscle Protein Turnover in Maintenance Hemodialysis Patients
2016 · ω-3 · Adults receiving maintenance hemodialysis with systemic inflammation
2.9 g12 weeks11
The Effects of Omega-3 and Branched-Chain Amino Acids Supplementation on Serum Apoptosis Markers Following Acute Resistance Exercise in Old Men
2019 · Omega-3 supplementation · Men aged 62.8 ± 2.2 years undergoing acute resistance exercise
2.7 g7 days11
Leukocyte Activation and Antioxidative Defense Are Interrelated and Moderately Modified by n-3 Polyunsaturated Fatty Acid-Enriched Eggs Consumption-Double-Blind Controlled Randomized Clinical Study
2020 · n-3 PUFA group · Healthy men and women aged 18–30 years with normal BMI, blood pressure and serum lipids
407 mg3 weeks11
Interaction of exercise training and n-3 fatty acid supplementation on postprandial lipemia
2007 · n-3 FA supplementation alone (FO) · Previously sedentary, overweight adults; 12 women and 10 men across the study, BMI 26.6 ± 0.7 kg/m²
4 g4 weeks10
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia
2011 · Omacor 1 g/day · Adults with documented stable coronary artery disease and triglycerides over 250 mg/dl, treated with aspirin and statins
1 g2 weeks10
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia
2011 · Omacor 2 g/day · Adults with documented stable coronary artery disease and triglycerides over 250 mg/dl, treated with aspirin and statins
2 g2 weeks10
Impact of Cranberry Juice Enriched with Omega-3 Fatty Acids Adjunct with Nonsurgical Periodontal Treatment on Metabolic Control and Periodontal Status in Type 2 Patients with Diabetes with Periodontal Disease
2018 · omega-3 (I1) · Adults aged 35–67 years with type 2 diabetes and periodontal disease
2 g8 weeks10
[Influence of Omega-3 PUFA on Non-invasive factors determining the risk of arrhYthmias eXcess and sudden cardiac death in patients with HFpEF with ischemic etiology (ONYX)]
2020 · Omacor 1 g/day treatment group · Adults with ischemic heart failure with reduced left ventricular ejection fraction (HFrEF) receiving optimal drug therapy; age and sex not reported
1 g1 year10
ω-3 polyunsaturated fatty acid supplementation improves postabsorptive and prandial protein metabolism in patients with chronic obstructive pulmonary disease: a randomized clinical trial
2022 · high dose · Normal-weight patients with moderate to severe COPD; age and sex not stated
3.5 g4 weeks10
ω-3 polyunsaturated fatty acid supplementation improves postabsorptive and prandial protein metabolism in patients with chronic obstructive pulmonary disease: a randomized clinical trial
2022 · low dose · Normal-weight patients with moderate to severe COPD; age and sex not stated
2 g4 weeks10
Impact of polyunsaturated fatty acids on human colonic bacterial metabolism: an in vitro and in vivo study
1995 · EPA-EE · 10 healthy volunteers
18 g7 days10
Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial
2005 · omega-3 group · Healthy young adults, men and women, with no chronic stress
762 mg60 days9
Effects of an ethyl ester preparation of fish oils (Himega) on lipids and lipoproteins in hyperlipidaemia
1990 · Himega, Study 1, 2 g/day n-3 fatty acid subgroup · Adults with primary hypertriglyceridaemia
2 g12 weeks9
Effects of an ethyl ester preparation of fish oils (Himega) on lipids and lipoproteins in hyperlipidaemia
1990 · Triglyceride-based fish oil, Study 1, 2 g/day n-3 fatty acid subgroup · Adults with primary hypertriglyceridaemia
2 g12 weeks9
Effects of an ethyl ester preparation of fish oils (Himega) on lipids and lipoproteins in hyperlipidaemia
1990 · Himega, Study 2 · Adults with primary hypercholesterolaemia
2 g9 weeks9
Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia
1993 · 3.0 g EPA+DHA per day · Patients with familial combined hyperlipidemia; age and sex not specified
3 g4 weeks9
Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia
1993 · 4.5 g EPA+DHA per day · Patients with familial combined hyperlipidemia; age and sex not specified
4.5 g4 weeks9
Dietary supplementation with omega-3-polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-1 beta content but not monokine secretion in healthy and insulin-dependent diabetic individuals
1991 · 4.0 g/day omega-3-PUFA, patients with recent-onset IDDM · Patients with recent-onset insulin-dependent diabetes mellitus; age and sex not reported
4 g7 weeks8
A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients
1991 · fish oil · adult men with non-insulin-dependent diabetes
10 g2 weeks8
Functions and tocopherol content of blood platelets from elderly people after low intake of purified eicosapentaenoic acid
1990 · EPA group · Elderly people; sex and specific condition not stated
100 mg60 days8
ω-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study
2013 · ω-3 fatty acids · Patients with cardiac syndrome X; age and sex not reported
1.44 g120 days8
Effect of Icosapent Ethyl on Gynoid Fat and Bone Mineral Health in the Metabolic Syndrome: A Preliminary Report
2020 · IPE treatment group · Adult men and women with metabolic syndrome
4 g270 days8
n-3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects
1990 · group 2 · Hypertriglyceridemic subjects; age range and sex not reported
1.1 g20 weeks7
Dietary n-3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes
1993 · n-3 fatty acid concentrate group · Human volunteers; age, sex, and health condition not specified
7 g6 weeks7
Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption, incorporation into serum phospholipids and postprandial triglyceridemia
1998 · EPA group · Healthy volunteers; age and sex not specified
4 g5 weeks7
Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C]alpha-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men
2003 · increased EPA+DHA intake · Healthy men, mean age 52 (SD 12) years
1.5 g8 weeks5
Effects of an ethyl ester preparation of fish oils (Himega) on lipids and lipoproteins in hyperlipidaemia
1990 · Himega, Study 1, 4 g/day n-3 fatty acid subgroup · Adults with marked primary hypertriglyceridaemia
4 g12 weeks4
Effects of an ethyl ester preparation of fish oils (Himega) on lipids and lipoproteins in hyperlipidaemia
1990 · Triglyceride-based fish oil, Study 1, 4 g/day n-3 fatty acid subgroup · Adults with marked primary hypertriglyceridaemia
4 g12 weeks4
Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients
1999 · EPA · Dialysis patients with relatively high plasma levels of remnant lipoproteins and ox-LDL
1.8 g90 days—
Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects
1999 · daily fish meal · Overweight adults treated for hypertension
3.65 g16 weeks—
Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects
1999 · fish meal plus weight-loss regimen · Overweight adults treated for hypertension
3.65 g16 weeks—
Effect of supplementation with dietary seal oil on selected cardiovascular risk factors and hemostatic variables in healthy male subjects
1999 · seal oil group · Healthy, normocholesterolemic male subjects
20 g6 weeks—
Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia
2000 · simvastatin+omega-3 fatty acids · Patients with combined hyperlipemia
3.36 g5 weeks—
Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses
2000 · Omacor · 14 patients with familial combined hyperlipidemia (FCHL); age and sex not specified
3.4 g8 weeks—
Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men
2000 · EPA group · Overweight, nonsmoking, mildly hyperlipidemic men; age range not reported
4 g6 weeks—
The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia
2000 · Omacor · Patients with primary hypertriglyceridemia
4 g12 weeks—
Eicosapentaenoic acid ethyl ester supplementation in cachectic cancer patients and healthy subjects: effects on lipolysis and lipid oxidation
2000 · EPA-EE supplementation · Weight-losing cancer patients of different tumor types and healthy subjects
6 g7 days—
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia
2001 · Omacor active-treatment group · Patients with coronary heart disease and triglycerides >2.3 mmol/L despite simvastatin treatment; age and sex not reported
4 g48 weeks—
Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia
2001 · omega-3 FA group · Adults with combined hyperlipemia
1.68 g5 weeks—
Omega-3 fatty acids enhance tumor necrosis factor-alpha levels in heart transplant recipients
2001 · omega-3 group · Long-time survivors of heart transplantation
3.4 g1 year—
Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients
2003 · EPA group · Treated-hypertensive men and postmenopausal women with type 2 diabetes
4 g6 weeks—
Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women
2003 · 4:0 (control group) · Women; age and health status not further specified
4 g4 weeks—
Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance
2003 · EPA group · Healthy subjects; age and sex not reported
4 g4 weeks—
Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects
2003 · 0.8 g EPA+DHA/d · Moderately hyperlipidemic subjects; age and sex not specified
800 mg26 weeks—
Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects
2003 · 1.7 g EPA+DHA/d · Moderately hyperlipidemic subjects; age and sex not specified
1.7 g26 weeks—
Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation
2003 · fish oil supplements · Men and women, mean age 49 years, participating in a controlled study; no specific condition reported
3.6 g90 days—
Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients
2003 · n-3FAs group · Hyperlipidemic patients with total cholesterol and triglycerides greater than 200 mg/dL; age and sex not specified
1 g10 weeks—
Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia
2003 · omega-3 fatty acids · Patients with combined hyperlipemia and elevated serum triglycerides and cholesterol
1.68 g5 weeks—
Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation
2003 · EPA+DHA 0.3 g/day course · Healthy men
300 mg4 weeks—
Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation
2003 · EPA+DHA 1.0 g/day course · Healthy men
1 g4 weeks—
Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation
2003 · EPA+DHA 2.0 g/day course · Healthy men
2 g4 weeks—
Influence of supplementation with N-3 fatty acids on different coronary risk factors in men--a placebo controlled study
1992 · 1.12 g n-3 FA/day · healthy men who were monks; age not reported
1.12 g1 year—
Influence of supplementation with N-3 fatty acids on different coronary risk factors in men--a placebo controlled study
1992 · 2.24 g n-3 FA/day · healthy men who were monks; age not reported
2.24 g1 year—
Influence of supplementation with N-3 fatty acids on different coronary risk factors in men--a placebo controlled study
1992 · 3.37 g n-3 FA/day · healthy men who were monks; age not reported
3.37 g1 year—
Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects
2003 · purified EPA · Adults with treated hypertension and type 2 diabetes; mean age 61.2 years
4 g6 weeks—
Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids
1992 · n-3 fatty acids (fish oil) · Patients with active rheumatoid arthritis
3.6 g12 weeks—
Triacylglycerol-rich lipoprotein margination: a potential surrogate for whole-body lipoprotein lipase activity and effects of eicosapentaenoic and docosahexaenoic acids
2004 · eicosapentaenoic acid (EPA) · healthy subjects; age and sex not stated
4 g4 weeks—
Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein
2004 · EPA-rich oil · Healthy human volunteers; age and sex not specified
9 g4 weeks—
Influence of eicosapentaenoic acid, an omega-3 fatty acid, on ultraviolet-B generation of prostaglandin-E2 and proinflammatory cytokines interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 in human skin in vivo
2004 · EPA · Healthy humans; age and sex not specified
4 g90 days—
Soluble adhesion molecules in healthy subjects: a dose-response study using n-3 fatty acids
2004 · n-3 PUFA 6.6 g · Healthy adult volunteers; age and sex distribution not stated
6.6 g12 weeks—
Soluble adhesion molecules in healthy subjects: a dose-response study using n-3 fatty acids
2004 · n-3 PUFA 2.0 g · Healthy adult volunteers; age and sex distribution not stated
2 g12 weeks—
Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia
2005 · n-3 PUFA supplementation (no dietary counseling) · Elderly men with long-standing hyperlipidemia
2.4 g3 years—
Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia
2005 · Dietary counseling and n-3 PUFA supplementation · Elderly men with long-standing hyperlipidemia
2.4 g3 years—
Fish oil treatment and apolipoprotein(a)
1992 · 3.5 g omega-3 fatty acids/day group · Subjects with apolipoprotein(a) values between 34 and 1062 U/l
3.5 g4 weeks—
Fish oil treatment and apolipoprotein(a)
1992 · 7.1 g omega-3 fatty acids/day group · Subjects with apolipoprotein(a) values between 34 and 1062 U/l
7.1 g4 weeks—
Fish oil treatment and apolipoprotein(a)
1992 · 10.6 g omega-3 fatty acids/day group · Subjects with apolipoprotein(a) values between 34 and 1062 U/l
10.6 g4 weeks—
Dietary supplementation with omega-3-polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-1 beta content but not monokine secretion in healthy and insulin-dependent diabetic individuals
1991 · 2.0 g/day omega-3-PUFA, healthy individuals · Healthy individuals; age and sex not reported
2 g7 weeks—
Dietary supplementation with omega-3-polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-1 beta content but not monokine secretion in healthy and insulin-dependent diabetic individuals
1991 · 4.0 g/day omega-3-PUFA, healthy individuals · Healthy individuals; age and sex not reported
4 g7 weeks—
Dietary (n-3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin F2alpha in healthy humans
2006 · fish-oil supplementation · Healthy men and women
3.6 g90 days—
Trans, and n-3 polyunsaturated fatty acids and vascular function-a yin yang situation?
2006 · 4 g n-3 PUFA group · Healthy males
4 g8 weeks—
Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder
2007 · ethyl-EPA treatment group · Female outpatients with bipolar disorder and moderate depressive symptoms
2 g12 weeks—
Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia
2006 · omega-3 PUFA supplementation (no dietary counselling) · elderly men with long-standing hyperlipidaemia
2.4 g3 years—
Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia
2006 · dietary counselling and omega-3 PUFA supplementation · elderly men with long-standing hyperlipidaemia
2.4 g3 years—
A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy
2006 · omega-3 fatty acid arm · HIV-infected males with hypertriglyceridemia receiving stable HAART
9 g8 weeks—
Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas
2007 · EPA supplementation · Patients with a history of colorectal adenomas
2 g90 days—
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia]
2006 · SR group · Patients with primary hyperlipidaemia; age and sex not reported
3.6 g1 year—
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
2007 · P-OM3 plus simvastatin · Adults with persistent hypertriglyceridemia receiving stable statin therapy
4 g8 weeks—
The effect of low dose omega-3 on plasma lipids in hemodialysis patients
2007 · Omega-3 group · Hemodialysis patients with serum triglycerides above 200 mg/dl and total cholesterol above 220 mg/dl
2 g12 weeks—
The lipid-lowering effects of phytosterols and (n-3) polyunsaturated fatty acids are synergistic and complementary in hyperlipidemic men and women
2008 · (n-3) LCPUFA alone · Men and women with hyperlipidemia; age range not reported
1.4 g3 weeks—
Effects of omega-3 fatty acid supplements on serum lipids, apolipoproteins and malondialdehyde in type 2 diabetes patients
2008 · purified omega-3 fatty acids · people with type 2 diabetes
2 g10 weeks—
Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia
2008 · P-OM3 + simvastatin · Men and women, average age 58 years, with mixed dyslipidemia (triglycerides 200–600 mg/dl and non-HDL cholesterol above treatment goals)
4 g6 weeks—
Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial
2008 · EPA group (blinded phase) · Adults with schizophrenia receiving antipsychotic medication
2 g12 weeks—
Effect of n-3 polyunsaturated fatty acids in asthma after low-dose allergen challenge
2009 · n-3 PUFA-enriched fat blend · House dust mite-allergic asthmatics aged 22–29 years
690 mg5 weeks—
Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans
2009 · EPA group · Healthy normolipidemic men and women aged 19–43 years
2.2 g6 weeks—
The effect of the plasma n-3/n-6 polyunsaturated fatty acid ratio on the dietary LDL phenotype transformation - insights from the LIPGENE study
2009 · LFHCC n-3 · Patients with metabolic syndrome
1.24 g12 weeks—
The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients
2010 · treatment group · patients with type 2 diabetes; age and sex not specified
3 g60 days—
Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men
2009 · n-3 PUFA supplementation · elderly high-risk men
2.4 g3 years—
Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men
2009 · dietary counseling plus n-3 PUFA supplementation · elderly high-risk men
2.4 g3 years—
Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy
2009 · omega-3 fatty acids · Women with polycystic ovary syndrome; mean age 32.7 years
4 g8 weeks—
Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipid and insulin sensitivity in persons with HIV
2009 · intervention group · Adults with HIV and elevated serum triglycerides and/or abnormal Quantitative Insulin Sensitivity Check Index values
6 g13 weeks—
The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial
2010 · treatment group · Postmenopausal women with osteoporosis
900 mg26 weeks—
The bleeding time effects of a single dose of aspirin in subjects receiving omega-3 fatty acid dietary supplementation
1991 · omega-3 fatty acid supplementation · 12 healthy adults
8 g3 weeks—
Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients
2010 · Switchers · Patients with hypertriglyceridemia (triglycerides 200–500 mg/dL) and LDL-C no greater than 10% above the treatment goal; adults, age and sex not stated
4 g2 years—
Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients
2010 · Non-switchers · Patients with hypertriglyceridemia (triglycerides 200–500 mg/dL) and LDL-C no greater than 10% above the treatment goal; adults, age and sex not stated
4 g2 years—
Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure
2010 · n-3 PUFA · Patients with NYHA class II–III chronic heart failure
900 mg24 weeks—
n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study
2010 · intervention dairy products · Adults with mild hypertriacylglycerolemia (TAG ≥1.5 mmol/L), 25 women and 26 men
3 g15 weeks—
The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebo-controlled interventions
2010 · EPA · Overweight, dyslipidaemic men (Study A) and treated-hypertensive patients with type 2 diabetes (Study B)
4 g6 weeks—
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial
2010 · omega-3 ethyl esters 90 · Patients with type 2 diabetes
2 g120 days—
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial
2010 · atorvastatin and omega-3 ethyl esters 90 · Patients with type 2 diabetes
2 g120 days—
Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation
2011 · n-3 PUFA only · Either-sex patients undergoing on-pump cardiac surgery
2 g——
Omega-3 fatty acids supplementation attenuates inflammatory markers after eccentric exercise in untrained men
2011 · experimental group · Men who had not participated in a training program for 60 days before the study; age and health condition not specified
1.8 g——
Dose-response effects of fish-oil supplementation in healthy volunteers
1990 · 1.5 g group · Healthy normotriglyceridemic men
1.5 g12 weeks—
Dose-response effects of fish-oil supplementation in healthy volunteers
1990 · 3 g group · Healthy normotriglyceridemic men
3 g12 weeks—
Dose-response effects of fish-oil supplementation in healthy volunteers
1990 · 6 g group · Healthy normotriglyceridemic men
6 g12 weeks—
The effect of n-3 polyunsaturated fatty acids on leukotriene B₄ and leukotriene B₅ production from stimulated neutrophil granulocytes in patients with chronic kidney disease
2011 · n-3 PUFA · Patients with CKD stage 2–5
2.4 g8 weeks—
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)
2011 · AMR101 2 g/day · Patients with fasting triglycerides of 500–2,000 mg/dl, with or without background statin therapy; age and sex not stated
2 g12 weeks—
Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients
2011 · marine omega-3 fatty acid group · Hemodialysis patients; age and sex not specified
2.08 g10 weeks—
Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients
2012 · n-3 PUFA group · Haemodialysis patients with cardiovascular disease
1.7 g90 days—
Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure
2011 · 1 g/day n3-PUFA · Patients with severe non-ischaemic chronic heart failure under optimised therapy
1 g12 weeks—
Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure
2011 · 4 g/day n3-PUFA · Patients with severe non-ischaemic chronic heart failure under optimised therapy
4 g12 weeks—
Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients
2011 · ω-3 fatty acids · Subjects with isolated hypertriglyceridemia
2 g12 weeks—
Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients
2011 · omega-3 fatty acids group · Hemodialysis patients; age range and sex not stated
2.08 g10 weeks—
[Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients]
2011 · RSI (oral powder supplement enriched with eicosapentaenoic acid) · Adults older than 18 years with cancer
1.5 g30 days—
Untitled
2012 · 1.25 g/d omega-3 group · Adults aged 40–85, men and women, healthy but overweight and sedentary
1.25 g120 days—
Untitled
2012 · 2.496 g/d n-3 group (high-dose group) · Adults aged 40–85, men and women, healthy but overweight and sedentary
2.5 g120 days—
Margarines fortified with α-linolenic acid, eicosapentaenoic acid, or docosahexaenoic acid alter the fatty acid composition of erythrocytes but do not affect the antioxidant status of healthy adults
2012 · EPA margarine group · Healthy men and women; age range and sex-specific numbers not reported
2.2 g6 weeks—
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
2012 · AMR101 4 g/day · High-risk statin-treated patients with triglycerides ≥200 and <500 mg/dl despite controlled LDL cholesterol of ≥40 and <100 mg/dl
4 g12 weeks—
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
2012 · AMR101 2 g/day · High-risk statin-treated patients with triglycerides ≥200 and <500 mg/dl despite controlled LDL cholesterol of ≥40 and <100 mg/dl
2 g12 weeks—
Untitled
2012 · AMR101 4 g/day · Patients with very high triglyceride levels (≥500 mg/dl)
4 g12 weeks—
Untitled
2012 · AMR101 2 g/day · Patients with very high triglyceride levels (≥500 mg/dl)
2 g12 weeks—
Untitled
2012 · n-3 PUFA group · Severely obese, nondiabetic patients scheduled to undergo elective bariatric surgery
3.36 g8 weeks—
Untitled
2013 · n-3PUFA group · Patients with chronic heart failure of any cause and severity
1 g1 year—
Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement
2013 · 0.45 g/day group · Healthy subjects; age and sex not specified
450 mg26 weeks—
Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement
2013 · 0.9 g/day group · Healthy subjects; age and sex not specified
900 mg26 weeks—
Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement
2013 · 1.8 g/day group · Healthy subjects; age and sex not specified
1.8 g26 weeks—
Untitled
2013 · supplement group · Overweight and obese participants; age and sex not specified
1.8 g4 weeks—
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)
2012 · IPE 4 g/day · Patients with very high triglyceride levels (≥500 mg/dL); age and sex not reported
4 g12 weeks—
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)
2012 · IPE 2 g/day · Patients with very high triglyceride levels (≥500 mg/dL); age and sex not reported
2 g12 weeks—
Effect of dietary intervention to reduce the n-6/n-3 fatty acid ratio on maternal and fetal fatty acid profile and its relation to offspring growth and body composition at 1 year of age
2013 · dietary intervention · Healthy pregnant women, from the 15th week of gestation through 4 months of lactation
1.2 g——
Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients
2013 · 3.6 g/d ω-3 PUFA group · Non-dialyzed patients with stage IV/V chronic kidney disease; age and sex not stated
3.6 g10 weeks—
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis
2014 · ω-3 PUFA group · Young people at ultra-high risk for transition to psychosis
1.2 g12 weeks—
Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals
2013 · 0.45 g/d group · Healthy men and women aged 45–70 years
450 mg1 year—
Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals
2013 · 0.9 g/d group · Healthy men and women aged 45–70 years
900 mg1 year—
Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals
2013 · 1.8 g/d group · Healthy men and women aged 45–70 years; the reported increase was in participants older than 58 years with the +45 TT genotype
1.8 g1 year—
Combined fish oil and high oleic sunflower oil supplements neutralize their individual effects on the lipid profile of healthy men
2013 · n-3 fatty acids only, 2 g/day · Healthy men; age range not reported.
2 g12 weeks—
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)
2013 · OM3-FFA 4 g/d · Adults with fasting triglycerides ≥200 mg/dL and <500 mg/dL, treated with a maximally tolerated statin or statin plus ezetimibe, and at high cardiovascular risk
4 g6 weeks—
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men
2014 · ATV plus ω-3 FAEEs · insulin-resistant obese men; the abstract does not report an age range
4 g6 weeks—
Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance
2014 · P-OM3 alone · Men and women aged 40–69 years with overweight or obesity, insulin resistance, and dyslipidemia
4 g16 weeks—
Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance
2014 · Combination (P-OM3 plus ERN) · Men and women aged 40–69 years with overweight or obesity, insulin resistance, and dyslipidemia
4 g16 weeks—
DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial
2014 · FlaxSaff · Volunteers with abdominal obesity
60 g4 weeks—
Effects of supplementation with omega-3 on insulin sensitivity and non-esterified free fatty acid (NEFA) in type 2 diabetic patients
2014 · Group A · People with type 2 diabetes; age range and sex not reported
4 g10 weeks—
Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults
2014 · 300 mg/d EPA+DHA group · Healthy adults aged 20–45 years, BMI 20–30 kg/m², with no or low habitual oily fish consumption and not taking n-3 PUFA supplements
300 mg150 days—
Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults
2014 · 600 mg/d EPA+DHA group · Healthy adults aged 20–45 years, BMI 20–30 kg/m², with no or low habitual oily fish consumption and not taking n-3 PUFA supplements
600 mg150 days—
Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults
2014 · 900 mg/d EPA+DHA group · Healthy adults aged 20–45 years, BMI 20–30 kg/m², with no or low habitual oily fish consumption and not taking n-3 PUFA supplements
900 mg150 days—
Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults
2014 · 1800 mg/d EPA+DHA group · Healthy adults aged 20–45 years, BMI 20–30 kg/m², with no or low habitual oily fish consumption and not taking n-3 PUFA supplements
1.8 g150 days—
A new, microalgal DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia
2014 · DHA-O · Adults with mild-to-moderate hypertriglyceridemia (TAG 150–499 mg/dL)
2.4 g14 weeks—
Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation
2014 · n-3 fatty acids plus aspirin · healthy human volunteers; age and sex not specified
2.4 g7 days—
Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation
2014 · n-3 fatty acids plus placebo · healthy human volunteers; age and sex not specified
2.4 g7 days—
Benefits of foods supplemented with vegetable oils rich in α-linolenic, stearidonic or docosahexaenoic acid in hypertriglyceridemic subjects: a double-blind, randomized, controlled trail
2015 · Stearidonic acid (SDA) group · Hypertriglyceridemic subjects with triglycerides ≥ 1.5 mmol/L; age and sex not stated
2 g10 weeks—
[Effect of Omega 3 fatty acids on body female obese composition]
2013 · Group 2 · Premenopausal obese women (BMI >30 kg/m²)
1 g90 days—
[Effect of Omega 3 fatty acids on body female obese composition]
2013 · Group 3 · Premenopausal obese women (BMI >30 kg/m²)
2 g90 days—
n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial
2015 · AG-PUFA group · Subjects with non-fasting plasma triacylglycerol levels of 1.7–5.65 mmol/L (150–500 mg/dL)
3 g8 weeks—
n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial
2015 · EE-PUFA group · Subjects with non-fasting plasma triacylglycerol levels of 1.7–5.65 mmol/L (150–500 mg/dL)
3 g8 weeks—
Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome
2015 · IPE 4 grams/day · Patients with metabolic syndrome and high or very high triglyceride levels, with or without stable statin therapy
4 g——
A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease
2016 · n-3 fatty acids · Patients with chronic kidney disease; age and sex not specified.
4 g8 weeks—
Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol
2015 · P-OM3 · Overweight patients with elevated triglyceride/HDL-C ratios; age and sex not specified
4 g16 weeks—
Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis
2015 · PUFA therapy group · Patients with pathologically diagnosed nonalcoholic steatohepatitis (NASH)
50 mL26 weeks—
n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease
2015 · n-3 fatty acids · Patients with chronic kidney disease
4 g8 weeks—
Marine n-3 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre- and postmenopausal women: A randomised study
2016 · marine n-3 PUFA · Healthy pre- and postmenopausal women
2.2 g12 weeks—
ω-3 fatty acids as an adjuvant therapy ameliorates methotrexate-induced hepatotoxicity in children and adolescents with acute lymphoblastic leukemia: A randomized placebo-controlled study
2016 · group A · Children and adolescents with acute lymphoblastic leukemia in the maintenance phase of chemotherapy, receiving methotrexate
1 g26 weeks—
Insulin resistance determines a differential response to changes in dietary fat modification on metabolic syndrome risk factors: the LIPGENE study
2015 · LFHCC diet supplemented with long-chain n-3 polyunsaturated fatty acids · Adults with metabolic syndrome; age and sex not specified
1.2 g12 weeks—
Short term omega-3 polyunsaturated fatty acid supplementation induces favorable changes in right ventricle function and diastolic filling pressure in patients with chronic heart failure; A randomized clinical trial
2016 · omega 3-PUFA supplementation · Adults with chronic compensated systolic heart failure due to ischemic or dilated cardiomyopathy, NYHA class I–III
1 g26 weeks—
Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial
2016 · icosabutate · Men and women with very high triglycerides (500–1500 mg/dL); age not reported
600 mg12 weeks—
Effect of ω-3 supplementation on placental lipid metabolism in overweight and obese women
2016 · DHA plus EPA (n–3 FAs) · Healthy overweight and obese pregnant women
2 g——
Omega-3 LCPUFA supplement: a nutritional strategy to prevent maternal and neonatal oxidative stress
2017 · supplemented group FO · Pregnant women receiving supplementation during pregnancy and lactation
400 mg——
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies
2016 · MARINE icosapent ethyl 4 g/day · Adults with very high triglyceride levels (≥500 and ≤2000 mg/dL)
4 g12 weeks—
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies
2016 · ANCHOR icosapent ethyl 4 g/day · Adults with high triglyceride levels (≥200 and <500 mg/dL) despite statin control of LDL-C
4 g12 weeks—
ω-3 Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia
2016 · ω-3 FAEE supplementation · Familial hypercholesterolemia patients receiving standard cholesterol-lowering treatment; age range and sex not stated
4 g8 weeks—
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies
2016 · MARINE icosapent ethyl 4 g/day · Adults with triglycerides ≥500 and ≤2000 mg/dL
4 g12 weeks—
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies
2016 · MARINE icosapent ethyl 2 g/day · Adults with triglycerides ≥500 and ≤2000 mg/dL
2 g12 weeks—
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies
2016 · ANCHOR icosapent ethyl 4 g/day · Adults with triglycerides ≥200 and <500 mg/dL despite statin-controlled LDL-C
4 g12 weeks—
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies
2016 · ANCHOR icosapent ethyl 2 g/day · Adults with triglycerides ≥200 and <500 mg/dL despite statin-controlled LDL-C
2 g12 weeks—
Potential Effects of Omega-3 Fatty Acids on Insulin Resistance and Lipid Profile in Maintenance Hemodialysis Patients: a Randomized Placebo-Controlled Trial
2016 · omega-3 fatty acids group · Adults receiving maintenance hemodialysis
1.8 g120 days—
Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial
2016 · EPA 600mg/d · Healthy, normolipidemic subjects; age and sex not specified
600 mg6 weeks—
Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial
2016 · EPA 1800mg/d · Healthy, normolipidemic subjects; age and sex not specified
1.8 g6 weeks—
The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia
2016 · OM3-CA 2 g/d · Subjects with fasting triglycerides of 500 to 2000 mg/dL (age and sex not specified)
2 g12 weeks—
The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia
2016 · OM3-CA 3 g/d · Subjects with fasting triglycerides of 500 to 2000 mg/dL (age and sex not specified)
3 g12 weeks—
The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia
2016 · OM3-CA 4 g/d · Subjects with fasting triglycerides of 500 to 2000 mg/dL (age and sex not specified)
4 g12 weeks—
Inflammatory gene expression in whole blood cells after EPA vs. DHA supplementation: Results from the ComparED study
2017 · EPA · Men and women with abdominal obesity and low-grade inflammation, at risk for cardiometabolic diseases
2.7 g10 weeks—
Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia
2017 · second group (statin + omega-3 PUFA) · People with combined dyslipidemia and elevated TAG levels; age and sex not reported
2.52 g90 days—
Oxidative stress reduction related to the efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial
2017 · n-3 PUFA intervention group · Patients aged 16–35 with first-episode schizophrenia
2.2 g26 weeks—
Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia
2017 · MAT9001 · Men and women aged 18–70 years with hypertriglyceridemia (fasting triglycerides 200–400 mg/dL)
4 g2 weeks—
Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia
2017 · EPA-EE (Vascepa, icosapent ethyl) · Men and women aged 18–70 years with hypertriglyceridemia (fasting triglycerides 200–400 mg/dL)
4 g2 weeks—
A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota
2018 · soft-gel capsule intervention · Healthy middle-aged volunteers
4 g8 weeks—
A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota
2018 · Smartfish drink intervention · Healthy middle-aged volunteers
4 g8 weeks—
The Effect of Eicosapentaenoic Acid on the Serum Levels and Enzymatic Activity of Paraoxonase 1 in the Patients With Type 2 Diabetes Mellitus
2017 · EPA supplement group · Patients with type 2 diabetes; age and sex not specified
2 g8 weeks—
Effects of prenatal n-3 fatty acid supplementation on offspring resolvins at birth and 12 years of age: a double-blind, randomised controlled clinical trial
2017 · n-3 fatty acid group · Atopic pregnant women
3.7 g——
Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial
2018 · ROSUMEGA group · Adults with residual hypertriglyceridemia despite statin treatment
4 g8 weeks—
Telomerase level increase is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized clinical trial
2018 · n-3 PUFA intervention group · patients aged 16–35 with first-episode schizophrenia
2.2 g26 weeks—
Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight
2018 · n-3 PUFA · Patients with NASH; age and sex not specified
945 mg26 weeks—
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial
2018 · OM3-CA 2 g daily · Adults with severe hypertriglyceridemia and qualifying serum triglycerides of at least 500 mg/dL and below 2500 mg/dL (below 2000 mg/dL in Canada)
2 g12 weeks—
The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease
2018 · n-3 FA · Patients with chronic kidney disease (CKD)
4 g8 weeks—
A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study
2018 · ω-3 group · Patients with episodic migraine
2.5 g60 days—
Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial
2019 · marine n-3 FA group · Norwegian renal transplant recipients
2.6 g44 weeks—
Effect of Low Dose Docosahexaenoic Acid-Rich Fish Oil on Plasma Lipids and Lipoproteins in Pre-Menopausal Women: A Dose⁻Response Randomized Placebo-Controlled Trial
2018 · 0.35 g/day n-3 LCPUFA group · Healthy premenopausal women aged 18–40 with mildly elevated triglycerides (>1.0 mmol/L) and regular menstrual cycles
350 mg8 weeks—
Effect of Low Dose Docosahexaenoic Acid-Rich Fish Oil on Plasma Lipids and Lipoproteins in Pre-Menopausal Women: A Dose⁻Response Randomized Placebo-Controlled Trial
2018 · 0.7 g/day n-3 LCPUFA group · Healthy premenopausal women aged 18–40 with mildly elevated triglycerides (>1.0 mmol/L) and regular menstrual cycles
700 mg8 weeks—
Effect of Low Dose Docosahexaenoic Acid-Rich Fish Oil on Plasma Lipids and Lipoproteins in Pre-Menopausal Women: A Dose⁻Response Randomized Placebo-Controlled Trial
2018 · 1.0 g/day n-3 LCPUFA group · Healthy premenopausal women aged 18–40 with mildly elevated triglycerides (>1.0 mmol/L) and regular menstrual cycles
1 g8 weeks—
The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients
2019 · ω3FA treatment group · Nondiabetic patients with Stage 3–4 chronic kidney disease
4 g8 weeks—
Comparing the serum TAG response to high-dose supplementation of either DHA or EPA among individuals with increased cardiovascular risk: the ComparED study
2019 · EPA · Men and women with increased cardiovascular risk
2.7 g10 weeks—
Four Weeks of Preoperative Omega-3 Fatty Acids Reduce Liver Volume: a Randomised Controlled Trial
2019 · Omega-3 fatty acids with a normal diet · Morbidly obese women undergoing laparoscopic Roux-en-Y gastric bypass surgery
2 g4 weeks—
EPA+DHA, but not ALA, Improved Lipids and Inflammation Status in Hypercholesterolemic Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
2019 · 1.8 g/d DHA+EPA · Adults with hypercholesterolemia; age range and sex not specified
1.8 g12 weeks—
EPA+DHA, but not ALA, Improved Lipids and Inflammation Status in Hypercholesterolemic Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
2019 · 3.6 g/d EPA+DHA · Adults with hypercholesterolemia; age range and sex not specified
3.6 g12 weeks—
Randomized Study of the Effect of Vitamin D and Omega-3 Fatty Acids Cosupplementation as Adjuvant Chemotherapy on Inflammation and Nutritional Status in Colorectal Cancer Patients
2020 · omega-3 fatty acid group · Colorectal cancer patients
660 mg8 weeks—
Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial
2019 · intensive therapy group · Patients with non-obstructive neoatherosclerotic plaques detected on OCT
1.8 g1 year—
EPA and DHA have divergent effects on serum triglycerides and lipogenesis, but similar effects on lipoprotein lipase activity: a randomized controlled trial
2019 · EPA group · Young, healthy normolipidemic men and women
3 g12 weeks—
Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia - A Randomized, Double-Blind, Placebo-Controlled, Phase III Study
2020 · 2 g AZD0585 group · Japanese patients with dyslipidemia, LDL-C controlled regardless of statin use, and triglyceride levels of 150–499 mg/dL
2 g52 weeks—
Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia - A Randomized, Double-Blind, Placebo-Controlled, Phase III Study
2020 · 4 g AZD0585 group · Japanese patients with dyslipidemia, LDL-C controlled regardless of statin use, and triglyceride levels of 150–499 mg/dL
4 g52 weeks—
Effects of Vitamin D and Omega-3 Fatty Acids Co-Supplementation on Inflammatory Factors and Tumor Marker CEA in Colorectal Cancer Patients Undergoing Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
2020 · omega-3 fatty acid · Patients with stage II or III colorectal cancer undergoing chemotherapy
660 mg8 weeks—
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results
2021 · icosapent ethyl (IPE) · Adults with coronary atherosclerosis, persistently high triglycerides, and stable statin therapy
4 g548 days—
Concomitant Use of Rosuvastatin and Eicosapentaenoic Acid Significantly Prevents Native Coronary Atherosclerotic Progression in Patients With In-Stent Neoatherosclerosis
2020 · intensive therapy · Patients with in-stent neoatherosclerosis and native coronary plaques
1.8 g1 year—
Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning
2020 · omega-3 · Adults with type 2 diabetes and no known cardiovascular events, managed in UK primary care and not thought to require immediate lipid-lowering treatment
2 g1 year—
Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning
2020 · atorvastatin + omega-3 · Adults with type 2 diabetes and no known cardiovascular events, managed in UK primary care and not thought to require immediate lipid-lowering treatment
2 g1 year—
Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning
2020 · omega-3 + action planning · Adults with type 2 diabetes and no known cardiovascular events, managed in UK primary care and not thought to require immediate lipid-lowering treatment
2 g1 year—
Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning
2020 · atorvastatin + omega-3 + action planning · Adults with type 2 diabetes and no known cardiovascular events, managed in UK primary care and not thought to require immediate lipid-lowering treatment
2 g1 year—
The prebiotic effects of omega-3 fatty acid supplementation: A six-week randomised intervention trial
2021 · omega-3 intervention · Adults over 18 years with BMI 20–39.9 kg/m² and habitual fiber consumption below 15 g/day; no particular disease or trait selected
500 mg6 weeks—
Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects
2021 · EPA · healthy volunteers
4 g30 days—
An Oily Fish Diet Improves Subclinical Inflammation in People at High Cardiovascular Risk: A Randomized Controlled Study
2021 · Low LCn3 and low PP · Adults aged 35–70 years with overweight or obesity, high waist circumference, and at least one additional metabolic syndrome criterion
1.5 g8 weeks—
An Oily Fish Diet Improves Subclinical Inflammation in People at High Cardiovascular Risk: A Randomized Controlled Study
2021 · High LCn3 and low PP · Adults aged 35–70 years with overweight or obesity, high waist circumference, and at least one additional metabolic syndrome criterion
4 g8 weeks—
An Oily Fish Diet Improves Subclinical Inflammation in People at High Cardiovascular Risk: A Randomized Controlled Study
2021 · Low LCn3 and high PP · Adults aged 35–70 years with overweight or obesity, high waist circumference, and at least one additional metabolic syndrome criterion
1.4 g8 weeks—
An Oily Fish Diet Improves Subclinical Inflammation in People at High Cardiovascular Risk: A Randomized Controlled Study
2021 · High LCn3 and high PP · Adults aged 35–70 years with overweight or obesity, high waist circumference, and at least one additional metabolic syndrome criterion
4 g8 weeks—
Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study
2021 · UI-018 fixed-dose combination atorvastatin/Ω-3 fatty acid · Patients with residual hypertriglyceridemia who responded poorly to atorvastatin 40 mg monotherapy
4 g8 weeks—
Omega 3-rich Camelina sativa oil in the context of a weight loss program improves glucose homeostasis, inflammation and oxidative stress in patients with NAFLD: A randomised placebo-controlled clinical trial
2021 · Camelina sativa oil (CSO) group · Patients with non-alcoholic fatty liver disease (NAFLD); age and sex not reported
20 g12 weeks—
Omega-3 polyunsaturated fatty acids supplementation improve clinical symptoms in patients with Covid-19: A randomised clinical trial
2021 · intervention group · Adult men and women diagnosed with Covid-19
2 g2 weeks—
Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial
2021 · OM3EE monotherapy in moderate HTG (mHTG cohort) · Adults aged 18 years or older with moderate hypertriglyceridemia (baseline triglycerides ≥200 and <500 mg/dL)
2 g12 weeks—
Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial
2021 · OM3EE with existing statin therapy (combination cohort) · Adults aged 18 years or older with hypertriglyceridemia receiving stable existing statin therapy
2 g12 weeks—
Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease
2021 · omega-3 free carboxylic acids (OM-3CA) · Overweight patients with non-alcoholic fatty liver disease and hypertriglyceridemia
4 g12 weeks—
A Randomized Trial of ω-3 Fatty Acid Supplementation and Circulating Lipoprotein Subclasses in Healthy Older Adults
2022 · n-3-PUFA ethyl esters · Men and women aged 65–85 years without cardiovascular disease or hypertriglyceridemia
3.9 g26 weeks—
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial
2022 · EPA 1 g/d · Adults with DSM-5 major depressive disorder, BMI >25 kg/m², and plasma hs-CRP ≥3.0 mg/L; mean age 45.5 years; 75% female
1 g12 weeks—
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial
2022 · EPA 2 g/d · Adults with DSM-5 major depressive disorder, BMI >25 kg/m², and plasma hs-CRP ≥3.0 mg/L; mean age 45.5 years; 75% female
2 g12 weeks—
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial
2022 · EPA 4 g/d · Adults with DSM-5 major depressive disorder, BMI >25 kg/m², and plasma hs-CRP ≥3.0 mg/L; mean age 45.5 years; 75% female
4 g12 weeks—
Increases in plasma n-3 tetracosapentaenoic acid and tetracosahexaenoic acid following 12 weeks of EPA, but not DHA, supplementation in women and men
2022 · EPA supplemented group · Women and men aged 19–30 years
3 g12 weeks—
Effects of Vitamin D(3) and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
2022 · Marine n-3 fatty acids active group · Men aged 50 years or older and women aged 55 years or older, without a history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke, transient ischemic attack, or coronary revascularization
1 g1935 days—
Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial
2023 · EPA alone · Trial participants in the seAFOod polyp prevention trial; age and sex are not specified in the abstract
2 g1 year—
Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial
2023 · Aspirin and EPA · Trial participants in the seAFOod polyp prevention trial; age and sex are not specified in the abstract
2 g1 year—
Omega-3 fatty acids supplementation improves early-stage diabetic nephropathy and subclinical atherosclerosis in pediatric patients with type 1 diabetes: A randomized controlled trial
2023 · intervention group · Pediatric patients with type 1 diabetes and diabetic nephropathy; mean age 15.2 ± 1.96 years
1 g26 weeks—
Monocyte transcriptomic profile following EPA and DHA supplementation in men and women with low-grade chronic inflammation
2024 · EPA supplementation · Men and postmenopausal women aged 50–75 years with chronic low-grade inflammation and at least one cardiometabolic risk characteristic
3 g10 weeks—
The effect of eight weeks combined training with omega-3 supplementation on the levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in older women
2024 · omega-3 supplement · Older women, mean age 66.7 ± 4.13 years
2 g8 weeks—
The effect of eight weeks combined training with omega-3 supplementation on the levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in older women
2024 · training + omega-3 · Older women, mean age 66.7 ± 4.13 years
2 g8 weeks—
APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trial
2024 · EPA supplementation · Participants undergoing colonoscopy surveillance after removal of colorectal polyps
2 g26 weeks—
Nutritional effect on lipoproteins and their subfractions in patients with Psoriatic Arthritis: a 12-week randomized trial-the DIETA trial
2024 · Diet + Supplementation · Patients with psoriatic arthritis; age and sex not specified
1.81 g12 weeks—
The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial
2025 · omega-3 fatty acid (ω3) group · Women newly diagnosed with breast cancer receiving chemotherapy; age range not reported
600 mg9 weeks—
Vitamin D(3) and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial
2025 · Marine n-3 fatty acids only · Females aged 55 years or older and males aged 50 years or older; no specific condition stated
1 g5 years—
Supplementation of Omega-3 Increases Serum Levels of Brain-Derived Neurotrophic Factor and Decreases Depression Status in Patients With Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
2025 · omega-3 supplements · Men with bipolar disorder; age not stated
2 g60 days—
The anti-inflammatory effects of three different dietary supplement interventions
2025 · Omega 3 arm · Adults aged 60 years and older with BMI 20–39.9 and habitual fibre consumption below 15 g/day
500 mg6 weeks—
Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial
1995 · Fish oil group · Adults with untreated hypertension recruited from a population survey; age and sex not reported
4 g16 weeks—
Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients
1995 · EPA-E administration · People with non-insulin-dependent diabetes mellitus and nephropathy
900 mg1 year—
The effect of n-3 fatty acids on neutrophil chemiluminescence
1995 · 0.65 g n-3 PUFA group · Adults; ages, sex, and health status not reported
650 mg6 weeks—
Prolonged inhibition of platelet aggregation after n-3 fatty acid ethyl ester ingestion by healthy volunteers
1995 · Low-dose n-3 fatty acid group · Healthy volunteers; age and sex not specified
3 g18 weeks—
n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes
1994 · n-3 fatty acid ethyl esters, healthy volunteers · Healthy volunteers; age and sex not reported
3 g18 weeks—
n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes
1994 · n-3 fatty acid ethyl esters, hypertriglyceridemic patients · Hypertriglyceridemic patients; age and sex not reported
3 g24 weeks—
The acute effects of a single very high dose of n-3 fatty acids on plasma lipids and lipoproteins in healthy subjects
1994 · n-3 PUFA group · Healthy volunteers; age and sex not specified
20 g1 day—
Fish oil reduces postprandial triglyceride concentrations without accelerating lipid-emulsion removal rates
1993 · fish oil (n-3 fatty acids) · Eight normal volunteers
64 mg/kg4 weeks—
Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM
1993 · 900-mg group · Adults with non-insulin-dependent diabetes mellitus (NIDDM); age and sex not stated
900 mg8 weeks—
Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM
1993 · 1800-mg group · Adults with non-insulin-dependent diabetes mellitus (NIDDM); age and sex not stated
1.8 g8 weeks—
Increased plasma thrombin-antithrombin III complex levels in non-insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate
1995 · Ethyl icosapentatenoate (EPA) treatment · Non-insulin-dependent diabetic patients; age and sex not reported
1.8 g4 weeks—
Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease
1996 · n-3 PUFA · Patients with chronic atherosclerotic disease
3 g16 weeks—
Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans
1996 · EPA · Normolipidemic subjects; age and sex not reported
3 g3 weeks—
Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans
1996 · DHA · Normolipidemic subjects; age and sex not reported
3 g3 weeks—
Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans
1997 · Menhaden oil without vitamin E · Healthy men; age not stated
6.26 g6 weeks—
Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants
1997 · omega-3 FAs · male smokers with combined hyperlipidemia
5 g6 weeks—
Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia
1998 · omega-3 fatty acids · Adults with combined hyperlipidemia
4 g5 weeks—
Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia
1998 · simvastatin plus omega-3 fatty acids · Adults with combined hyperlipidemia
4 g5 weeks—
One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations
1998 · n-3 fatty acid ethyl ester group · Patients with hypertriglyceridemia and additional cardiovascular risk factors, including glucose intolerance, NIDDM and/or arterial hypertension
2 g26 weeks—
Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers
1998 · n-3 fatty acids without antioxidants · adult male smokers with hyperlipidaemia
4.8 g6 weeks—
Safety and efficacy of Omacor in severe hypertriglyceridemia
1997 · Omacor · 42 patients with severe hypertriglyceridemia; age and sex not reported
4 g120 days—
Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study
1999 · omega-3 fatty acids · Volunteers; no age, sex, or health condition specified
7 g4 weeks—
Omega-3 fatty acids supplements for dry eye - Are they effective or ineffective?
2023 · O3FA group · Symptomatic visual display terminal users with dry eye; mean age 26.5 years; men and women
360 mg180 days470
Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN)
2018 · MF4637 omega-3 concentrate · Adults aged 18 years or older with suspected non-alcoholic fatty liver disease (NAFLD)
1.38 g24 weeks87
Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Bone Turnover in Older Women
2014 · n-3 LCPUFA group · Postmenopausal women, mean age 75±7 years
1.2 g26 weeks85
Consumption of echium oil increases EPA and DPA in blood fractions more efficiently compared to linseed oil in humans
2016 · Echium oil (EO) · Adults aged 20–69 years, women and men, including normal-weight and overweight participants; no chronic disease reported
17 g8 weeks60
Supplementation of EPA and DHA in pregnant women with type 1 diabetes mellitus
2021 · intervention group · Pregnant women aged 17–35 with type 1 diabetes mellitus and well-controlled glycaemia; supplementation began at 11–12 gestational weeks
120 mg—42
Habitual diets rich in dark-green vegetables are associated with an increased response to ω-3 fatty acid supplementation in Americans of African ancestry
2014 · EPA + DHA supplementation · Participants of African ancestry; age and sex not stated
2 g6 weeks41
Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index
2010 · n-3 fatty acid drink · Adults with atherosclerotic disease and an n-3 index below 5%
200 mg8 weeks40
Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults
2025 · microalgal oil arm · Adults aged 21–82, men and women, with fasting triglycerides of 149–450 mg/dL
656 mg14 weeks37
Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans
2014 · 2 continuous portions (2C) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition
429 mg1 year35
A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction
2014 · rTG concentrated triglyceride fish oil · Healthy adults aged 19–60 years, women and men, without diagnosed illness
1.1 g4 weeks35
A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction
2014 · EE ethyl ester fish oil · Healthy adults aged 19–60 years, women and men, without diagnosed illness
984 mg4 weeks35
Comparative Pharmacokinetic of Curcuminoids Formulations with an Omega-3 Fatty Acids Monoglyceride Carrier: A Randomized Cross-Over Triple-Blind Study
2022 · Curcuminoids extract emulsified in MAG-OM3 oil · Healthy males and females aged 18–50 years
760 mg1 day31
Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans
2014 · 2 intermittent portions (2I) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition
429 mg1 year30
Women have higher levels of CoQ(10) than men when supplemented with a single dose of CoQ(10) with monoglycerides omega-3 or rice oil and followed for 48 h: a crossover randomised triple blind controlled study
2022 · CoQ10 + MAG-OM3 · Healthy men and women aged 18–50 years
1 g1 day30
Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial
2022 · Soup · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese
13.6 mg1 day27
Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial
2022 · Extruded rice snack · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese
13.8 mg1 day27
Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial
2022 · Gel capsule (control) · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese
14.7 mg1 day27
Treatment with n-3 polyunsaturated fatty acids overcomes the inverse association of vitamin D deficiency with inflammation in severely obese patients: a randomized controlled trial
2013 · n-3 PUFA group · Severely obese, non-diabetic adults; sex and age range not specified
3.36 g8 weeks26
A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on neural processing speed and efficiency
2014 · Multi · Healthy adults aged 18–32 years
190 mg120 days25
Comparison of the effects of a phospholipid-enhanced fish oil versus krill oil product on plasma levels of eicosapentaenoic and docosahexaenoic acids after acute administration: A randomized, double-blind, crossover study
2023 · krill oil (KO) · Healthy adult men and women
206 mg1 day24
Bioavailability of Dietary Omega-3 Fatty Acids Added to a Variety of Sausages in Healthy Individuals
2017 · verum group · Healthy adults aged 20–60 years with Omega-3 Index below 5%
250 mg8 weeks22
Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial
2021 · MAG (monoglyceride) · Healthy adults aged 18–50 years, men and women
1.21 g1 day22
Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial
2021 · EE (ethyl ester) · Healthy adults aged 18–50 years, men and women
1.21 g1 day22
Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial
2021 · TG (triglyceride) · Healthy adults aged 18–50 years, men and women
1.21 g1 day22
Circulating levels of endocannabinoids and oxylipins altered by dietary lipids in older women are likely associated with previously identified gene targets
2016 · fish oil supplement · Postmenopausal women, mean age 75±7 years
1.2 g180 days20
Influence of Fish Consumption and ω-3 Supplementation on the ω-3 Index of Young Adults: A 2 × 2 Factorial Randomized Controlled Trial (YouFish Study)
2025 · ω-3 supplement · Healthy young adults aged 18–30 years, male and female, low habitual fish consumers with ω-3 index <6%
400 mg8 weeks20
Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption
2016 · Calanus Oil condition · Healthy adults; age and sex not specified
4 g1 day18
Incorporation of n-3 PUFA and γ-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial
2011 · n-3 LC-PUFA + GLA (group 3) · Adults aged 18–90 with rheumatoid arthritis or psoriatic arthritis and at least medium disease activity
1.58 g12 weeks15
A randomized controlled trial of the effect of fish oil supplementation in late pregnancy and early lactation on the n-3 fatty acid content in human breast milk
2004 · FO(pregn/lact) · Healthy pregnant Danish women, starting in the third trimester and continuing during early lactation
2.2 g—12
A randomized controlled trial of the effect of fish oil supplementation in late pregnancy and early lactation on the n-3 fatty acid content in human breast milk
2004 · FO(pregn) · Healthy pregnant Danish women, starting in the third trimester; women stopped supplementation at delivery
2.2 g—11
Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk
2018 · 675+270 mg/day group · Pregnant women
270 mg—11
Omega-3 fatty acid supplementation affects tryptophan metabolism during a 12-week endurance training in amateur runners: a randomized controlled trial
2024 · O-3 + SEDEN · Physically inactive men, mean age 38 years
3.16 g12 weeks11
Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk
2018 · 225+90 mg/day group · Pregnant women
90 mg—9
Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk
2018 · 450+180 mg/day group · Pregnant women
180 mg—9
The effects of omega-3 fatty acid on vitamin D activation in hemodialysis patients: a pilot study
2015 · Cholecalciferol with omega-3 FA group · Hemodialysis patients with baseline 25(OH)D levels below 30 ng/mL; mean age 62.1 years; 33.3% men
2.4 g12 weeks8
In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA
2021 · Lys-FFA · Eight female volunteers
500 mg1 day8
In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA
2021 · EE · Eight female volunteers
504 mg1 day8
Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk
2018 · 900+360 mg/day group · Pregnant women
360 mg—7
Perioperative immunonutrition in well-nourished patients undergoing surgery for head and neck cancer: evaluation of inflammatory and immunologic outcomes
2013 · Immunonutrition (IMN) group · Patients aged 17 years and older with normal nutritional status undergoing radical resection for oral cavity, pharyngeal or laryngeal cancer
6.1 g11 days4
Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients
2003 · VitC + n-3FAs group · Hyperlipidemic patients with total cholesterol and triglycerides greater than 200 mg/dL; age and sex not specified
1 g10 weeks—
The influence of different combinations of gamma-linolenic, stearidonic and eicosapentaenoic acids on the fatty acid composition of blood lipids and mononuclear cells in human volunteers
2004 · STA plus GLA oil blend · Healthy young males
1 g12 weeks—
Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids
2006 · fish oil · 20 study participants; age, sex, and health condition not specified
1.3 g8 weeks—
Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial
2007 · FO · Pregnant women from gestation week 22 until delivery
150 mg——
Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial
2007 · FO with MTHF · Pregnant women from gestation week 22 until delivery
150 mg——
Erythrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations?
2008 · omega-3 FA supplementation · Patients with epilepsy; age and sex not reported
1 g12 weeks—
Dietary intake of stearidonic acid-enriched soybean oil increases the omega-3 index: randomized, double-blind clinical study of efficacy and safety
2010 · EPA group · Overweight adults; age and sex not reported
1 g12 weeks—
Consumption of salmon v. salmon oil capsules: effects on n-3 PUFA and selenium status
2011 · 2 salmon oil capsules/d · Healthy volunteers; age and sex not specified
240 mg8 weeks—
Consumption of salmon v. salmon oil capsules: effects on n-3 PUFA and selenium status
2011 · 4 salmon oil capsules/d · Healthy volunteers; age and sex not specified
470 mg8 weeks—
Consumption of salmon v. salmon oil capsules: effects on n-3 PUFA and selenium status
2011 · 6 salmon oil capsules/d · Healthy volunteers; age and sex not specified
690 mg8 weeks—
Consumption of stearidonic acid-rich oil in foods increases red blood cell eicosapentaenoic acid
2013 · positive control · Healthy men and women aged 21 to 65 years
1.5 g12 weeks—
Consumption of stearidonic acid-rich oil in foods increases red blood cell eicosapentaenoic acid
2013 · active · Healthy men and women aged 21 to 65 years
7 g12 weeks—
Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats
2015 · Butter meal · Healthy adult men and women
300 mg1 day—
Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats
2015 · Sunflower seed oil meal · Healthy adult men and women
300 mg1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · unmodified fish oil TAG (uTAG) · Healthy men in the postprandial crossover study
1.1 g1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · re-esterified TAG · Healthy men in the postprandial crossover study
1.1 g1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · free fatty acids (FFA) · Healthy men in the postprandial crossover study
1.1 g1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · ethyl esters (EE) · Healthy men in the postprandial crossover study
1.1 g1 day—
Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions
2016 · MAG-enriched oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion
500 mg3 weeks—
Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions
2016 · TAG fish oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion
500 mg3 weeks—
Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies
2017 · Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder
1.67 g12 weeks—
Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies
2017 · PEP plus Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder
1.67 g12 weeks—
Maternal Pre-Pregnancy Obesity Attenuates Response to Omega-3 Fatty Acids Supplementation During Pregnancy
2018 · n-3 PUFA supplementation group · Pregnant women with a history of at least one prior singleton preterm delivery, enrolled at 16 to 21 6/7 weeks; lean, overweight, and obese women were included
1.2 g8 weeks—
n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized controlled trial
2019 · n-3 PUFA supplementation · Adults with small abdominal aortic aneurysm (AAA), diameter 3.0–4.5 cm
1.8 g12 weeks—
Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy: Can they help predict risk of preterm birth?
2020 · DHA supplementation group · Pregnant Australian women enrolled before 20 weeks of gestation; age and condition range not specified
100 mg——
Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation
2021 · EPA 1 g/day · Overweight or obese adults with major depressive disorder and chronic inflammation
1.3 g12 weeks—
Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation
2021 · EPA 2 g/day · Overweight or obese adults with major depressive disorder and chronic inflammation
2.6 g12 weeks—
Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation
2021 · EPA 4 g/day · Overweight or obese adults with major depressive disorder and chronic inflammation
5.2 g12 weeks—
Intake of Docosahexaenoic Acid-Enriched Milk Beverage Prevents Age-Related Cognitive Decline and Decreases Serum Bone Resorption Marker Levels
2021 · docosahexaenoic acid-enriched milk beverage · Healthy elderly Japanese individuals with a Mini-Mental State Examination score of 28 or higher at baseline
137 mg1 year—
Effects of EPA+DHA and Corn Oil Supplementation on PUFA Concentrations across Plasma Lipid Pools and on Downstream Oxylipins: Exploratory Results from a Randomized Controlled Trial in Healthy Humans
2026 · EPA+DHA concentrate · Healthy adults aged 35–49 years; 20 women and 1 man in the available-sample analysis
1.1 g12 weeks—
Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men
1993 · ethyl ester (EE) · healthy normolipaemic men
2.2 g7 weeks—
Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men
1993 · triglyceride (TG) · healthy normolipaemic men
2.2 g7 weeks—
Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
1997 · fish diet group · Healthy men aged 19–32 years
380 mg14 weeks—
Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
1997 · fish oil group · Healthy men aged 19–32 years
1.33 g14 weeks—
Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors
2013 · yoghurt enriched with 0.8 g n-3 LC-PUFA/d · Mildly hypertriacylglycerolemic subjects with TAG ≥ 1.7 mmol/L; age and sex not specified
800 mg10 weeks—
Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial
2023 · Marine omega-3 only · Generally healthy, robust, community-dwelling adults aged 70 years or older
1 g3 years—
Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease
1995 · fish-oil group · Patients with coronary artery disease; age range and sex not stated
3.4 g39 weeks260
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
2015 · Statin + OM3-CA 2 g/d plus olive oil 2 g/d · Adults aged 18 years or older, men and non-pregnant, non-lactating women, at high cardiovascular risk with residual hypertriglyceridemia while taking a statin
2 g6 weeks215
Supplementation-induced increase in circulating omega-3 serum levels is not associated with a reduction in depressive symptoms: Results from the MooDFOOD depression prevention trial
2020 · Supplement without F-BA · Adults aged 18–75 who were overweight (BMI 25–40) and had at least mild depressive symptoms but no current major depressive episode
1.41 g1 year174
Supplementation-induced increase in circulating omega-3 serum levels is not associated with a reduction in depressive symptoms: Results from the MooDFOOD depression prevention trial
2020 · Supplement with F-BA · Adults aged 18–75 who were overweight (BMI 25–40) and had at least mild depressive symptoms but no current major depressive episode
1.41 g1 year169
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes
1.86 g1 year147
Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial
2017 · Omega-3 ethyl-ester group · Adults aged 21–80 with stable coronary artery disease and overweight or metabolic risk features; predominantly men
3.36 g913 days143
Effects of EPA, γ-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomised, double-blind trial
2013 · group 1 (n-3 fatty acids) · Healthy men with serum PSA ≤ 2.5 ng/ml
4.48 g12 weeks126
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
2014 · OM3-FFA 3 g/d (plus OO 1 g/d) · Men and women with severe hypertriglyceridemia (triglycerides ≥500 mg/dL and <2000 mg/dL)
3 g12 weeks101
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
2014 · OM3-FFA 2 g/d (plus OO 2 g/d) · Men and women with severe hypertriglyceridemia (triglycerides ≥500 mg/dL and <2000 mg/dL)
2 g12 weeks100
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study
2013 · n - 3/n - 3 group · Older adults with Alzheimer's disease; mean age 75 years; 57% women
600 mg1 year89
Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B₄ and leukotriene B₅ production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial
2014 · n-3 FA (active) · Adults aged 41–89 with colorectal cancer awaiting surgery
2 g7 days74
Effects of enriched seafood sticks (heat-inactivated B. animalis subsp. lactis CECT 8145, inulin, omega-3) on cardiometabolic risk factors and gut microbiota in abdominally obese subjects: randomized controlled trial
2022 · SIAP2 · Adults older than 18 years with abdominal obesity
370 mg12 weeks57
Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes
2016 · omega-3 group · Adults over 18 years with diagnosed dry eye disease, meibomian gland dysfunction stage 1 or 2, and elevated tear osmolarity
1.68 g12 weeks54
The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial
2021 · Low-calorie diet + n-3 PUFA · Adults aged 25–65 with overweight or obesity and abdominal obesity
1.8 g90 days50
Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease
2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported
650 mg1 year50
Joint effects of one year of marine omega-3 fatty acid supplementation and participant dietary fish intake upon circulating lipid mediators of inflammation resolution in a randomized controlled trial
2024 · n-3 fatty acid supplementation · Women aged 55 years or older and men aged 50 years or older; participants selected from the VITAL trial by baseline fish intake, without a stated diagnosis
1 g1 year50
Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study
2020 · EPA+DHA group · Adults with acute coronary syndrome after successful PCI; age and sex mix not restricted
930 mg1 year48
Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial
2023 · D+ group · Jordanian participants with vitamin D deficiency and no other medical conditions; age and sex not specified
300 mg8 weeks47
Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids
2013 · n-3 PUFA / fish oil treatment · Adults with type 2 diabetes and hypertension, and adults with hypertension without diabetes; age- and sex-matched groups
460 mg8 weeks45
The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial
2021 · Isocaloric diet + n-3 PUFA · Adults aged 25–65 with overweight or obesity and abdominal obesity
1.8 g90 days45
Omega-3 Fatty Acid Supplementation is Associated With Oxidative Stress and Dyslipidemia, but Does not Contribute to Better Lipid and Oxidative Status on Hemodialysis Patients
2017 · n-3 PUFA group · Adults aged 18 years or older receiving hemodialysis for at least 6 months
1.28 g12 weeks43
A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha
2002 · 300 mg DHA + 70 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported
70 mg4 weeks40
A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha
2002 · 600 mg DHA + 140 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported
140 mg4 weeks40
Untitled
2013 · low dose fish oil arm · Men and women aged 40–85; overweight or obese, without the listed excluded medical conditions; not selected for a diagnosed disease or nutrient deficiency.
1.25 g120 days40
Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements
2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication
4.4 g30 days40
Hyaluronic acid is associated with organ dysfunction in acute respiratory distress syndrome
2017 · fish oil treatment · Adults with acute respiratory distress syndrome in intensive care
16.5 g2 weeks38
Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines
2018 · EPA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history
1.06 g14 weeks37
The effects of fish oil plus vitamin D(3) intervention on non-alcoholic fatty liver disease: a randomized controlled trial
2022 · FO + D group · Adults aged 56.0 ± 15.9 years with non-alcoholic fatty liver disease
2.34 g90 days37
Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes
2017 · n-3 PUFAs · Adults, mean age 65.6 years, men and women, with type 2 diabetes and established atherosclerotic cardiovascular disease
1 g90 days36
Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines
2018 · DHA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history
180 mg14 weeks36
Effects of maternal allergy and supplementation with ω-3 fatty acid and probiotic on human milk oligosaccharides
2025 · OL (ω-3 PUFA + L. reuteri) · Pregnant women with a family history of allergies who intended to breastfeed for the first 3 months; maternal age median about 30 years
3.84 g230 days36
A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction
2014 · PL phospholipid krill oil · Healthy adults aged 19–60 years, women and men, without diagnosed illness
240 mg4 weeks35
A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction
2014 · TG salmon oil triglyceride · Healthy adults aged 19–60 years, women and men, without diagnosed illness
400 mg4 weeks35
The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes
2017 · vitamin D + omega-3 fatty acids · Patients with gestational diabetes; age and sex not otherwise specified
2 g6 weeks35
A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial
2019 · Omega-3 fatty acids group · Adults aged 51–65 with impaired glucose regulation
1.4 g12 weeks35
The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome
2017 · omega-3 fatty acids and vitamin E · Women aged 18–40 years with polycystic ovary syndrome diagnosed according to the Rotterdam criteria
1 g12 weeks34
The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Indices of Insulin Resistance and Hormonal Parameters in Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
2017 · omega-3 fatty acids and vitamin E co-supplementation · Women aged 18–40 years with polycystic ovary syndrome
1 g12 weeks34
Effects of omega-3 fatty acids supplementation on serum adiponectin levels and some metabolic risk factors in women with polycystic ovary syndrome
2012 · omega-3 fatty acids · Overweight or obese women aged 20–35 years with polycystic ovary syndrome
1.2 g8 weeks32
Phytosterols and Omega 3 Supplementation Exert Novel Regulatory Effects on Metabolic and Inflammatory Pathways: A Proteomic Study
2017 · ω3-supplemented milk · Healthy adults aged 25–70 with overweight or grade 1 obesity (BMI 25–35)
375 mg4 weeks32
A randomized-controlled clinical trial investigating the effect of omega-3 fatty acids and vitamin E co-supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes
2016 · omega-3 fatty acids plus vitamin E group · Women with gestational diabetes who were not taking oral hypoglycemic agents
1 g6 weeks30
A Randomized Controlled Clinical Trial Investigating the Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Biomarkers of Oxidative Stress, Inflammation and Pregnancy Outcomes in Gestational Diabetes
2017 · omega-3 fatty acids plus vitamin E · Women with gestational diabetes who were not taking oral hypoglycemic agents
1 g6 weeks30
The Effects of Omega-3 Fatty Acids Supplementation on Gene Expression Involved in the Insulin and Lipid Signaling Pathway in Patients with Polycystic Ovary Syndrome
2017 · omega-3 fatty acids from flaxseed oil · Women aged 18–40 diagnosed with polycystic ovary syndrome according to the Rotterdam criteria
2 g12 weeks30
The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome
2018 · Vitamin D and omega-3 co-supplementation · Women aged 18–40 years with polycystic ovary syndrome (PCOS)
2 g12 weeks30
Long-term vitamin D and high-dose n-3 fatty acids' supplementation improve markers of cardiometabolic risk in type 2 diabetic patients with CHD
2019 · Vitamin D and n-3 fatty acids co-supplementation · Vitamin D-deficient patients with type 2 diabetes and coronary heart disease; age and sex not reported
2 g26 weeks30
The effects of n-3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomised, double-blind, placebo-controlled trial
2020 · n-3 fatty acids from flaxseed oil · Women with gestational diabetes mellitus
2 g6 weeks30
Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia
1999 · n-3 fatty acids · Adults with combined (type IIb) hyperlipidaemia who had not responded to a therapeutic diet
4 g12 weeks28
Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers
2014 · Lovaza 1/day · Healthy men and non-pregnant, non-lactating women aged 18–45 years
465 mg7 weeks28
Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial
2017 · ω-3 supplement group · Children and adolescents aged 7–14 years with mood disorders, including bipolar disorder, major depressive disorder, or dysthymic disorder
2.4 g12 weeks28
Metabolic Response to Omega-3 Fatty Acids and Vitamin E Co-Supplementation in Patients with Fibrocystic Breast Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
2017 · omega-3 fatty acids plus vitamin E · Patients with fibrocystic breast disease
1 g12 weeks28
Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression
2015 · EPA group · Men and postmenopausal women aged 21–70 with mildly elevated plasma Lp-PLA2
1.8 g6 weeks27
Maternal AA/EPA Ratio and Triglycerides as Potential Biomarkers of Patients at Major Risk for Pharmacological Therapy in Gestational Diabetes
2022 · intervention group · Pregnant women aged 18 or older at 24–28 weeks’ gestation with gestational diabetes
2.4 g10 weeks26
Marine ω-3 PUFA Supplementation Enhances FFAR4 Activation and Reduces Inflammatory Markers in PBMC of Subjects with Obesity: A Randomized Controlled Trial (EPICO)
2025 · marine-derived ω-3 · Adults aged 25–59 years with obesity or abdominal obesity, without major health complications
1.8 g8 weeks26
Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress--a prospective preliminary study
2002 · group 2 (Maxigard group) · Adults with type 2 diabetes and BMI <27 kg/m²; age and sex not specified
1.2 g6 weeks25
Generation and dietary modulation of anti-inflammatory electrophilic omega-3 fatty acid derivatives
2014 · fish oil group (treatment) · Healthy adults aged 30–54 years, employed at least 25 hours per week, with dietary EPA and DHA consumption below 300 mg/day
1 g120 days24
Omega-3 Fatty Acid Could Increase One of Myokines in Male Patients with Coronary Artery Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
2017 · Omega-3 · Men with coronary artery disease and more than 50% stenosis in at least one major coronary vessel
720 mg8 weeks24
Cytokine distribution in mothers and breastfed children after omega-3 LCPUFAs supplementation during the last trimester of pregnancy and the lactation period: A randomized, controlled trial
2017 · FO group · Pregnant women recruited at week 28 of pregnancy and followed through lactation
72 mg—24
Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism
2020 · omega-3 FA group · Men aged 35–55 years with fasting plasma TAG concentrations of at least 1.5 mmol/L; nondiabetic and free from known disease
1.84 g8 weeks24
Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome
2011 · flaxseed oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m²
3.27 g6 weeks23
Omega-3 fatty acids, inflammatory status and biochemical markers of patients with systemic lupus erythematosus: a pilot study
2017 · omega-3 group · Women with systemic lupus erythematosus (SLE), median age 37 years; low disease activity
1.28 g12 weeks22
Changes in peripheral immune populations during pregnancy and modulation by probiotics and ω-3 fatty acids
2020 · ω3 + L. reuteri · Pregnant women included at gestational week 20, with at least one parent or sibling with allergic disease history or symptoms
1.28 g137 days22
Effect of chia seeds or concentrated fish oil on cardiometabolic risk markers in subjects with hypertriglyceridaemia: a parallel clinical trial
2024 · low-calorie diet with concentrated fish oil · Patients with hypertriglyceridaemia; age and sex not specified
1.8 g8 weeks22
Efficacy of probiotic co-supplementation with omega-3 PUFAs on pancreatic beta-cell function in type 2 diabetes
2025 · Probiotic-Omega group · Adults aged 18–75 with type 2 diabetes and pancreatic beta-cell dysfunction
250 mg8 weeks22
Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome
2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m²
2.15 g6 weeks21
Omega-3 supplementation on inflammatory markers in patients with chronic Chagas cardiomyopathy: a randomized clinical study
2017 · intervention group · Adults older than 18 years with chronic Chagas cardiomyopathy, stages B, C or D
3 g8 weeks21
Secondary data analysis investigating effects of marine omega-3 fatty acids on circulating levels of leptin and adiponectin in older adults
2021 · EPA+DHA Group · Adults aged 50–85 with chronic inflammatory conditions, including nonhealing venous leg ulcers; overweight or obese older adults
1.5 g8 weeks21
Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men
2014 · LC n-3 PUFA supplementation · Men aged 24–48 years: 10 normolipidemic and 10 with mild combined hyperlipidemia
2.52 g12 weeks20
Effects of administration of omega-3 fatty acids with or without vitamin E supplementation on adiponectin gene expression in PBMCs and serum adiponectin and adipocyte fatty acid-binding protein levels in male patients with CAD
2015 · OE (omega-3 fatty acid & vitamin E) · Adult men with coronary artery disease and more than 50% stenosis
4 g8 weeks20
Beneficial effects of omega-3 and vitamin E coadministration on gene expression of SIRT1 and PGC1α and serum antioxidant enzymes in patients with coronary artery disease
2016 · Group 2 (OE) · Male patients with coronary artery disease; age range not reported
4 g60 days20
The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial
2019 · omega-3 fatty acids plus vitamin E · Patients with Parkinson's disease; age range and sex not reported
1 g12 weeks20
N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial
2022 · n-3 FA · Caucasian men and women aged 50–79 with combined hyperlipidemia, taking stable atorvastatin
3 g8 weeks20
The effect of omega-3 fatty acids supplementation on inflammatory biomarkers in subjects with migraine: a randomized, double-blind, placebo-controlled trial
2023 · omega-3 supplementation group · Patients prone to episodic migraines
1.8 g60 days20
Effects of Long Chain Omega-3 Polyunsaturated Fatty Acids on Brain Function in Mildly Hypertensive Older Adults
2018 · LCn-3PUFA group · Adults aged 40–85 with borderline or mild hypertension and low fish/seafood intake
2 g20 weeks19
Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study
2023 · high-dose EPA/DHA group · Adults aged 20 years or older receiving hemodialysis and diagnosed with dyslipidemia
1.86 g90 days19
Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation
2025 · ω-3VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase
100 mg/kg6 weeks19
The effect of highly purified eicosapentaenoic and docosahexaenoic acids on monocyte phagocytosis in man
1997 · highly purified DHA · healthy men
3.6 g7 weeks19
Dietary supplementation with fish oil in ulcerative colitis
1992 · fish oil · Adults with active ulcerative colitis
3.24 g120 days18
Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial
2012 · oxidised fish oil · Healthy adults aged 18–50 years
1.6 g7 weeks18
n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
2016 · n-3 fatty acids + CoQ · Men and women aged 25–75 years with chronic renal impairment (eGFR >15 and <60 mL/min/1.73 m²)
4 g8 weeks18
Dietary supplementation with omega-3 fatty acids and oleate enhances exercise training effects in patients with metabolic syndrome
2016 · Ω-3 + OLE · Patients with metabolic syndrome; age range and sex not reported
275 mg24 weeks18
Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial
2012 · fish oil · Healthy adults aged 18–50 years
1.6 g7 weeks17
Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach
2014 · FO group · Healthy men and women aged 18–50 years
700 mg7 weeks17
Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial
2019 · FO (fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women
1.2 g12 weeks17
Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans
2015 · n-3 (EPA+DHA) · Overweight insulin-resistant, nondiabetic adults; 8 men and 23 women were randomized, ages not stated
1.5 g26 weeks16
Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial
2019 · CC-FO (curcumin plus fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women
1.2 g12 weeks16
Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study
2023 · low-dose EPA/DHA group · Adults receiving hemodialysis and diagnosed with dyslipidemia who continued after the initial control period
930 mg90 days16
Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes
2000 · Fish oil · Postmenopausal women
2 g—15
Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate
2001 · fish oil (FO) · Postmenopausal women; ages and health conditions not specified
2 g—15
Omega-3 fatty acids effect on wound healing
2008 · EPA/DHA supplement group · Healthy men and women aged 18–45 years
1.6 g5 weeks15
Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial
2014 · Omega-3 fatty acid capsules · Adults aged 40–60 of both sexes with BMI >25, apparently healthy and overweight
300 mg6 weeks15
Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial
2014 · Omega-3 capsule + VSL#3 capsule · Adults aged 40–60 of both sexes with BMI >25, apparently healthy and overweight
300 mg6 weeks15
Dietary supplementation with low-dose omega-3 fatty acids reduces salivary tumor necrosis factor-α levels in patients with chronic periodontitis: a randomized controlled clinical study
2017 · test group · Systemically healthy patients with chronic periodontitis; age and sex not reported
6.25 mg26 weeks15
Untargeted metabolomic on urine samples after α-lipoic acid and/or eicosapentaenoic acid supplementation in healthy overweight/obese women
2018 · EPA + α-LA · Healthy sedentary overweight/obese women, mean age 37.3 years; following a hypocaloric diet
1.3 g10 weeks15
Curcumin alleviates postprandial glycaemic response in healthy subjects: A cross-over, randomized controlled study
2018 · fish oil (FO) · Healthy men and women aged 18–45 years with BMI below 30 kg/m²
550 mg1 day15
Curcumin alleviates postprandial glycaemic response in healthy subjects: A cross-over, randomized controlled study
2018 · curcumin + fish oil (CC-FO) · Healthy men and women aged 18–45 years with BMI below 30 kg/m²
550 mg1 day15
Supplementation of Re-Esterified Docosahexaenoic and Eicosapentaenoic Acids Reduce Inflammatory and Muscle Damage Markers after Exercise in Endurance Athletes: A Randomized, Controlled Crossover Trial
2020 · DHA + EPA · Healthy male amateur endurance athletes aged 18–45 years
240 mg10 weeks15
An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia
2004 · Omacor · 14 patients with familial combined hyperlipidemia (FCHL); age range and sex not reported
1.88 g8 weeks14
Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen
2004 · PFA group · Patients with severe IgA nephropathy, including patients with advanced renal disease
850 mg4 years14
Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study
2009 · EPA/DHA · Exercise-trained men; ages 25.5 ± 4.8 years; no stated cardiovascular or metabolic disorders
2.22 g6 weeks14
Effect of long-chain omega-3 polyunsaturated fatty acids on cardiometabolic factors in children with acute lymphoblastic leukemia undergoing treatment: a secondary analysis of a randomized controlled trial
2023 · ω3-LCPUFAs · Children aged 6.1 ± 2.3 years on average with newly diagnosed acute lymphoblastic leukemia undergoing chemotherapy
100 mg/kg90 days14
Omega-3 fatty acid supplementation affects tryptophan metabolism during a 12-week endurance training in amateur runners: a randomized controlled trial
2024 · O-3 + TRAIN · Male amateur endurance runners, mean age 37 years, without chronic disease
3.16 g12 weeks14
Functional and metabolic effects of omega-3 polyunsaturated fatty acid supplementation and the role of β-hydroxy-β-methylbutyrate addition in chronic obstructive pulmonary disease: A randomized clinical trial
2024 · EPA/DHA + HMB · Patients with COPD, GOLD stages II–IV; age and sex not stated
2 g10 weeks14
Effects of dietary n-3 polyunsaturated fatty acids from plant and marine origin on platelet aggregation in healthy elderly subjects
1999 · EPA/DHA diet, elderly subjects · Adults older than 60 years, healthy elderly subjects
1.05 g6 weeks13
Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
2012 · Combination · Adults aged 40–69 with metabolic syndrome
4 g16 weeks13
Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial
2012 · EPA group · Adults aged 18–75 years with type 1 or type 2 diabetes mellitus and major depressive disorder
1 g12 weeks13
Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial
2020 · n-3 PUFA group · Adults aged 19 years or older, both sexes, with ultrasound-confirmed non-alcoholic fatty liver disease
306 mg26 weeks13
Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome
2024 · Combination · Adults aged 40–69 with metabolic syndrome
4 g16 weeks13
Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes
2008 · fish oil · Adults with normotriglyceridemic type II diabetes who were not receiving insulin treatment
5.9 g9 weeks12
Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study
2014 · EPA group · Adults older than 65 years with mild cognitive impairment
1.67 g26 weeks12
Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study
2014 · DHA group · Adults older than 65 years with mild cognitive impairment
400 mg26 weeks12
Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study
2018 · High DHA-FO concentrate · Obese men and women with BMI >30
400 mg12 weeks12
The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners
2021 · ω-3 PUFA group · Healthy physically active male recreational marathon runners, with no stated disease; age range not reported
2.45 g3 weeks12
Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial
2025 · EPA-rich fish oil · Adults aged 18–65 with non-severe burns covering less than 20% of total body surface area
2.1 g3 weeks12
Effect of 21-Day Omega-3 Polyunsaturated Fatty Acid Supplementation on Exercise-Induced Secretory Factors and Inflammation Status in Young Men: A Randomized Double-Blind Trial
2026 · supplementation group · Physically active, healthy men aged approximately 22 years
3.25 g3 weeks12
Procoagulant activity and cytokine expression in whole blood cultures from patients with atherosclerosis supplemented with omega-3 fatty acids
1999 · Group I · Patients with atherosclerosis; age and sex not reported
5.1 g30 weeks11
Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women
2012 · n-3 PUFA-enriched juice · Healthy women; ages not reported
250 mg2 weeks11
Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial)
2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication
4.4 g90 days11
Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial)
2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication
4.4 g90 days11
Enrichment of n-3 containing ether phospholipids in plasma after 30 days of krill oil compared with fish oil supplementation
2022 · krill oil group · Healthy women aged 18–45 years
1.27 g30 days11
Enrichment of n-3 containing ether phospholipids in plasma after 30 days of krill oil compared with fish oil supplementation
2022 · fish oil group · Healthy women aged 18–45 years
1.44 g30 days11
The influence of low intake of n-3 fatty acids on platelets in elderly people
1999 · n-3 PUFA group · healthy elderly people; age range and sex not stated
600 mg6 weeks10
n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes
2016 · n-3 PUFA (fish oil) supplementation · Men with type 2 diabetes; mean age 54.7 ± 7.6 years
3 g8 weeks10
Effect of dietary n-3 PUFA supplementation on the muscle transcriptome in older adults
2016 · n-3 PUFA group · Healthy men and women aged 60–85 years
3.36 g26 weeks10
Impact of Cranberry Juice Enriched with Omega-3 Fatty Acids Adjunct with Nonsurgical Periodontal Treatment on Metabolic Control and Periodontal Status in Type 2 Patients with Diabetes with Periodontal Disease
2018 · cranberry juice enriched with omega-3 (I3) · Adults aged 35–67 years with type 2 diabetes and periodontal disease
2 g8 weeks10
Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study
1996 · Fish oil (FO) · Patients with hyperlipidemic non-insulin-dependent diabetes mellitus; age and sex not reported
4.6 g2 weeks10
Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study
2010 · omega-3 group (fish oil) · Patients with Alzheimer disease; age and sex not reported
2.3 g26 weeks9
Fish oil supplementation alters levels of lipid mediators of inflammation in microenvironment of acute human wounds
2011 · Active Group (EPA + DHA supplement) · Healthy adults aged 18–45 years, both sexes
1.6 g4 weeks9
Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study
1994 · fish oil group · Adults with non-insulin-dependent diabetes mellitus (NIDDM)
2.5 g6 weeks9
[Effect of short-term use of omega-3-type polyunsaturated fatty acids in subjects with hypertriglyceridemia]
1992 · fish oil · Patients with hypertriglyceridemia; age and sex not reported
1.8 g12 weeks8
Modulation of fibrinolytic response to venous occlusion in humans by a combination of low-dose aspirin and n-3 polyunsaturated fatty acids
1992 · n-3 PUFA supplementation · Healthy adults aged 24–37 years, three men and three women
5.3 g43 days6
Effects of eicosapentaenoic acid supplementation in the treatment of chronic hepatitis C patients
2005 · EPA group · Patients with chronic hepatitis C receiving interferon alpha-2b and ribavirin; age and sex not reported
1.8 g24 weeks5
Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation
2018 · EPA and DHA (3.4 g/day) · Healthy men aged 29–32 years
1.84 g8 weeks3
Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation
2018 · 1800 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group
1.1 g150 days2
Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation
2018 · 900 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group
550 mg150 days1
Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics
1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract
1.4 g12 days—
Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion
1999 · fish oil supplement group · Human volunteers; age, sex, and health status not specified
3.6 g15 days—
Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion
1999 · soy lecithin supplement group · Human volunteers; age, sex, and health status not specified
500 mg15 days—
Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions
2000 · fish oil (FO) · Healthy subjects; age and sex not specified
2.1 g12 weeks—
Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women
2003 · 4:1 · Women; age and health status not further specified
4 g4 weeks—
Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women
2003 · 4:2 · Women; age and health status not further specified
4 g4 weeks—
n-3 long-chain FA decrease serum levels of TG and remnant-like particle-cholesterol in humans
2003 · n-3 FA group · Volunteers with serum triglyceride concentrations of 100–300 mg/dL; age and sex not specified
860 mg12 weeks—
Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects
2003 · 10 g PLT 3514 emulsion group · Healthy adults; age range and sex not specified.
500 mg2 weeks—
Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects
2003 · 20 g PLT 3514 emulsion group · Healthy adults; age range and sex not specified.
1 g2 weeks—
Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects
2003 · 100 g PLT 3514 emulsion group · Healthy adults; age range and sex not specified.
5 g2 weeks—
Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: a randomized, placebo-controlled, parallel-group, prospective trial
2003 · 10 g PLT 3514 emulsion · Patients with mild to moderate atopic asthma; age not specified
500 mg4 weeks—
Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: a randomized, placebo-controlled, parallel-group, prospective trial
2003 · 15 g PLT 3514 emulsion · Patients with mild to moderate atopic asthma; age not specified
750 mg4 weeks—
Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study
2004 · n-3 PUFA group · Healthy adult males
4 g8 weeks—
Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins
2006 · 500 mg DHA + 150 mg eicosapentaenoic acid · Healthy pregnant women during the second half of gestation
150 mg——
Influence of low-dose polyunsaturated fatty acids supplementation on the inflammatory response of healthy adults
2007 · group A (anti-inflammatory blend) · healthy adult volunteers
169 mg2 weeks—
The effect of n - 3 PUFA/gamma-cyclodextrin complex on serum lipids in healthy volunteers--a randomized, placebo-controlled, double-blind trial
2007 · n-3 group · Adults aged 35–66; mostly healthy volunteers, including some with hypertriglyceridemia
940 mg8 weeks—
Influence of a concentrated ethylester compound of n-3 fatty acids on lipids, platelets and coagulation in patients undergoing coronary bypass surgery
1991 · n-3 fatty acids · Patients eligible for coronary bypass surgery with fasting triglyceride levels of at least 1.6 mmol/L
3.15 g26 weeks—
The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients
2008 · low dose (Trial 1) · Atopic adults with mild-to-moderate asthma
500 mg4 weeks—
The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients
2008 · high dose (Trial 1) · Atopic adults with mild-to-moderate asthma
750 mg4 weeks—
The lipid-lowering effects of phytosterols and (n-3) polyunsaturated fatty acids are synergistic and complementary in hyperlipidemic men and women
2008 · Combination of phytosterols and (n-3) LCPUFA · Men and women with hyperlipidemia; age range not reported
1.4 g3 weeks—
Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals
2009 · n-3 PUFA capsules with plant sterols · Hyperlipidemic participants; age and sex not specified
1.4 g3 weeks—
Effect of n-3 oral supplements on the n-6/n-3 ratio in young adults
2010 · experimental group · healthy young adults
1.6 g4 weeks—
Th1 and Th2 chemokines, vaccine-induced immunity, and allergic disease in infants after maternal ω-3 fatty acid supplementation during pregnancy and lactation
2011 · ω-3 fatty acid supplementation · Pregnant women at risk of having an allergic infant
1.6 g——
Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation
2011 · n-3 PUFA plus antioxidant vitamins · Either-sex patients undergoing on-pump cardiac surgery
2 g——
Effects of 6 weeks of n-3 fatty acids and antioxidant mixture on lipid peroxidation at rest and postexercise
2011 · LCPUFA supplementation alone · Judoists; age and sex not reported; no diagnosed condition stated
1 g6 weeks—
Effect of mixed flavonoids, n-3 fatty acids, and vitamin C on oxidative stress and antioxidant capacity before and after intense cycling
2011 · QFO · Athletes; age and sex not specified
400 mg17 days—
Untitled
2012 · N3 + placebo · Participants with baseline homocysteine >8.0 µmol/L
3.2 g12 weeks—
Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients
2012 · treatment group · Adults aged 45–85 years with type 2 diabetes mellitus for at least two years
1.89 g8 weeks—
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load
2012 · n-3 PUFAs · Patients with combined dyslipidemia; age and sex not specified
3 g26 weeks—
Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial
2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified
30 mg1 year—
Combined fish oil and high oleic sunflower oil supplements neutralize their individual effects on the lipid profile of healthy men
2013 · n-9 (OSO) 8 g/day with n-3 1 g/day · Healthy men; age range not reported.
1 g12 weeks—
Combined fish oil and high oleic sunflower oil supplements neutralize their individual effects on the lipid profile of healthy men
2013 · n-9 (OSO) 8 g/day with n-3 2 g/day · Healthy men; age range not reported.
2 g12 weeks—
Combined fish oil and high oleic sunflower oil supplements neutralize their individual effects on the lipid profile of healthy men
2013 · n-9 (OSO) 8 g/day with n-3 4 g/day · Healthy men; age range not reported.
4 g12 weeks—
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)
2013 · OM3-FFA 2 g/d (plus 2 g/d olive oil) · Adults with fasting triglycerides ≥200 mg/dL and <500 mg/dL, treated with a maximally tolerated statin or statin plus ezetimibe, and at high cardiovascular risk
2 g6 weeks—
Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder
2012 · n-3 group · Children aged 6–12 years with ADHD receiving maintenance therapy
635 mg8 weeks—
Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia
2014 · omega-3 fatty acid treatment · HIV-seropositive adults with hypertriglyceridemia (≥150 mg/dl) on active antiretroviral therapy
3.4 g——
Low doses of eicosapentaenoic acid and docosahexaenoic acid from fish oil dose-dependently decrease serum triglyceride concentrations in the presence of plant sterols in hypercholesterolemic men and women
2014 · Intervention spread with 0.9 g/d EPA+DHA · Hypercholesterolemic men and women aged 25–74 years
900 mg4 weeks—
Low doses of eicosapentaenoic acid and docosahexaenoic acid from fish oil dose-dependently decrease serum triglyceride concentrations in the presence of plant sterols in hypercholesterolemic men and women
2014 · Intervention spread with 1.3 g/d EPA+DHA · Hypercholesterolemic men and women aged 25–74 years
1.3 g4 weeks—
Low doses of eicosapentaenoic acid and docosahexaenoic acid from fish oil dose-dependently decrease serum triglyceride concentrations in the presence of plant sterols in hypercholesterolemic men and women
2014 · Intervention spread with 1.8 g/d EPA+DHA · Hypercholesterolemic men and women aged 25–74 years
1.8 g4 weeks—
Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study
2015 · n-3 FA treatment · Patients with Alzheimer's disease
600 mg26 weeks—
The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses
2015 · PS (2.5 g/day) and EPA+DHA (0.9 g/day) spread · Hypercholesterolemic subjects; age and sex not specified
900 mg4 weeks—
The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses
2015 · PS (2.5 g/day) and EPA+DHA (1.3 g/day) spread · Hypercholesterolemic subjects; age and sex not specified
1.3 g4 weeks—
The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses
2015 · PS (2.5 g/day) and EPA+DHA (1.8 g/day) spread · Hypercholesterolemic subjects; age and sex not specified
1.8 g4 weeks—
Safety and lipid-altering efficacy of a new omega-3 fatty acid and antioxidant-containing medical food in men and women with elevated triacylglycerols
2015 · PDL-0101 · Adults with triacylglycerols 150–499 mg/dL and LDL cholesterol ≥70 mg/dL
1.8 g8 weeks—
n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease
2015 · n-3 fatty acids and CoQ · Patients with chronic kidney disease
4 g8 weeks—
The Pattern of Fatty Acids Displaced by EPA and DHA Following 12 Months Supplementation Varies between Blood Cell and Plasma Fractions
2015 · 1 portion per week · Healthy non-oily-fish-consuming adults; age range and sex distribution not stated
214 mg1 year—
The effect of 12-wk ω-3 fatty acid supplementation on in vivo thalamus glutathione concentration in patients "at risk" for major depression
2015 · ω-3 FA supplements · Older adults at risk for depression; age range and sex not specified
4 g12 weeks—
A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease
2017 · krill oil · People with mild to moderate dry eye disease; age and sex not reported
945 mg90 days—
A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease
2017 · fish oil · People with mild to moderate dry eye disease; age and sex not reported
1 g90 days—
Treatment for 6 months with fish oil-derived n-3 polyunsaturated fatty acids has neutral effects on glycemic control but improves dyslipidemia in type 2 diabetic patients with abdominal obesity: a randomized, double-blind, placebo-controlled trial
2017 · fish oil group · Adults with type 2 diabetes and abdominal obesity; mean age 65.4 years; 35 men and 64 women completed the study
2.4 g26 weeks—
Changes in relative and absolute concentrations of plasma phospholipid fatty acids observed in a randomized trial of Omega-3 fatty acids supplementation in Uganda
2016 · omega-3 supplement · Adult men and women with HIV and HHV8 infection, with or without Kaposi's sarcoma
3.09 g12 weeks—
Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia
2017 · third group (statin + omega-3 PUFA + CoQ10) · People with combined dyslipidemia and elevated TAG levels; age and sex not reported
2.52 g90 days—
The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease
2018 · n-3 FA plus CoQ · Patients with chronic kidney disease (CKD)
4 g8 weeks—
A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study
2018 · Combination of ω-3 fatty acids plus nano-curcumin · Patients with episodic migraine
2.5 g60 days—
Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects
2020 · Saury oil · Healthy adults, mean age 34.8 years; 60% female; no history of chronic disease
3.4 g8 weeks—
Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects
2020 · Control oil · Healthy adults, mean age 34.8 years; 60% female; no history of chronic disease
3 g8 weeks—
Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial
2020 · n-3 LCPUFA plus vitamin D · Pregnant women enrolled at pregnancy week 24; age range and health condition not specified
2.4 g17 weeks—
Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial
2020 · FO group · People with non-alcoholic fatty liver disease (NAFLD); age and sex not reported
1.95 g——
Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial
2020 · PS + FO combination group · People with non-alcoholic fatty liver disease (NAFLD); age and sex not reported
1.95 g——
Omega-3 Supplementation Improves Isometric Strength But Not Muscle Anabolic and Catabolic Signaling in Response to Resistance Exercise in Healthy Older Adults
2021 · ω-3 PUFA (ω-3) supplementation condition · Adults aged 65–83 years, both sexes, healthy and nonsarcopenic older adults
3.06 g14 weeks—
The effect of combined supplementation with vitamin D and omega-3 fatty acids on blood glucose and blood lipid levels in patients with gestational diabetes
2021 · test group · Women aged 18–40 with gestational diabetes
16 g6 weeks—
Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial
2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications
1.1 g12 weeks—
Effects of Vitamin D(3) and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
2022 · Vitamin D3 and marine n-3 fatty acids active group · Men aged 50 years or older and women aged 55 years or older, without a history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke, transient ischemic attack, or coronary revascularization
1 g1935 days—
Effects of Exercise and Omega-3-Supplemented, High-Protein Diet on Inflammatory Markers in Serum, on Gene Expression Levels in PBMC, and after Ex Vivo Whole-Blood LPS Stimulation in Old Adults
2023 · high-protein, omega-3-enriched (protein + omega-3) · Community-dwelling adults aged 65–85 years without the specified malignant or severe chronic diseases, diabetes, dementia, or severe food allergies
2.2 g8 weeks—
The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial
2024 · EPA+DHA supplementation · Adults with coronary artery disease on statin therapy, with and without diabetes
1.86 g913 days—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 DHA plus EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
650 mg5 years—
Vitamin D(3) and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial
2025 · Vitamin D3 plus marine n-3 fatty acids · Females aged 55 years or older and males aged 50 years or older; no specific condition stated
1 g5 years—
Normal subjects consuming physiological levels of 18:3(n-3) and 20:5(n-3) from flaxseed or fish oils have characteristic differences in plasma lipid and lipoprotein fatty acid levels
1996 · Fish oil · Normal adults; sex and age not stated; no stated condition
35 mg90 days—
Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans
1997 · Menhaden oil with vitamin E · Healthy men; age not stated
6.26 g6 weeks—
Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial
2024 · intervention group · Adults aged 18–70 with obesity and dyslipidemia
700 mg90 days105
A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial
2019 · PS plus omega-3 fatty acids group · Adults aged 51–65 with impaired glucose regulation
1.4 g12 weeks41
Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome
2006 · test group · Patients with metabolic syndrome; age and sex not specified
200 mg90 days36
Untitled
2013 · high dose fish oil arm · Men and women aged 40–85; overweight or obese, without the listed excluded medical conditions; not selected for a diagnosed disease or nutrient deficiency.
4.93 g120 days35
The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial
2019 · Multinutrient supplementation group · Women aged 19–35 with polycystic ovary syndrome (PCOS)
500 mg90 days30
Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial
2019 · Nutraceutical A · Adults aged 18–75 with elevated serum cholesterol not requiring statins or statin-intolerant; people with cardiovascular disease and uncontrolled diabetes were excluded.
400 mg6 weeks24
Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study
2024 · SynΩ3 group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP
167 mg4 weeks24
Consumption of Hen Eggs Enriched with n-3 Polyunsaturated Fatty Acids, Selenium, Vitamin E and Lutein Incites Anti-Inflammatory Conditions in Young, Healthy Participants - A Randomized Study
2022 · 4Nutri group · Young, healthy participants; age range and sex not stated
1.03 g3 weeks20
Effects of baked products enriched with n-3 fatty acids, folates, β-glucans, and tocopherol in patients with mild mixed hyperlipidemia
2012 · active diet · Adults with mild plasma lipid abnormalities (mild mixed hyperlipidemia)
1.2 g30 days16
The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial
2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease
300 mg4 weeks16
The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial
2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program
3.6 g4 weeks11
Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration
2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment
1.05 g—10
Plasma Instead of Serum Avoids Critical Confounding of Clinical Metabolomics Studies by Platelets
2024 · Omega-3 treatment cohort · Healthy adults; age and sex not specified for this cohort
1.74 g7 days6
Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects
2009 · seal oil capsules · Hypertriglyceridaemic volunteers recruited from the Wollongong community; age and sex not reported
2.02 g6 weeks—
Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects
2009 · fish oil capsules · Hypertriglyceridaemic volunteers recruited from the Wollongong community; age and sex not reported
1.05 g6 weeks—
Effects of 6 weeks of n-3 fatty acids and antioxidant mixture on lipid peroxidation at rest and postexercise
2011 · LCPUFA plus antioxidant mixture · Judoists; age and sex not reported; no diagnosed condition stated
1 g6 weeks—
Untitled
2012 · MVit + N3 · Participants with baseline homocysteine >8.0 µmol/L
3.2 g12 weeks—
Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled Trial
2022 · Active treatment group · Adults aged 65–80 with low-grade inflammation (hs-CRP 1.5–6 mg/L) and BMI 18.5–27 kg/m²
640 mg8 weeks—
Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study
2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP
180 mg4 weeks—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
650 mg5 years—
Multimicronutrient and omega-3 fatty acid supplementation reduces low-grade inflammation in older participants: An exploratory study
2025 · multimicronutrient and n-3 PUFA supplementation · Healthy, physically active older adults; mean age 75.6 ± 3.9 years; sex not specified
1 g12 weeks—
Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants
1997 · omega-3 FAs and antioxidants · male smokers with combined hyperlipidemia
5 g6 weeks—
Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers
1998 · n-3 fatty acids with antioxidants · adult male smokers with hyperlipidaemia
4.8 g6 weeks—
The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial
2024 · Group (2) / EP (EPA plus placebo) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women
1 g12 weeks25
The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial
2024 · Group (3) / CE (curcumin plus EPA) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women
1 g12 weeks25
Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial
2023 · Vitamin D3 plus marine omega-3s · Generally healthy, robust, community-dwelling adults aged 70 years or older
1 g3 years—
Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study
2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed
225 mg3 years401
Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study
2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed
225 mg3 years399
Effect of the omega-3 fatty acid plus vitamin E supplementation on subjective global assessment score, glucose metabolism, and lipid concentrations in chronic hemodialysis patients
2016 · omega-3 fatty acid + vitamin E placebo · Chronic hemodialysis patients; age and sex not specified
1.25 g12 weeks30
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides
2019 · icosapent ethyl 2 g/day · Adults with stage 3 chronic kidney disease, high triglycerides, and increased cardiovascular risk despite statin treatment
2 g12 weeks30
Changes in lipoprotein particle subclasses, standard lipids, and apolipoproteins after supplementation with n-3 or n-6 PUFAs in abdominal obesity: A randomized double-blind crossover study
2021 · Males: EPA + DHA (n-3) · Males with abdominal obesity
4 g7 weeks23
Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals
2009 · n-3 PUFA capsules without plant sterols · Hyperlipidemic participants; age and sex not specified
1.4 g3 weeks—
Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome
2015 · IPE 2 grams/day · Patients with metabolic syndrome and high or very high triglyceride levels, with or without stable statin therapy
2 g——
A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease
2016 · n-3 fatty acids and Coenzyme Q10 · Patients with chronic kidney disease; age and sex not specified.
4 g8 weeks—
Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects
2021 · fish oil (2:1 EPA:DHA) · healthy volunteers
4 g30 days—
Omega-3 Supplementation for the Prevention of Cognitive Decline in Older Adults: Does It Depend on Homocysteine Levels?
2022 · Multidomain intervention combined with n-3 PUFA supplementation · Community-dwelling men and women aged 70 years or older without dementia, with spontaneous memory complaints, slow gait speed, or limitations in instrumental activities of daily living
513 mg3 years—
Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial
2024 · omega-3 fatty acid · Men aged 50 years or older and women aged 55 years or older, free of cardiovascular disease and cancer at baseline
1 g1935 days—